Cas9-Primed Adaptive Immunity During the CRISPR-Cas Response by Nussenzweig, Philip M
Rockefeller University 
Digital Commons @ RU 
Student Theses and Dissertations 
2020 
Cas9-Primed Adaptive Immunity During the CRISPR-Cas 
Response 
Philip M. Nussenzweig 
Follow this and additional works at: https://digitalcommons.rockefeller.edu/
student_theses_and_dissertations 
 Part of the Life Sciences Commons 
  
 
 
 
 
 
CAS9-PRIMED ADAPTIVE IMMUNITY DURING THE CRISPR-CAS RESPONSE 
 
 
 
A Thesis Presented to the Faculty of 
The Rockefeller University 
in Partial Fulfillment of the Requirements for 
the degree of Doctor of Philosophy 
 
 
 
 
 
 
 
by 
Philip M. Nussenzweig 
June 2020  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©  Copyright by Philip M. Nussenzweig 2020  
CAS9-PRIMED ADAPTIVE IMMUNITY DURING THE CRISPR-CAS RESPONSE 
Philip M. Nussenzweig, Ph.D. 
The Rockefeller University 2020 
 Prokaryotes have developed numerous defense strategies to combat the constant 
threat of viruses (bacteriophages) that endanger them. Clustered, regularly interspaced 
short palindromic repeats (CRISPR) loci provide archaea and bacteria with adaptive 
immune systems that allow them to counteract these rapidly evolving genetic parasites. 
These diverse systems all generally contain two components: a set of CRISPR-associated 
(cas) genes and a series of repetitive DNA elements intercalated with variable sequences 
known as spacers. Following viral infection, these sequences are acquired from the viral 
genome and integrated in the CRISPR array as new spacers. Spacers are then 
transcribed into CRISPR RNAs (crRNAs) that direct the Cas nucleases to destroy the 
invader following sequence-specific recognition of either DNA or RNA. Thus, spacers 
function as a form of immunologic memory that can be called upon again and again to 
defend the cell from reinfection. 
 In type II CRISPR-Cas systems, spacer sequences direct the Cas9 nuclease to 
target infecting bacteriophages and cleave their double-stranded (ds)DNA genomes. 
Whether and how pre-exiting anti-viral spacers in type II systems affect memory 
generation and the acquisition of new spacers is unknown. Here, in my thesis work, I 
demonstrate that previously acquired spacers promote additional spacer capture from 
the vicinity of the Cas9 cut site at an enhanced rate. I go on to show that Cas9-mediated 
dsDNA break (DSB) formation is required for spacer-mediated spacer acquisition and 
that the rate of spacer acquisition is correlated with the efficiency of Cas9 cleavage. As a 
result of this mechanism, cells with preexisting viral immunity can utilize their spacer-
derived crRNAs to direct the acquisition of additional spacers in a new phase of 
immune response known as primed spacer acquisition or priming. 
 A consequence of priming is that immune cells can acquire additional spacers as 
Cas9 destroys the infecting virus. I go on to show that spacers acquired during Cas9-
mediated priming endow potent benefits to bacterial communities faced with virulent 
bacteriophages. In particular, priming suppresses the emergence of CRISPR escaper   
and related viruses that emerge during Cas9 targeting. I show that this anti-viral 
immunity is achieved in three ways. Firstly, priming expands the hosts immune 
repertoire, thereby improving the existing anti-phage immunity. In addition, I show 
that primed spacer acquisition allows the host to contain the propagation escapers that 
have mutations in their target sequence that abrogate Cas9 targeting. Finally, by 
preemptively immunizing the host with additional spacers during the initial Cas9 
targeting response, priming allows the host to anticipate secondary infections by 
escaper and related viruses. This “prophylactic” immunity is a unique feature in 
CRISPR systems that allows type II systems to overcome future threats from viruses 
that would have overcome the defense provided by the initial anti-viral spacer.   
 CRISPR-Cas immune systems allow their host to rapidly adapt to the viruses that 
challenge them. Collectively, my thesis work has revealed a new phases of the type II-A 
CRISPR-Cas9 immune response that is fundamental to how these systems defend their 
hosts against bacteriophages. 
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CHAPTER 1: INTRODUCTION 
 
1.1. Bacteriophages: central actors in biology  
 
 
 
Figure 1.1. Red Queen interactions between host and viruses. 
A schematic outlining the Red Queen hypothesis. Host defense systems restrict 
the replication of viruses and in response viral escaper variants are selected over 
time that evade host restriction (red hexagon and circle). As a consequence of 
viral evolution, mutations in the host that restrict escaper viruses are adapted 
and selected for (red surface on host) giving rise to an ongoing genetic arms race. 
Adapted from (Daugherty and Malik, 2012). 
 
Bacteriophages (phages) are the viruses that infect and parasitize bacterial cells. 
Phages have been identified in every biome where bacteria are found and they 
often vastly outnumber their hosts (Dion et al., 2020). In some marine 
environments, for instance, the viral particle-to-bacterial cell ratio has been 
measured to be as high as 100:1 (Brum et al., 2013). As a result, bacteriophages 
subject their bacterial hosts to continuous selective pressure and serve as major 
drivers of microbial evolution (Fernandez et al., 2018). To counteract this 
constant threat, bacteria have developed a diverse set of defense systems that 
restrict viral propagation and protect bacterial populations from extinction 
(Rostol and Marraffini, 2019a). Bacteriophages are however highly mutable and 
continually acquire means of escaping host immunity (Kupczok et al., 2018). 
Bacteria and their phages therefore engage in a classic evolutionary paradigm 
known as the “Red Queen hypothesis” (Daugherty and Malik, 2012). This 
hypothesis, whose name derives from the Red Queen in Lewis Carroll’s Through 
the Looking Glass, states an organism must continually evolve in order to maintain 
its fitness when confronted with a predator. This struggle for fitness forces both 
the bacterium and the phage into a perpetual cycle of adaptation and counter-
adaptation in order to survive (Figure 1.1). The consequence of this ongoing 
genetic arms race can be felt across biology. In the oceans, aquatic phage 
infections turnover 20% of the microbial biomass and influence nutrient cycles 
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(Suttle, 2005, 2007). In the gut microbiome, the competition between bacteria and 
their phages modulates the composition of the microbial community and the 
metabolites they produce (Hsu et al., 2019). Finally, bacteriophages that have 
evaded anti-phage immunity are well documented contributors to human 
disease due to their role as vectors for the horizontal transmission of virulence 
and antibiotic resistance genes to bacterial pathogens (Brüssow et al., 2004). 
Phages have also been widely adopted in the laboratory as model organisms and 
have confirmed some of the most fundamental principles in molecular biology 
including the random nature of mutation(Luria and Delbruck, 1943), the identity 
of DNA as the genetic material (Hershey and Chase, 1952), and the basis of gene 
expression (Jacob and Monod, 1961). More recently, bacteriophages have been 
repurposed as novel therapeutic agents capable of treating bacterial infections 
refractory to conventional antimicrobial therapies (Bikard et al., 2014; Nobrega et 
al., 2015). The continued understanding of the coevolution of these viruses and 
their bacterial hosts therefore remains enshrined as a central focus in biology. 
   
 Figure 1.2. The morphology of a phage lambda. 
A schematic and electromicrograph of phage lambda; a prototypic, temperate, 
tailed dsDNA phage of Siphoviridae family. Adapted from (Dion et al., 2020). 
 
 While tremendously diverse in their genomic composition and structure, 
all bacteriophages typically contain protein-based capsids that encases their 
DNA- or RNA-based genomes (Figure 1.2) (Dion et al., 2020). In addition to these 
structures, a large majority of isolated phages have a hollow tail structure (Brum 
et al., 2013) that allows the virus to penetrate the bacterial cell wall and 
membrane and then inject their genomes into the host cytosol. Following 
injection, the phage begins either their lytic or lysogenic lifecycle (Herskowitz 
and Hagen, 1980). Lytic phages immediately begin replicating multiple copies of 
their genomes and producing the components necessary for packaging and lysis 
of the host cells. Lysogenic phages by contrast integrate their genomes into the 
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host chromosome as “prophages” and have their lytic genes repressed. As a 
result, these integrated prophages can remain in the host as genetic parasites that 
are replicated together with the bacterial chromosome. Temperate phages, such 
as the classic genetic model phage lambda (Figure 1.2), can choose to engage in 
either lifecycle (Oppenheim et al., 2005) (Figure 1.3). This lysis-lysogen decision 
is controlled by a transcriptional repressor that acts as a regulatory ‘genetic 
switch’ that prevents the transcription of lytic genes necessary for replication 
(Oppenheim et al., 2005). Functional temperate prophages however retain the 
ability to reverse this genetic switch and initiate the lytic cycle. To do so, the 
“induced” prophage must excise from the bacterial chromosome and derepress 
its lytic genes following proteolytic cleavage of the repressor. As a consequence 
of Red Queen interactions, anti-phage defense systems have developed 
mechanisms that inhibit every stage of the lifecycle of both lytic and lysogenic 
phages (Rostol and Marraffini, 2019a). One of the most versatile and diverse of 
these defenses is the CRISPR-Cas system. 
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Figure 1.3. The lifecycles of temperate phages. 
A schematic depicting the potential lifecycles of a temperature phage. Free 
virions are adsorbed onto the bacterial cell wall and then inject their DNA into 
the host cytosol. The phage can choose to either to initiate lysogeny (bottom right 
cell) and integrate into the bacterial chromosome (blue segment) as a prophage 
(red segment) or immediately begin replicating (red circles) and expressing 
genes required for packaging and lysis (bottom left cell). Prophages can however 
be induced to excise from the bacterial chromosome and enter the lytic cycle of 
replication. Adapted from (Ofir and Sorek, 2018).  
 5 
 
 
1.2 CRISPR-CAS SYSTEMS: RNA-GUIDED PROKARYOTIC ADAPTIVE 
IMMUNE SYSTEMS 
 
Prokaryotic organisms have evolved multiple defense systems to protect 
themselves against parasitic nucleic acids such as plasmids and bacteriophages 
(Rostol and Marraffini, 2019a). Clustered regularly interspaced short palindromic 
repeats (CRISPRs) are unique among these systems in that they are able to 
continually update and tailor their immune responses to match the specific 
nucleic acid sequence of their invaders. CRISPR loci are widely distributed and 
are present in 42% bacteria and 85% of archaea (Makarova et al., 2019), and have 
been reported to exist within bacteriophages (Al-Shayeb et al., 2020; Seed et al., 
2013) as well as other mobile genetic elements (McDonald et al., 2019). Research 
over the last decade has revealed a remarkable diversity in the architecture and 
mechanisms employed by these systems. Currently, CRISPRs are organized into 
two classes, comprised of six types (I–VI) and a total of 50 subtypes based on 
their sequences (Makarova et al., 2019). Despite this diversity between systems, 
CRISPR loci all contain two basic core anatomical features (Figure 1.4). The first 
is a series of CRISPR-associated (cas) genes dedicated to nucleic acid 
manipulation (Jansen et al., 2002), and the second is an array of short partially 
palindromic, repetitive non-coding DNA sequences interlaced by equally short, 
variable sequences known as ‘spacers’ (Barrangou et al., 2007; Marraffini and 
Sontheimer, 2008). These spacers specify the sequence of the targets of Cas 
nucleases and lie at the center of the CRISPR-Cas immune response, which 
consists of three phases. In the first phase, known as spacer acquisition or 
immunization, new spacers are captured from the invader’s nucleic acids and are 
integrated into the CRISPR array (Figure 1.4A). In the second phase, the newly 
acquired spacers are transcribed into small CRISPR RNAs (crRNAs) that 
combine with RNA-guided Cas nucleases to recognize and destroy foreign 
nucleic acids (Figure 1.4B). Class 1 systems, including types I, III, and IV, are 
defined by the use of multisubunit RNA-guided Cas nucleases, whereas Class II 
systems, including types II, V, and VI, use a single crRNA:Cas ribonucleoprotein 
complex. Due to the sequence-specific nature of the CRISPR-Cas response, 
immunity can be overcome when parasites mutate the target sequence in their 
genomes, thus preventing immune recognition (Andersson and Banfield, 2008; 
Deveau et al., 2008). To counteract these ‘escapers’, CRISPR systems have 
developed a third phase in their mechanism of immunity: primed spacer 
acquisition (Figure 1.4C).  During CRISPR priming, preexisting spacers direct the 
targeting machinery to catalyze a second, more rapid round of spacer acquisition 
(Datsenko et al., 2012; Nussenzweig et al., 2019; Swarts et al., 2012). Here we 
summarize the molecular mechanisms used by different CRISPR-Cas systems to 
execute these three phases of immunity. 
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Figure 1.4. The anatomy of CRISPR locus and phases of the CRISPR-Cas 
immune response.  
The three phases of CRISPR-Cas immunity against bacteriophages. CRISPR loci 
comprise of a set of CRISPR-associated (cas) genes, encoding the machinery for 
nucleic acid targeting (red and blue arrows) as well as the Cas1-Cas2 spacer 
acquisition machinery (yellow and orange arrows). The CRISPR array comprises 
of semi-palindromic repeats (black diamonds) interlaced with short ‘spacer’ 
sequences (colored rectangles). (A) In the first phase, naive spacer acquisition or 
immunization, a spacer is selected and integrated by the Cas1-Cas2 complex into 
the CRISPR array (orange spacer). (B) In the second ‘targeting’ phase, the newly 
immunized CRISPR array is transcribed into pre-crRNAs that are processed into 
mature CRISPR RNAs (crRNAs). The mature crRNAs combine with the Cas 
targeting complex and together seek out and destroy foreign nucleic acid in a 
sequence-specific manner. (C) In the primed spacer acquisition phase, new 
substrates for spacer acquisition are generated concurrently with target 
destruction and integrated into the CRISPR array (green spacer). 
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1.3 crRNA biogenesis: the forging of specificity 
CRISPR RNAs (crRNAs) have two features: a constant palindromic sequence 
derived from the CRISPR array’s repeats and a variable sequence derived from 
the array’s spacers that are complementary to the targets of the immune 
system(Bolotin et al., 2005; Brouns et al., 2008; Haft et al., 2005; Pourcel et al., 
2005). Fundamentally, all CRISPR systems must distinguish between these RNAs 
and other transcripts to execute immunity. To solve this, the constant region is 
used as an identifier to distinguish it from other cellular RNAs and specify its 
recruitment for RNA processing (Hale et al., 2008; Haurwitz et al., 2010). In 
addition, recognition of the constant region of the crRNA by the CRISPR 
immunosurveillance complex is also often coupled to the complex’s activation 
(Jackson et al., 2014; Jinek et al., 2014; Liu et al., 2017b). crRNA maturation 
therefore potentially represents a central point of regulation before the targeting 
phase of immunity is initiated. Production of crRNAs usually initiates with the 
transcription of a long-precursor crRNA (pre-crRNA), containing several repeat 
spacer units (Figure 1.4B), typically from a promoter located in the leader region 
upstream of the CRISPR array. How subsequent maturation of the pre-crRNA is 
mechanistically coordinated is CRISPR class specific, with Class 1 systems (types 
I and III) employing a dedicated endoribonuclease (Carte et al., 2008; Haurwitz et 
al., 2010) and Class 2 systems (types II, V, and VI) executing maturation with the 
same machinery that performs target destruction (Deltcheva et al., 2011; East-
Seletsky et al., 2016; Fonfara et al., 2016). 
 
1.3.1 Class 1 crRNA maturation 
Both type I and III systems utilize the endoribonucleases Cas6 or Cas5d to 
process their pre-crRNAs (Carte et al., 2008; Haurwitz et al., 2010; Nam et al., 
2012). In both systems, the palindromic sequences within the constant region of 
the pre-crRNA allow for the formation of stem-loop structures that are 
recognized by Cas6 (Carte et al., 2008; Haurwitz et al., 2010). These stem-loops of 
type I and III cRNAs are in fact so similar that the archaeon Sulobobus islandicus 
utilizes the same Cas6 enzyme to process the crRNAs from both its type I-A and 
its two type III-B systems (Deng et al., 2013). The importance of the stem-loop 
structure is highlighted by studies on the type I-B system, whose repeats are non-
palindromic and therefore cannot produce hairpin structures autonomously. 
Crystal structures of Methanococcus maripaludis Cas6b in complex with crRNA 
reveal that upon RNA binding, Cas6 utilizes a tyrosine aromatic ring as an RNA 
base-pair mimic to help form a hybrid stem-loop structure necessary for crRNA 
maturation (Shao et al., 2016). Generally, Cas6 recognition of the hairpin 
stimulates a conformational rearrangement that licenses cleavage immediately 
downstream of the hairpin, thus liberating the individual mature crRNA from 
the longer precursor (Sashital et al., 2011). For the majority of type I systems, 
Cas6 remains bound to the crRNA post-processing, protecting it from cellular 
RNases, and the Cas6:crRNA complex is incorporated together into the larger 
multiprotein surveillance complex (Jore et al., 2011). Type III crRNAs, however, 
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undergo a second trimming step that removes the hairpin and releases the 
crRNA from Cas6 (Hale et al., 2008). How these unprotected mature crRNAs 
produced by type III systems are trafficked into their respective complexes is 
currently unanswered (Sokolowski et al., 2014).  
 
1.3.2 Class 2 crRNA maturation 
 
Class 2 systems lack a dedicated crRNA maturation factor and instead rely on 
the same machinery that performs nucleic acid defense to handle crRNA 
processing (Deltcheva et al., 2011; East-Seletsky et al., 2017; Fonfara et al., 2016). 
The problem of correctly sorting crRNAs from the total pool of cellular nucleic 
acid is therefore particularly important. Class 2 systems have developed two 
strategies to address this challenge. The first strategy, carried out by type V-A 
and VI systems, is to recognize 5’-hairpins or ‘pseudoknots’ in pre-crRNA and 
cleave upstream of them, like in Class 1 Cas5/6 RNases (Dong et al., 2016; Liu et 
al., 2017b; Yamano et al., 2016). Alternatively, type II and V-B systems require a 
second trans-activating CRISPR (tracr) RNA to anneal to the constant region of 
the crRNA to act as an intermediate between the nascent crRNA and the effector 
(Cas9 and Cas12b, respectively) (Deltcheva et al., 2011; Shmakov et al., 2017). 
Stem-loop structures on the tracr side of the duplex are then used to recruit Cas9 
or Cas12. Intriguingly, the original study that identified the tracrRNA in 
Streptococcus pyogenes showed that it is initially transcribed in two forms in vivo, 
as a 181- and an 89-nucleotide species, from two distinct promoters (Deltcheva et 
al., 2011). Both of these isoforms are capable of being processed into functional, 
mature tracrRNAs, but how these isoforms are regulated and if they have 
different effects on immunity are yet unknown. In addition, the S. pyogenes 
CRISPR-Cas9 system is distinct in that, following pre-crRNA:tracr binding, Cas9 
outsources its processing to host ribonucleases; first RNase III cleaves the 5’-end 
of the crRNA:tracrRNA duplex, thus separating individual crRNAs from the 
long transcript, and then an unidentified factor executes a second 5’-trimming 
reaction (Deltcheva et al., 2011). This requirement is not universal in type II 
CRISPRs: crRNA processing and anti-plasmid immunity occur in the Neisseria 
meningitidis type II-C in the absence of RNase III in vivo (Zhang et al., 2013). 
 
1.4 CRISPR targeting: executing sequence-specific immunity 
Once mature crRNAs are loaded into their cognate RNA-guided Cas nucleases, 
they form a ribonucleoprotein complex that surveys the host cytosol for the 
presence of foreign invaders (Brouns et al., 2008). The subsequent targeting 
phase is defined by a highly accurate and programmable sequence-specific 
cleavage of the target nucleic acid (Gasiunas et al., 2012; Jinek et al., 2012). This 
unique feature has allowed many CRISPR systems to be repurposed as genome 
editing tools (Doudna and Charpentier, 2014) and has generated a wealth of 
mechanistic insight into how Cas effectors execute nucleic acid cutting. 
Traditionally, CRISPR systems have been organized according to their class (ie 
use of a single protein or multiprotein effector complex) (Makarova et al., 2019). 
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While this class-based organization is highly useful for examining other facets of 
CRISPR biology, here we have chosen to organize CRISPR systems based on the 
identity of the nucleic acid that activates them: DNA- versus RNA-activated 
CRISPR systems. 
 
1.4.1 DNA-activated CRISPR targeting (Types I, II, and V) 
Type I systems are the most widely distributed CRISPR-Cas systems and 
historically the first to be characterized in depth (Makarova et al., 2019). The type 
I-E system, originally identified in Escherichia coli, serves as the model locus and 
its targeting machinery comprises of two core components: (1) the crRNA-
containing complex known as the CRISPR-associated complex for antiviral 
defense (Cascade) and (2) the signature ATP-dependent helicase/nuclease Cas3 
that defines the locus (Brouns et al., 2008; Sinkunas et al., 2011) (Figure 1.5A). 
Following crRNA binding, Cascade employs its Cse1 (Cas8) subunit to survey 
the cell for a three nucleotide DNA sequence known as the protospacers adjacent 
motif (PAM) (Sashital et al., 2012). Correct PAM recognition triggers Cascade-
induced DNA strand separation and invasion of the crRNA into target DNA 
(Hayes et al., 2016; Sinkunas et al., 2013). The crRNA then directionally zips with 
the complementary DNA and expands toward the end of the protospacer, 
forming an R-loop that stably locks the complex onto the DNA (Blosser et al., 
2015; Rutkauskas et al., 2015; Xiao et al., 2017a). A particularity of Cascade 
complex is that its Cas7 backbone introduces kinks in the crRNA at every 6th 
base, leading to their outward exposure and precludes their participation in 
immunity in vivo (Fineran et al., 2014; Jackson et al., 2014; Mulepati et al., 2014). 
Following full base-pairing and R-loop induced locking, Cascade undergoes a 
conformational change that is sufficient to recruit Cas3 by the Cse1 subunit of the 
complex (Hochstrasser et al., 2014; Huo et al., 2014; Mulepati and Bailey, 2013; 
Westra et al., 2012).The first Cas3 to arrive cleaves the non-complementary 
strand and generates a 200-300 nucleotide single-stranded DNA (ssDNA) gap, 
thereby destroying the R-loop and unlocking Cascade from its target (Mulepati 
and Bailey, 2013; Sinkunas et al., 2013). Cas3 then utilizes its helicase activity to 
translocate 3’->5’ along the non-complimentary strand (Mulepati and Bailey, 
2013; Redding et al., 2015). Data from plasmid and phage infections suggests that 
Cas3-mediated immunity ultimately generates full double-stranded DNA 
(dsDNA) degradation, but how this is achieved in vivo remains unclear. Early 
studies of the type I system demonstrated that Cas3 helicase activity is essential 
for plasmid immunity (Westra et al., 2012), suggesting that Cas3 may remove 
secondary structures or proteins as it moves along the ssDNA; this could allow 
the binding of host nucleases or additional Cas3s responsible for further DNA 
degradation, dsDNA formation, and the completion of targeting (Mulepati and 
Bailey, 2013; Redding et al., 2015). 
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Figure 1.5. DNA-activated CRISPR targeting. 
The mechanism of action of three prototypical DNA-activated CRISPR-Cas 
targeting complexes. (A) The type I-E targeting machinery comprises two 
components: (1) the CRISPR-associated complex for antiviral defense (Cascade) 
and (2) the helicase/nuclease Cas3. Cascade identifies DNA targets by searching 
for the protospacer adjacent motif (PAM) and then recruiting Cas3 via Cse1. Cas3 
then unidirectionally translocates along one strand away from Cascade and 
performs DNA nicking. (B) The type II-A targeting machinery is composed of 
Cas9 and the crRNA:tracrRNA duplex. Cas9 identifies DNA targets by searching 
for the PAM. Target recognition simultaneously realigns the HNH and RuvC 
domains, leading to blunted double-stranded DNA (dsDNA) breaks. (C) The 
type V-A targeting machinery contains Cas12 and the crRNA guide. DNA targets 
are identified by searching for the PAM. After target binding, the non-target 
strand is the first to cleaved by the RuvC domain and is then released. The target 
strand then moves into the RuvC domain for its cleavage. Following staggered 
dsDNA break formation and release of the target strand, the PAM-proximal 
dsDNA remains bound, allowing the RuvC to remain active and capable of 
cleaving single-stranded DNA (ssDNA) substrates. 
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The type II and V effectors Cas9 and Cas12 (Figure 1.5B-C), famous for 
their use in genome engineering (Cong et al., 2013; Zetsche et al., 2015), are 
remarkably similar in their structure and execution of immunity but differ in 
how they generate dsDNA breaks. While Cas9 contains two nuclease domains 
(an HNH and a RuvC domain) that cleave each strand of the target DNA and 
generate blunt breaks (Sapranauskas et al., 2011), Cas12 uses a single RuvC 
nuclease domain to generate staggered dsDNA breaks (Swarts et al., 2017; 
Zetsche et al., 2015). For both enzymes, as with Cascade, the loading of a mature 
crRNA initiates a search for compatible PAMs that are obligate for DNA 
recognition and subsequent strand invasion (Jeon et al., 2018; Redding et al., 
2015; Rollins et al., 2017; Singh et al., 2018; Sternberg et al., 2014). Directional 
DNA unwinding dependent on crRNA-DNA complementarity then drives the 
rearrangement of the nuclease domains allowing them to engage with their 
cleavage sites (Jeon et al., 2018; Singh et al., 2018; Sternberg et al., 2015; Sternberg 
et al., 2014; Szczelkun et al., 2014). For Cas9, movement of the HNH domain 
simultaneously triggers activation of the RuvC domain at the non-
complementary strand, ensuring the cleavage of both strands (Sternberg et al., 
2015). How Cas12’s single RuvC domain could generate a staggered double-
stranded break remained a mystery until recently. Using DNA substrates 
containing phosphorothioate to inhibit nuclease activity on one strand or the 
other, biochemical analysis revealed that the non-targeting strand is cleaved first, 
thereby releasing the target strand and making it accessible to the RuvC for a 
second cleavage event (Swarts and Jinek, 2019). 
 The shared strategy adopted by DNA-targeting systems (Figure 1.5) for 
executing target search and recognition brings several advantages. The initial 
search of a PAM allows these enzymes to first interact with a small portion of the 
overall binding site before deciding to probe flanking sequences with the crRNA, 
and as a result these enzymes dramatically reduce the total number of sequences 
they sample (Jeon et al., 2018; Redding et al., 2015; Rollins et al., 2015; Singh et al., 
2018; Sternberg et al., 2014). The effectiveness of this simplified target search is 
illustrated by a single-molecule study that demonstrated that the crRNA-
Cascade complex can avoid 90% of the lambda phage genome while searching 
for its cognate target (Redding et al., 2015). PAM recognition has added benefits 
given that Cascade, Cas9, and Cas12 all lack ATP-dependent helicase activity 
and therefore rely on the energy released from PAM strand separation to initiate 
R-loop formation (Hayes et al., 2016; Jeon et al., 2018; Singh et al., 2018; Sternberg 
et al., 2014). The dependence on the PAM, however, makes DNA-activated 
systems highly vulnerable to CRISPR escaper viruses that can break CRISPR 
immunity by introducing a single point mutation at this sequence (Deveau et al., 
2008; Pyenson et al., 2017; Semenova et al., 2011). An additional strategy adopted 
by DNA-activated CRISPR-Cas systems is the use of crRNA to proofread the 
PAM-flanking sequence for mismatches during complex activation (Jeon et al., 
2018; Rollins et al., 2015; Singh et al., 2018; Sternberg et al., 2014). This successive 
base-pairing step between the crRNA and the target allows for a second round of 
quality control to avoid incorrect, “off” targets (Rouillon et al., 2013; Sternberg et 
al., 2015; Szczelkun et al., 2014). The initial base pairing with the 7-12 nucleotides 
that flank the PAM, known as the seed sequence, is critical for target cleavage 
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(Jinek et al., 2012; Semenova et al., 2011). Mismatches between the seed region 
and the crRNA will prematurely abort the stable heteroduplex formation 
required for complex activation(Rutkauskas et al., 2015; Singh et al., 2018; 
Sternberg et al., 2014). Indeed, phages that mutate their target seed sequence 
have been shown to be able to escape DNA-activated CRISPR targeting 
(Nussenzweig et al., 2019; Semenova et al., 2011). 
 Fundamental differences between the systems emerge when comparing 
mechanistic requirements for DNA cleavage. Cascade is far more promiscuous in 
terms of the number of PAMs it can recognize because Cse1’s uses of the minor 
rather than the major groove of DNA to establish contacts (Hayes et al., 2016). In 
addition, a full R-loop must form before Cascade can recruit Cas3 and initiate 
DNA destruction (Rutkauskas et al., 2015). By contrast, Cas9’s and Cas12’s 
nucleases are gradually activated in concert with successive base-pairing with 
the target, meaning that they probably sample partially-activated conformations 
prior to full R-loop formation (Jiang et al., 2016a; Jiang et al., 2015; Singh et al., 
2018). These differences likely have profound effects on how these systems 
interact with targets that have only partial homology to the crRNA and on how 
the subsequent primed spacer acquisition response is stimulated (Chapter 1.6).  
 In addition to the sequence-specific dsDNA cleavage activity of Cas12, 
studies have shown that Cas12 can also perform sequence-independent single-
stranded DNA cleavage in trans across multiple V subtypes (Chen et al., 2018) 
(Figure 1.5C). A recent structural study of the Francisella novicida Cas12a has 
revealed how this trans nuclease activity is triggered following annealing of the 
crRNA with its target sequence (Swarts and Jinek, 2019). Following cis-cleavage 
of the target strand, the PAM-proximal end of the DNA is released, freeing the 
RuvC domain to interact with new substrates. Crucially, the crRNA and target 
DNA strand remain paired, allowing Cas12a to stay active and cleave incoming 
non-target ssDNAs. Thus, type V systems possess the cis-cleavage properties 
observed in type I and II DNA-activated CRISPR-Cas systems while also 
possessing the collateral, non-specific trans activity of RNA-activated type III and 
VI systems. What role Cas12 trans cleavage plays in its immune response is 
unknown but ssDNA destruction may be important for interfering with the 
lifecycle of mobile genetic elements such as phages and conjugative plasmids 
that generate multiple ssDNA intermediates during rolling circle replication 
(Novick, 1998). Interestingly, like Cas9, Cas12a remains firmly bound to its target 
DNA after double-stranded cis-cleavage occurs (Jeon et al., 2018; Singh et al., 
2018), implying that Cas12a stays active in the trans-cleavage competent state 
until it is actively dislodged. This suggests that a prolonged state of trans-activity 
may be induced leading to degradation of host ssDNA and entry into a 
dormancy state similar to that observed in the Csm6 and Cas13 responses. 
Finally, another recent study reports the existence of a type V-G locus encoding a 
Cas12 capable of recognizing and cleaving ssRNA in cis (Yan et al., 2018), further 
suggesting that some type V loci may use elements of both DNA- and RNA-
activated systems. Uncovering the nature of immune responses guided by these 
new CRISPR-Cas12 systems should prove to be exciting new avenue of future 
research 
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 Finally, the events that follow target DNA cleavage by DNA-activated 
systems, which are ultimately responsible for target destruction in vivo, remain 
uncharacterized. Neither Cas9 nor Cas12 dissociates from its cleaved DNA 
targets in vitro except under extremely harsh conditions (Jeon et al., 2018; Singh 
et al., 2018; Sternberg et al., 2014), suggesting that other cellular factors are 
required for their dislodgment. In agreement with this observation, a study 
demonstrated that collisions between RNA polymerase and Cas9 are sufficient to 
dislodge Cas9 and convert it into a multi-turnover enzyme with enhanced anti-
phage immunity in vivo (Clarke et al., 2018). Alternatively, tight post-cleavage 
binding may be needed to ensure that DNA repair enzymes do not immediately 
mend the nascent dsDNA break. Cascade’s status after Cas3 nicking remains less 
clear. One single-molecule study on the E. coli type I-E complex demonstrated 
that, like Cas9 and Cas12, Cascade remains tightly bound (Redding et al., 2015), 
while a second study on the type I-E complex from Thermobifida fusca showed 
that Cascade translocates along ssDNA in complex with Cas3 (Dillard et al., 
2018). A better understanding of these discrepancies will yield further 
mechanistic insights into how DNA-activated immunity is ultimately achieved.  
 
1.4.2 RNA-activated CRISPR targeting (Types III and VI) 
Type III CRISPR loci are defined by the presence of the signature Cas10 nuclease 
which organizes with Csm2-5 (type III-A) (Rouillon et al., 2013) or Cmr1,3,4, and 
5 (type III-B)  (Zhang et al., 2012) to form a surveillance complex guided by the 
crRNA (Makarova et al., 2019) (Figure 1.6A). The surveillance complexes of these 
type III systems are unique in that they can degrade both DNA and RNA (Deng 
et al., 2013; Goldberg et al., 2014; Hale et al., 2009; Peng et al., 2015; Samai et al., 
2015; Staals et al., 2014; Tamulaitis et al., 2014; Zebec et al., 2014). This is achieved 
by base pairing between the crRNA and nascent RNA transcripts, which allows 
for non-specific Cas10 DNA binding and activates the single-stranded DNase 
(ssDNase) activity of its HD domain (Kazlauskiene et al., 2016). Type III 
immunity thus requires active transcription across the target DNA in order to 
create RNA targets capable of activating the complex and tethering it to 
DNA(Deng et al., 2013; Goldberg et al., 2014; Liu et al., 2019). The ssDNase 
activity of Cas10 is, however, turned off by the sequence-specific RNase activity 
of Csm3 or Cmr4 that destroys the target RNA bound to the complex, leading to 
Cas10’s deactivation and dissociation from DNA (Kazlauskiene et al., 2016; 
Samai et al., 2015; Staals et al., 2014; Tamulaitis et al., 2014). It is believed that the 
cleavage of the activating transcript both limits the region of DNase activity to 
the area of target transcription and also prevents “off-target” trans cleavage of 
ssDNA that might result in host DNA damage.  
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Figure 1.6. RNA-activated CRISPR targeting.  
The mechanism of action of two prototypical RNA-activated CRISPR-Cas 
targeting complexes. (A) The type III-A targeting machinery has two 
components: the Cas10-Csm complex containing the crRNA, and the HEPN-
domain-containing RNase Csm6. Cas10 has two activities: (1) DNA nicking 
mediated by the HD domain and (2) conversion of ATP to cyclic oligoadenylate 
(cOA) (red diamonds) mediated by the Palm domain. Targeting begins with the 
search for crRNA-matching target RNAs lacking the sequence complementary to 
the crRNA tag (the anti-tag). Binding to the nascent RNA transcripts tethers the 
complex to DNA and activates Cas10’s dual activity. Csm6 is activated by newly 
produced cOA leading to non-specific, global RNA depletion. Csm6 and Cas10 
are deactivated following Csm3 cleavage of the target transcript. (B) The type VI 
targeting machinery is composed of Cas13 and tag-containing crRNA.  Target 
identification leads to HEPN domain allosteric activation, creating a composite 
RNase active-site that leads to non-specific RNA degradation and cell dormancy.   
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 Cas10 has a recently discovered secondary function as an oligonucleotide 
synthetase that converts cytosolic ATP into cyclic oligoadenylates (cOAs) (Figure 
1.6A). This activity is performed by Cas10’s Palm domain following target RNA 
binding to the complex (Kazlauskiene et al., 2017; Niewoehner et al., 2017). cOA 
acts as a second messenger that induces a secondary immune response directed 
by the RNase Csm6 (Kazlauskiene et al., 2017; Niewoehner et al., 2017). The 
presence of cOA is sensed by Csm6’s CRISPR-associated Rossman fold (CARF) 
domain triggering the allosteric activation of its two Higher Eukaryotes and 
Prokaryotes Nucleotide binding (HEPN) domains, thereby creating a composite 
ribonuclease active site that executes non-specific RNA degradation (Jia et al., 
2019a). This results in a global depletion of both host and foreign transcripts, 
causing a growth arrest (Rostol and Marraffini, 2019b) that prevents the 
propagation of the invader (Jiang et al., 2016b) in a manner that resembles the 
activity of toxins in abortive infection (Abi) systems. The potentially toxic effects 
of Csm6 are restricted by three events: (1) Csm3/Cmr4-mediated deactivation of 
Cas10 following cleavage of the activating RNA transcript, which prevents 
further cOA synthesis (Rouillon et al., 2018) (2) degradation of existing cOA by 
host ring nucleases or the Csm6 CARF domain itself (Athukoralage et al., 2018) 
and (3) the ultimate destruction of the invading DNA by Cas10’s ssDNase 
activity, preventing de novo transcription and Cas10 reactivation (Rostol and 
Marraffini, 2019b). 
The Csm6 RNase response is essential when the DNase activity of Cas10 is 
compromised or weakened during the initial type III response. This can occur 
when the target is transcribed at low levels, leading to slower complex 
recruitment (Rostol and Marraffini, 2019b), when the Cas10-Csm complex is 
activated by transcripts expressed late during infection and the phage has 
already replicated too many copies of its genome (Jiang et al., 2016b), or when 
the target contains mismatches with the crRNA that inhibits HD activation (Jiang 
et al., 2016b). It is hypothesized that during these scenarios, the secondary Csm6 
response is compensatory and arrests replication of the invader via the global 
reduction of the host’s and the invader’s transcripts (Rostol and Marraffini, 
2019b). The ensuing growth arrest gives the Cas10-Csm complex the added time 
needed to destroy the invader. 
 Type VI systems, defined by the signature Cas13 nucleases, are the most 
recent CRISPR loci to have their immune response characterized (Makarova et 
al., 2019; Meeske et al., 2019) (Figure 1.6B). Like other class 2 effectors, Cas13 
forms a bilobed structure whose ability to interact with targets is triggered 
following crRNA binding to its central channel (Liu et al., 2017a). Unlike Cas9 
and Cas12, Cas13 lacks a DNase domain and instead contains two conserved 
HEPN domains (Liu et al., 2017a). Following base-pairing with the crRNA, target 
RNA functions as an activator that triggers a conformational change that, similar 
to Csm6/Csx1, induces the allosteric activation of the HEPN domain and creates 
a composite catalytic site capable of non-specific RNase activity (Liu et al., 
2017a). The location of this active site on the outer surface further distinguishes 
Cas13 from Cas9 and Cas12 and facilities trans cleavage of non-target RNAs 
(East-Seletsky et al., 2016; Liu et al., 2017b). In vitro studies have also shown that 
Cas13 is capable of degrading the target RNA responsible for activating it (East-
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Seletsky et al., 2016). These cis-cleavage events of the target RNA are, however, 
not confined to the region of crRNA-target RNA complementarity and their 
mechanistic basis remains unclear.  
Given its crRNA-guided RNase activity, Cas13 was initially hypothesized 
to defend against RNA phages. However, analysis of its associated type VI loci 
revealed that they contained spacers matching dsDNA phages. This raised the 
question of how type VI immunity against DNA parasites could be achieved 
using the cis- and/or trans-RNase activity of Cas13. The answer came in a study 
that examined the consequences of Cas13 trans-cleavage during DNA phage 
infection (Meeske et al., 2019). As with Csm6 in type III systems, Cas13 non-
specific degradation of host and invader transcripts is sufficient to arrest phage 
replication (Meeske et al., 2019), but unlike Csm6, which is deactivated by the 
regulatory RNase Csm3/Cmr4, Cas13 activity is not shut-off (presumably 
because the viral DNA is not degraded and continues to produce target 
transcripts), and the host cell enters a state of dormancy following transcript 
depletion (Meeske et al., 2019). Immunity is therefore passively achieved at the 
population level as infected cells harboring activated Cas13 trap viruses in their 
cytosol, thus preventing viral spread to uninfected sister cells. In addition, by 
inducing prolonged global RNA destruction, type VI systems provide broad 
cross-protection against phage viruses not recognized by the crRNA, including 
CRISPR escapers, that infect concurrently or after Cas13 activation (Meeske et al., 
2019).  
 The requirement for target RNAs to stimulate type III and VI systems 
provides them with the distinct advantage of being able to coexist with foreign 
DNAs under the condition that they remain transcriptionally silent. The best 
example of this conditional tolerance comes from type III-A systems that target 
the lytic genes of temperate phages (Goldberg et al., 2014). As part of their 
lifecycle, temperate phages integrate into the host genome as quiescent 
prophages that actively repress their own transcription. The type III CRISPR 
system cannot recognize a prophage that does not transcribe its target and 
therefore allows the prophage to remain in the host genome. In turn, the 
CRISPR-immune host cell can receive the beneficial phenotypes that accompany 
stable prophage symbiosis (Brüssow et al., 2004). 
 Interestingly, bioinformatic searches have identified many different 
CARF-domain-containing genes associated with type III CRISPR loci (Burroughs 
et al., 2015; Makarova et al., 2014; Shah et al., 2018; Shmakov et al., 2018). These 
genes are predicted to encode a diverse set of proteins, including nucleases, 
kinases, transmembrane domains, and transcription factors, that could be 
involved in foreign nucleic acid defense (Anantharaman et al., 2013; Shah et al., 
2018). This suggests that cOAs produced during CRISPR-Cas10 targeting is a 
signal to activate wide range of uncharacterized immune responses. Indeed, two 
studies have shown that CARF-domain containing nucleases associated with 
type III loci can be activated by either cyclic triadenylates or tetra-adenylates (cA3 
or cA4) (Lau et al., 2020; McMahon et al., 2020). Intriguingly, Cas10 can produce 
multiple cOA isoforms with different ring sizes (Kazlauskiene et al., 2017), 
suggesting that individual, isoform specific effectors may be activated during a 
coordinated immune response. Future structural and in vivo studies will be 
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needed to elucidate the complexity of these novel CRISPR-associated genes and 
the immune response they execute. 
 
1.4.3 Self or Non-self?: avoiding autoimmunity 
The success of any immune system requires a mechanism to distinguish between 
invasive foreign (non-self) elements and its own intrinsic (self) components. For 
CRISPR-Cas systems this represents an especially difficult challenge because the 
“antigenic” sequences they recognize are by definition already present within 
their own loci as spacers in the CRISPR array. How each systems avoids self-
targeting is based on the identity of the nucleic acids that activates it, with DNA-
activated systems (types I, II, V) prioritizing the recognition of non-self (Mojica et 
al., 2009; Semenova et al., 2011; Zetsche et al., 2015) and RNA-activated systems 
(types III and VI) prioritizing the recognition of self (Marraffini and Sontheimer, 
2010; Meeske and Marraffini, 2018). 
DNA-activated Cascade, Cas9, and Cas12 (Figure 1.5) all rely on unique 
PAMs required for initiating targeting binding during their DNA targeting 
responses (Chapter 1.4.1). As a result these complexes only stably interact with 
DNAs that contains both a PAM and a crRNA-matching sequences. Because 
repeat sequences lack PAMs, the spacers within the CRISPR array are protected 
against self-targeting (Mojica et al., 2009). This conservative approach of solely 
interacting with “non-self” DNAs, while well-suited to avoid off-targets, makes 
these immune systems susceptible to rapidly evolving phages that can mutate 
their PAMs and thereby no longer be recognized (Deveau et al., 2010; Pyenson et 
al., 2017; Semenova et al., 2011). Indeed, it may be the selective pressure posed by 
these viral escapers that has driven both type I and type II systems to evolve 
primed spacer acquisition mechanisms to counteract them (Chapter 1.6 and 
Chapter 3). 
The type III and VI RNA-activating CRISPR systems, by contrast, avoid 
autoimmunity by identifying self (Marraffini and Sontheimer, 2010; Meeske and 
Marraffini, 2018) (Figure 1.6). Because transcription of the CRISPR array 
generates RNAs that have the same sequence as, rather than being 
complementary to, the crRNA, auto-activation of these systems can only occur 
after antisense transcription of the CRISPR array: a common phenomenon in 
prokaryotes (Lillestøl et al., 2009). Sensing of self-transcripts is achieved via an 
extended, invariant 5’-region of the crRNA derived from the CRISPR repeat 
known as the “tag” (Marraffini and Sontheimer, 2010; Meeske and Marraffini, 
2018). Base pairing between the tag and its complementary sequence on the 3’ 
end of the target RNA (i.e., the “anti-tag”) is sufficient to identify the RNA as a 
“self” and abort both type III and VI targeting (Marraffini and Sontheimer, 2010; 
Meeske and Marraffini, 2018). Three recent studies on the type III-A systems 
have provided mechanistic insights into this process (Jia et al., 2019b; Wang et al., 
2019; You et al., 2019). Collectively they present a model in which base-paring 
between the tag and anti-tag locks the Csm complex preventing the activation of 
the HD and Palm domains of Cas10, thereby inhibiting both ssDNA degradation 
and Csm6/Csx1 activation during the type III response. Csm3-mediated cis-
cleavage of the anti-tag containing RNA is however permitted thereby releasing 
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the “lock” on the complex and allowing subsequent RNA binding (Kazlauskiene 
et al., 2016; Samai et al., 2015; Staals et al., 2014; Tamulaitis et al., 2014). Structures 
of Cas13 in complex with the anti-tag have yet to be solved but structures of 
Cas13 bound to an activating RNA suggest that base-pairing with the tag may 
similarly interfere with the allosteric activation of its HEPN1 domain (Liu et al., 
2017a). Together these data suggest that RNA-activating systems avoid 
autoimmunity by deliberately inhibiting their own activation when encountering 
a “self-antigen". 
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1.5 Spacer acquisition: the creation of immunologic memory 
The ability of CRISPR-Cas loci to provide an adaptive immune response, capable 
of being continuously updated to target new invader sequences, is unique 
among prokaryotes. CRISPR immunization is achieved by adding new fragments 
of foreign DNA to the CRISPR array as spacers, therein protecting the cell from 
subsequent infection (Barrangou et al., 2007). The CRISPR array can therefore be 
seen as a molecular memory system that holds records of its previous encounters 
with foreign genetic elements. Unlike higher order eukaryotes, the immunologic 
memories generated by CRISPRs are heritable and passed down to daughter 
cells, thereby rapidly transmitting immunity across the microbial community. 
The basis for this powerful and lasting immunization hinges on a two-part 
cleavage-ligation reaction that integrates new spacers into the CRISPR array 
(Arslan et al., 2014; Nunez et al., 2014; Nunez et al., 2015b) (Figure 1.7). Processed 
precursors (pre-spacers) containing two 3’-OH groups on each strand are used 
for a two-step nucleophilic attack on the first repeat of the array catalyzed by 
Cas1 within the Cas1/Cas2 complex. The first nucleophilic reaction likely uses 
the 5’-OH of the pre-spacer to attack the leader-repeat junction, generating a half-
integrated intermediate. A second nucleophilic attack resolves this intermediate 
by ligating the 3’ end of the pre-spacer to a leader-distal site within the repeat. At 
the end of this reaction, the newly integrated, double-stranded spacer is ligated 
to single-stranded repeat DNA, which are then “filled-in” by host DNA repair 
enzymes and polymerases (Arslan et al., 2013; Ivancic-Bace et al., 2015; Nunez et 
al., 2014; Nunez et al., 2015b; Wright and Doudna, 2016; Wright et al., 2017; Xiao 
et al., 2017b; Yosef et al., 2012). For this integration reaction to successfully yield 
immunity the acquisition machinery must first perform three quality-control 
steps: (1) functional DNA sequences that meet the requirements for targeting 
(pre-spacers) must be captured, (2) the 5’-3’ orientation pre-spacer must be 
controlled to ensure the transcription of an targeting crRNA, and finally (3) pre-
spacers must be localized to the CRISPR array for site-specific integration (Figure 
1.7). An almost universal participant in spacer acquisition across CRISPR classes 
and types is the conserved Cas1-Cas2 complex which participates during all 
three aspects of spacer acquisition (Arslan et al., 2014; Makarova et al., 2020; 
Nunez et al., 2014; Nunez et al., 2015b; Wang et al., 2015; Wright et al., 2017). The 
molecular mechanisms used to solve these challenges are among the least 
thoroughly characterized aspects CRISPR immunity. Although considerable 
improvements in our understanding have been made in recent years, spacer 
acquisition in the laboratory setting has yet to be reported for type V, type VI, or 
canonical type III systems, despite the fact that all of these loci encode the 
required cas1 and cas2 genes. The sections below describe the known molecular 
mechanisms and tools used to acquire spacers 
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Figure 1.7. Naïve spacer acquisition.  
The type I and type II naïve spacer acquisition mechanisms against a 
bacteriophage. (A) During type I spacer acquisition functional viral targets (pre-
spacers) are identified by Cas1-Cas2 binding the PAM in type I-E system and 
Cas1-Cas2-Cas4 in type I-A, I-A, -C, -D, and -U. Pre-spacers are then processed, 
creating asymmetric substrates with 3’-OH groups on each strand. The pre-
spacers are localized to the CRISPR array by integration host factor (IHF) which 
introduces a 120° bend in the DNA. (B) In type II spacer acquisition, pre-spacers 
are identified by Cas9 binding to the PAM. The spacer acquisition complex 
(Cas1-Cas2-Csn2) is recruited and pre-spacers are processed creating asymmetric 
substrates with 3’-OH groups on each strand. Csn2 dissociates from the 
acquisition complex and Cas1-Cas2 are localized to the CRISPR array by binding 
the leader-anchoring sequence (LAS). In both types, Cas1 mediates spacer 
integration by carrying out a two-step transesterification reaction that separates 
the first repeat (black diamond) into single-strands. The split repeat is repaired 
and ligated, completing the integration reaction. 
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 In order to generate immunity, acquired spacers must match sequences 
that can be recognized and cleaved by the effector complex. An early question in 
the field was whether CRISPR systems contain an active quality-control 
mechanism that guarantees the selection of these “functional” spacers. 
Alternatively, without any pre-spacer discrimination, cells that acquired non-
functional spacers would be killed by pathogens and disappear from the 
population. A hallmark of the characterized spacer acquisition mechanisms 
(types I and II) is the development of strategies to prioritize the capture of PAM-
flanked pre-spacers. In type I systems, the Cas1-Cas2 complex is composed of 
two Cas1 dimers sandwiching a single Cas2 dimer in a butterfly shaped 
arrangement (Nunez et al., 2014; Wang et al., 2015). In the type I-E subtype, the 
Cas1-Cas2 complex selects functional spacers by directly interacting with the 
PAM sequence via Cas1 (Wang et al., 2015) (Figure 1.7A). Substrate binding 
rearranges the complex, allowing the Cas1 homodimer to trim the respective 
ends of the pre-spacer and generate the 3’-OH groups needed for integration 
(Arslan et al., 2013; Nunez et al., 2014). Cas1-mediated PAM selection is however 
not universal to all type I subtypes. In the Bacillus halodurans type I-C system, 
Cas4 forms a symmetric complex with Cas1-Cas2 (Cas42-Cas14-Cas22) with a 
Cas4 monomer pairing with a Cas1 on each side of the butterfly structure (Lee et 
al., 2019) (Figure 1.7A). In this system, as well in type I-A and -D, Cas1-Cas2 
alone are sufficient to mediate spacer acquisition but, in the absence of Cas4, the 
selection of functional spacers is lost (Lee et al., 2018; Shiimori et al., 2018). Cas4 
ensures spacer functionality by recognizing PAM-containing pre-spacers bound 
by Cas1-Cas2 (Almendros et al., 2019; Lee et al., 2018; Shiimori et al., 2018). These 
PAM-containing pre-spacers are then trimmed at their ends producing ssDNA 
overhangs with 3’-OH groups. In all these systems, quality control is ensured by 
coupling the identification of PAM to pre-spacer processing, thereby allowing for 
the preferential acquisition of functional spacers (Lee et al., 2018; Shiimori et al., 
2018). In addition to type I systems, Cas4 is also found in type II, III, and V loci, 
raising the question of whether Cas4 performs a similar quality-control function 
in spacer acquisition for these systems. 
 In type II-A systems, the spacer acquisition machinery comprises of Cas1, 
Cas2, Csn2, and the Cas9:tracr:crRNA complex, all of which are required for 
spacer acquisition in vivo (Heler et al., 2015; Wei et al., 2015b) (Figure 1.7B). Here, 
selection of PAM-containing pre-spacers is performed by Cas9 with the same 
PAM-interacting residues used to identify the PAM during target DNA cleavage 
(Heler et al., 2015). The pre-spacer is then presumably handed off to the Cas1-
Cas2 sub-complex, where it is processed prior to integration, although 
mechanistic details of this transition have yet to be elucidated. Notably, spacer 
acquisition can occur when Cas9’s dsDNase activity of Cas9 is eliminated 
(dCas9), and therefore Cas9 cleavage is not essential for function during pre-
spacer capture (Heler et al., 2015; Wei et al., 2015b). How the third member of the 
type II spacer acquisition complex, Csn2, fits into this model has remained 
mysterious. In vitro integration reactions with S. pyogenes Cas1-Cas2 are inhibited 
in the presence of Csn2 (Wright and Doudna, 2016), suggesting that it is not part 
of the complex when pre-spacers are integrated into the CRISPR array. This, 
combined with genetic and structural data showing that two Csn2 tetramers 
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form a channel that threads dsDNA ends (Arslan et al., 2013; Bernheim et al., 
2017; Wilkinson et al., 2019), suggests that Csn2 may traffic Cas1-Cas2 to PAM-
containing pre-spacers identified by Cas9.  
 The type III system requires its targets to be transcribed in order to 
provide full immunity. This requirement therefore presents a unique problem for 
the type III spacer acquisition machinery: how to prioritize the acquisition of the 
spacers from actively transcribed regions? The Marinomonas mediterranea type III-
B system has ingeniously solved this problem by fusing a reverse transcriptase 
(RT) domain to Cas1, allowing it to capture transcripts, integrate them into the 
array first as ssRNA spacers, and then convert them to cDNAs (Silas et al., 2016). 
Bioinformatic studies have recently uncovered several type VI loci that contain 
RT-Cas1 fusions (Toro et al., 2019) suggesting that this strategy may also have 
been adopted by these systems. The vast majority of conventional type III 
systems however lack RT-Cas1 fusions (Makarova et al., 2019). This raises the 
question of whether these systems bias their spacer acquisition toward 
transcriptionally active sites or simply rely on negative selection to remove non-
functional spacers from the population. 
 All Cas1-Cas2 complexes seem to use free DNA ends as the substrates for 
pre-spacers. These free ends originate by dsDNA breaks that occur at the origin 
of replication of plasmids and phages (Levy et al., 2015) or at the ends of the 
phage genome injected during infection (Modell et al., 2017). For type I and II 
systems, this bias has been shown to help avoid the acquisition of self-targeting 
spacers derived from the host chromosome, since these are circular DNA 
molecules that replicate relatively infrequently compared with multi-copy 
plasmids and phages (Levy et al., 2015). As a consequence of this, deleterious 
self-acquisition from host chromosome events preferentially occur at the 
terminus and at highly transcribed genes such as ribosomal RNAs (Shiimori et 
al., 2017), regions that often accumulate dsDNA breaks and therefore contain free 
DNA ends. 
 A striking feature of CRISPR arrays across types is the relatively constant 
length of spacers, implying that it is fixed prior to integration. Structural studies 
on the E. coli Cas1-Cas2 complex have demonstrated that the length of the spacer 
is intrinsically set by the distance between the two Cas1 homodimers that flank 
the complex (Nunez et al., 2015a; Wang et al., 2015). Whether the Cas1-Cas2 
complex acts as the molecular ruler for other systems’ spacers is unknown but 
uncovering the basis of spacer length will undoubtedly provide further insights 
into how pre-spacers are processed.  
 In order to ensure the transcription of functional crRNAs, newly acquired 
spacers must be oriented properly so that they match their targets. For all DNA-
activated CRISPR-Cas systems, spacer orientation is likely determined in part by 
the presence of the PAM in pre-spacers captured by Cas1-Cas2. In the Cas4 
containing type I systems, differential single-stranded trimming of the PAM-
containing and PAM-lacking ends of the pre-spacer creates an asymmetric 
substrate that can be used to determine the spacer orientation (Lee et al., 2018; 
Shiimori et al., 2018) (Figure 1.7A). In the Pyrococcus furiosus type I-A system, this 
asymmetry is additionally reinforced by using two distinct Cas4 genes (cas4-1 
and cas4-2), each providing unique sequence specificity (Shiimori et al., 2018). 
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Whereas Cas4-1 recognizes the PAM, Cas4-2 recognizes a NW motif on the 
opposite side of the pre-spacer. Each of these sequence motifs are then used as 
molecular rulers to determine the length of 3’-overhangs generated by both Cas4 
proteins. In both type I and II systems that lack Cas4, PAM sequences must also 
be removed prior to spacer integration, implying the existence of similar PAM-
processing steps. For type I-E systems, recent in vitro studies have suggested that 
asymmetry is generated due to Cas1 binding and protecting the PAM proximal 
end of the prespacer while host 3’-5’ exonucleases trim the PAM-distal end (Kim 
et al., 2020; Ramachandran et al., 2019). This is in agreement with the finding that 
in Streptococcus thermophilus Cas2 is fused with an exonuclease DnaQ-like 
domain that aids in the maturation of prespacers (Drabavicius et al., 2018). 
Additionally, how spacer orientation is coordinated in RNA-activated CRISPR 
systems that lack PAMs is completely unknown. Notably, when the M. 
mediterranea type III-B system that harbors RT-Cas1 is heterologously expressed 
in E. coli or used for in vitro integration reactions, it integrates spacers in both 
directions (Silas et al., 2016). This suggests that additional factors biasing spacer 
orientation, yet undiscovered, are present in the natural host.  
 Once pre-spacers have been captured and oriented according to the 
location of the PAM, they must be brought to the CRISPR array for integration. 
Specific integration is particularly important to prevent the genomic instability 
that would be generated from non-specific integration of viral sequences 
elsewhere in the host chromosome (Wright and Doudna, 2016). Cas1 is believed 
to have evolved from an ancestral transposase (Casposon) (Krupovic et al., 2017), 
and therefore its domestication from a non-specific to an array-specific integrase 
represents a pivotal moment in CRISPR-Cas evolution. An early clue for how this 
specificity is achieved came from the observation that spacer acquisition is 
polarized; with new spacers successively added to the leader end of the array 
(Barrangou et al., 2007). The explanation for both of these phenomena comes 
from the intrinsic specificity of Cas1 for sequences at the leader-repeat junction. 
In type II systems this sequence, known as the leader-anchoring sequence (LAS), 
is essential for polarized acquisition (McGinn and Marraffini, 2016; Wei et al., 
2015a). Absence of a LAS in either engineered bacteria (McGinn and Marraffini, 
2016) or naturally occurring mutants (Wright and Doudna, 2016), results in 
ectopic integration of spacers at LAS-like sites in the CRISPR array. In the type I-
E system, a leader sequence also specifies polarized integration, but here the host 
integration factor (IHF) protein is also required (Nunez et al., 2016). IHF binds 
the leader sequence and generates a 120° bend in the DNA, inducing Cas1-Cas2 
binding and spacer integration (Yoganand et al., 2017). It has been hypothesized 
that the bent leader-repeat site may create an ideal integration target for the Cas1 
integrase but exactly how this topology promotes spacer acquisition is unclear. 
Notably bacteriophages, transposases, and mammalian retroviruses all 
preferentially integrate at bent target sites (Muller and Varmus, 1994). IHF is, 
however, not present in gram-positive bacteria or many archaea, suggesting that 
these organisms have repurposed other DNA-bending factors for integration or 
depend solely on Cas1-Cas2 intrinsic specificity. Interestingly, polarized 
acquisition has potential long-term consequences for immunity, as the first 
spacer in the CRISPR array provides the strongest defense (McGinn and 
Marraffini, 2016). Transcriptional profiling of several CRISPR loci revealed that 
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spacers located closer to the leader end are transcribed to higher levels resulting 
in higher amounts of leader-proximal crRNAs (Deltcheva et al., 2011; Hale et al., 
2008), and therefore it has been hypothesized that this results in enhanced 
immunity (McGinn and Marraffini, 2016). 
 After the pre-spacer has been localized and undergone its first 
transesterification reaction at the leader-repeat junction, the second nucleophilic 
attack has to take place in the repeat. This step is vital for ensuring proper 
placement of the spacer within the array and to guarantee that the repeats are 
duplicated correctly following integration. Multiple studies in both type I and II 
systems have shown that the decision of where to anchor the spacer is dictated 
by sequence motifs at the distal end of the repeat (Goren et al., 2016; Wang et al., 
2016). These sequences are believed to act as molecular rulers that specify where 
the second nucleophilic attack occurs. Recent structural studies of the type II-A 
Cas1-Cas2 complex bound to the repeat during integration indicate that the 
Cas1-Cas2 complex induces sequence-independent bending that is necessary for 
positioning the Cas1 active site during spacer placement (Xiao et al., 2017b). 
Future studies will be needed to resolve the interplay between these “ruler 
motifs” and the complicated structural gymnastics that guide Cas1-Cas2 spacer 
insertion. Finally, the characterization of the steps that occur after spacer 
integration and that lead to complex disassembly and repeat duplication is still 
needed to complete our understanding of spacer acquisition. 
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1.6 crRNA-directed “primed” spacer acquisition in the type I CRISPR-Cas 
systems 
The sequence-specificity of CRISPR-Cas immunity makes it vulnerable to escape 
by rapidly evolving invaders such as bacteriophages that can mutate the target 
sequences recognized by the crRNA. Indeed, escaper viruses rapidly emerge 
within hours of infection of monoclonal CRISPR-immune hosts with a single 
targeting spacer (Pyenson et al., 2017). As a result, many targeting spacers must 
be present in the population to produce sterilizing immunity that eliminates the 
existing bacteriophages and prevents the emergence of new escaper viruses (van 
Houte et al., 2016). In order to rapidly acquire a diverse pool of spacers, CRISPR 
systems have developed a third phase to their immune response known as 
primed spacer acquisition or priming. CRISPR priming utilizes preexisting 
spacers already present in the array to mediate further spacer acquisition 
(Nussenzweig et al., 2019; Semenova et al., 2011). Thus, priming is able to 
enhance the rate of spacer acquisition by using the crRNA to direct the 
acquisition machinery to the invaders’ nucleic acids. Furthermore, by selectively 
biasing spacer acquisition to foreign nucleic acids, priming may limit acquisition 
of DNA from the host chromosome and avoid self-targeting. Primed spacer 
acquisition has been reported extensively in type I systems. Here we review the 
molecular mechanisms of type I priming.   
 Type I priming (Figure 1.8) has been observed in multiple CRISPR 
systems, with the E. coli type I-E and the potato bacterium Pectobacterium 
atrosepticum type I-F systems being the most thoroughly characterized to date. In 
both systems, mutations that diminish the ability of Cascade to form an R-loop 
with the target sequence stimulate the priming response (Datsenko et al., 2012; 
Fineran et al., 2014; Richter et al., 2014). As a result, CRISPR escapers with 
mutations in either the PAM or target sequence are subject to primed spacer 
acquisition (Datsenko et al., 2012). The mechanistic basis for the primed spacer 
response against these targets is dependent on recruitment of the Cas1-Cas2 
complex to Cascade (Redding et al., 2015). If R-loop formation is impaired by 
mutations at the PAM or target sequence, Cas3 recruitment is abrogated, 
allowing Cas1-Cas2 to arrive before Cas3 and act as a negative regulator of Cas3 
nuclease activity (Redding et al., 2015; Rollins et al., 2015). Cas1-Cas2 and Cas3 
then translocate together along the non-targeted strand as a “primed acquisition 
complex” (PAC) (Dillard et al., 2018; Redding et al., 2015). Cas3-dependent 
translocation of Cas1-Cas2 along ssDNA therefore provides an elegant 
explanation for the strand bias observed during type I priming (Datsenko et al., 
2012; Swarts et al., 2012). In agreement with this, in the type I-B system, in which 
Cas3 can be loaded onto either strand, priming yields spacers from both strands 
(Li et al., 2014). Notably, primed spacer acquisition has also been observed in the 
presence of perfectly matching targets with canonical PAMs but at lower rates 
than priming against imperfect targets (Semenova et al., 2016; Staals et al., 2016; 
Xue et al., 2015). This may be explained by the fact that when Cascade is bound 
to perfect targets, Cas3 is likely recruited before Cas1-Cas2 and rapidly destroys 
the target before robust spacer acquisition can occur. In support of this model, 
inhibition of Cas3 nuclease activity with a phage derived CRISPR inhibitor can 
increase the rate of primed spacer acquisition against a perfect target (Staals et 
al., 2016). Interestingly, in type I-F, Cas2 and Cas3 are fused, further suggesting a 
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functional link between DNA destruction and spacer acquisition (Fagerlund et 
al., 2017; Rollins et al., 2017). A fundamental question left unanswered by this 
model is how pre-spacers are generated following Cas1-Cas2-Cas3 translocation 
away from Cascade. Crucially, Cas3-mediated target degradation is capable of 
producing DNA fragments with the characteristic asymmetric structure needed 
for functional spacer acquisition (see Chapter 1.5), implying that Cas3 directly 
participates in pre-spacer production (Künne et al., 2016; Shiriaeva et al., 2019). If 
Cas3 activity is required for spacer acquisition, how is the nuclease reactivated 
following Cas1-Cas2 inhibition? One possibility is that collisions between the 
PAC and DNA-binding proteins stall its translocation and allow sufficient time 
for Cas3 to reactivate and produce DNA breaks (Dillard et al., 2018). 
Alternatively, the inherent ability of Cas1-Cas2 to recognize PAMs may cause the 
PAC to stall at PAMs and allow for Cas3-mediated pre-spacer generation.  
 
 
Figure 1-8. Primed spacer acquisition in the type I CRISPR-Cas system.  
The mechanism of spacer acquisition in type I CRISPR-Cas systems. In the type I-
E system, Cascade binds PAM-containing targets and Cas3 associates with the 
complex prior to Cas1-Cas2 recruitment. The primed spacer acquisition complex 
(PAC) forms and translocates unidirectionally producing substrates (pre-spacers) 
(colored squares) for spacer acquisition from one strand. 
 
 A central question in type I priming is how Cascade chooses to either 
recruit Cas3 and engage in DNA targeting or recruit Cas1-Cas2 and engage in 
spacer acquisition. One “conformation controlled” model based on structural 
and single-molecule studies proposes that Cascade enters into a priming-specific 
state during primed spacer acquisition (Blosser et al., 2015; Redding et al., 2015). 
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In this model, the Cse1 subunit of Cascade has an “open” conformation in the 
presence of mismatched targets or mutant PAMs which promotes Cas1-Cas2-
dependent recruitment of Cas3 for priming (Xue et al., 2015; Xue et al., 2016). In 
addition, a distinct, “locked”, state recruits Cas3 to perfect targets for their 
destruction (Blosser et al., 2015; Redding et al., 2015). Alternatively, a model that 
does not rely on alternative conformations has been proposed in which targeting 
and priming are the results of the same DNA destroying pathway (Semenova et 
al., 2016). This second model is based on two findings. First, when priming is 
stimulated against perfect and imperfect targets the same pattern of spacer 
acquisition is generated (Semenova et al., 2016), suggesting that there is no 
functional distinction in how Cascade interacts with these targets. Second, target 
mutations that differentially affect Cascade’s ability to form R-loops, and 
presumably enter the “locked” confirmation, do not correlate with differences in 
the efficiency of priming against these targets (Krivoy et al., 2018; Musharova et 
al., 2019). In this alternative, “kinetically controlled”, model of priming, 
imperfect targets produce more potent priming solely because they are destroyed 
less rapidly and are therefore more readily available to the acquisition machinery 
(Semenova et al., 2016). Future work will be needed to distinguish between these 
two competing models.  
 
1.7 Studying type II-A spacer acquisition in a Staphylococcus aureus 
heterologous system 
 
When this work began the use of the gram-positive bacterium Staphylococcus 
aureus as a model organism to study CRISPR-Cas immune systems had been well 
established by our laboratory (Goldberg et al., 2014; Heler et al., 2015; Marraffini 
and Sontheimer, 2008). In these studies, the native Streptococcus pyogenes SF370 
type II-A CRISPR-Cas locus and the native RP62a type III-A CRISPR-Cas locus 
were individually cloned into plasmid vectors (pCRISPRs) (Goldberg et al., 
2014). In addition, Drs. David Bikard and Wenyan Jiang had together developed 
parental pCRISPR vectors that had their endogenous CRISPR arrays replaced 
with simplified arrays containing a single set of repeats flanking a placeholder 
spacer with two oppositely oriented BsaI restriction sties (pCRISPR-BsaI) (Jiang 
et al., 2013). This allowed for the programing of pCRISPR systems with a spacer 
of interest following digestion of pCRISPR-BsaI vectors with BsaI and ligation 
with annealed oligonucleotides containing BsaI-compatible overhangs.  
The laboratory strain derived from NCTC8325, RN4220 (Nair et al., 2011) 
was selected to carry these pCRISPRs. The rationale for the use of RN4220 is 
based on three features of this cell line: (1) it lacks functional restriction-
modification (R-M) systems allowing it to be easily transformed with plasmids 
and genetically manipulated, (2) it has been cured of all its prophages making it 
highly susceptible to bacteriophage infection, and (3) it lacks endogenous 
CRISPR-Cas systems allowing the immunity provided by heterologously 
expressed pCRISPRs to be examined in isolation (Nair et al., 2011). Genetic 
manipulation and phage infection of S. pyogenes SF370 by contrast was 
significantly more difficult and, at the time, our lab lacked the genetic tools and 
phages to carry out such work. 
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 An equally important component for this model system was the isolation 
of phages capable of infecting these pCRISPR-containing RN4220 derivates and 
activating the CRISPR-Cas immune response. In this respect, I was very 
fortunate for the work of Dr. Gregory Goldberg who had, shortly before I had 
joined the lab, isolated strictly lytic variants of the staphylococcal temperate 
phages ΦNM1 and ΦNM4 (known as ΦNM1γ6 and ΦNM4γ4 respectively) 
(Goldberg et al., 2014) that were originally present in the S. aureus Newman 
chromosome as prophages (Bae et al., 2006).  Finally, it was experimentally 
validated by Dr. Robert Heler that these lytic phages could elicit naive spacer 
acquisition in RN4220 containing pCRISPRs derived from the wild-type SF370 
locus that lacked any pre-exiting immunity to these phages (Heler et al., 2015). 
Robert also developed an assay to assess the acquisition of new spacers into the 
SF370 type II-A locus via PCR amplification of the pCRISPR array (Heler et al., 
2015).  This previous work established an ideal model system to investigate type 
II-A spacer acquisition in vivo. In brief, RN4220 containing pCRISPRs were 
infected in liquid culture or soft agar with ΦNM1γ6 and/or ΦNM4γ4 and then 
assayed for de novo spacer acquisition via PCR (Figure 1.9) (Heler et al., 2015).  
Thus, I was given an ideal platform from which to explore the central question of 
my thesis: how CRISPR-Cas9 targeting affects de novo spacer acquisition. 
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Figure 1.9. The S. aureus model system for studying type II-A CRISPR-Cas 
immunity 
A schematic of showing the experimental model system used in this work to 
study type II CRISPR-Cas immunity. The SF370 S. pyogenes type II-A CRISPR-Cas 
locus is located on a plasmid that expresses the cas genes and crRNA. This 
system is capable of both spacer acquisition and DNA targeting against lytic 
staphylococcal phages leading to the destruction of the phage. 
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CHAPTER 2: CAS9 CLEAVAGE OF VIRAL GENOMES GENERATES 
IMMUNOLOGICAL MEMORIES 
 
2.1 CRISPR immune cells acquire additional spacers 
Recently we discovered that spacer acquisition in this system has a marked 
preference for linear dsDNA ends (Modell et al., 2017). Since it is well established 
that these are also the products of Cas9 cleavage both in vivo (Garneau et al., 
2010) and in vitro (Gasiunas et al., 2012; Jinek et al., 2012), we decided to 
investigate if type II-A CRISPR-Cas targeting of phage invaders could lead to 
spacer acquisition in cultures that are already immune. To test this, the native 
CRISPR array of pCRISPR was replaced with a single-spacer array containing 
spacer 174 [pCRISPR(spc174); the sequences of all spacers used in this study are 
compiled in Table 4.5], a spacer commonly acquired by this heterologous system 
following infection with the staphylococcal phage ΦNM4γ4 (Figure 2.1A) (Heler 
et al., 2019). As a control, we utilized a pCRISPR(SR) harboring a single-repeat 
CRISPR locus; i.e. lacking a pre-existing spacer (we were concerned that possible 
off-target effects of a “non-targeting” spacer could invalidate it as a negative 
control). One caveat of this approach is the possibility of a cis effect of the pre-
existing spacer on the integration of new ones, which could lead to differences of 
spacer acquisition due to divergent levels of spacer integration into the “regular” 
vs. “single-repeat” CRISPR loci.  
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Figure 2.1. Immune cells acquire can additional spacers upon infection. 
Staphylococcal phage ΦNM4γ4 genome and the Cas9 targets analyzed in this 
study. (B) Staphylococci harboring pCRISPR(spc174) that targets the phage 
ΦNM4γ4 and pCRISPR(SR) were infected (+) or mock-infected (-) for 30 minutes 
and their DNA purified to amplify the CRISPR locus. PCR products were 
separated by gel electrophoresis to detect the acquisition of new spacers. Grey 
and black arrows: non-expanded and expanded, respectively, CRISPR arrays. (C) 
Fraction (%) of spacer sequences matching to the genome of phage ΦNM4γ4 
detected in the PCR product of the expanded CRISPR array of staphylococci 
harboring either pCRISPR(spc174) or pCRISPR(SR). Mean ± StDev values of three 
independent experiments are shown. (D-H) Distribution of new spacer 
sequences detected 30 minutes after infection of staphylococci expressing Cas9 
programmed to cleave the targets shown in (A). Reads per million of phage reads 
(RPMphage) are mapped to 1 kb bins of the ΦNM4γ4 genome (shown in linear 
form, with the specified target in the center). Average curve of three independent 
experiments is shown. 
 
 To avoid spacer integration biases, we deleted part of the leader sequence 
in both plasmids (generating pCRISPR(spc174)DL and pCRISPR(SR)DL, Figure 
2.2B-C), a mutation that prevents the integration of new spacers (Figure 2.2D) in 
cis. We then transformed the cells with a second plasmid containing only the 
leader sequence and a single repeat (pLR), which will enable spacer acquisition 
in trans into genetically equivalent CRISPR loci (Figure 2.2B-D). We corroborated 
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efficient targeting by spc174 in this dual plasmid system (Figure 2.2E) and 
proceeded to test our hypothesis. Cells carrying either sets of plasmids were 
infected with ΦNM4γ4, collected 30 minutes after infection for plasmid DNA 
extraction and amplification of its CRISPR locus. In line with previous 
observations that type II systems acquire spacers preferentially from free DNA 
ends, we detected an expansion of the CRISPR array (Figure 2.1B). This result 
demonstrated that not only naïve cells, which must acquire new spacers to 
survive infection, but also immune cells, which a priori do not need extra spacers 
to destroy the phage, can generate new CRISPR memories. 
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Figure 2.2: Design of a two-plasmid system for the study of the effect of pre-
existing spacers in type II-A CRISPR-Cas spacer acquisition 
(A) Type II-A CRISPR-cas locus of S. pyogenes SF370. White rectangles, CRISPR 
repeats; colored and numbered rectangles, spacers; “L”, leader sequence; blue 
arrows, protein-coding genes; yellow arrow, tracrRNA gene. (B) 
pCRISPR(spc174) was generated by cloning the S. pyogenes SF370 type II-A 
CRISPR- cas locus into the staphylococcal pC194 vector, and the 6-spacer CRISPR 
array replaced with a single-spacer array harboring the spc174 sequence. 
pCRISPR(spc174)DL was generated after the deletion of the leader, which 
prevents spacer acquisition. To enable the capture of new spacers, a second 
plasmid (pE194) containing only the leader and a single repeat was added. 
Arrows indicate priming sites of oligonucleotides used to detect spacer 
acquisition via PCR. (C) To generate a “no pre-existing spacer” control, 
pCRISPR(SR)DL was constructed, which contains only a single repeat sequence. 
(D) Detection of spacer acquisition by agarose gel electrophoresis of PCR 
products obtained with primers and plasmid templates shown in (B) and (C). 
Grey and black arrows: non-expanded and expanded, respectively, CRISPR 
arrays. (E) Comparison of the efficiency of plaquing (EOP) of ΦNM4γ4 on 
staphylococci carrying pCRISPR plasmids programmed with spacers 174, 256, 
300, 303 and 305, or without a spacer (SR). Mean ± StDev values of three 
independent experiments are shown.  
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2.2 Pre-existing spacers determine the pattern of spacer acquisition 
Next, we wanted to determine how the presence of a targeting spacer influences 
the acquisition of additional ones. To do this, we compared spacer acquisition in 
cells carrying pCRISPR(spc174)DL or pCRISPR(SR)DL. Both strains were infected 
with ΦNM4γ4, pLR was extracted, the new spacers amplified and the products 
subject to next-generation sequencing. Analysis of the data indicated a striking 
difference in the acquisition of new spacers from the phage genome, with the 
presence of the pre-existing spacer spc174 resulting in ~ 30-fold more anti-viral 
spacer acquisition (Figure 2.1C). We then mapped the acquired spacers and their 
abundances along the ΦNM4γ4 genome. We found that, in the presence of 
spc174, the new spacers clustered around the targeting site (tgt174, Figure 2.1D). 
We corroborated this finding by investigating the sequences acquired in the 
presence of four different targeting spacers, spc256, spc300, spc303 and spc305 
(Figure 2.1A). All these spacers provided efficient immunity against ΦNM4γ4 
(Figure 2.2E) and, although not as striking as the peak generated at the tgt174 
site, we observed distinguishable spacer acquisition peaks at the targets of all of 
them (Figure 2.1E-H). Together these results show that the presence of a pre-
existing spacer not only increases dramatically the spacer acquisition rate, but 
also determines the genomic location of the new spacers. 
 
 
2.2.1 The isolation of spc174 mutant escaper phages 
To investigate the molecular mechanisms behind the enhanced spacer acquisition 
observed in immune cells that already contain a functional spacer, we decided to 
test if its targeting capabilities are required. Therefore we looked for phages that 
were able to escape spc174 immunity. We analyzed 30 escaper plaques and, as 
previously described for type II CRISPR-Cas systems (Deveau et al., 2008; 
Pyenson et al., 2017), we found two types of mutations: within the seed region 
within the protospacer or within the PAM sequence immediately flanking the 
protospacer (Figure 2.3A-B).  
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Figure 2.3. Analysis of phages that evade spc174-mediated CRISPR immunity.  
(A) Agarose gel electrophoresis of PCR products obtained after amplification of 
the tgt174 region of 30 different ΦNM4γ4 “escapers”. (B) Summary of the tgt174 
sequences within the PCR products shown in (A), with the mutations in the PAM 
or seed sequences highlighted.  
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2.2.2 PAM, but not seed, target mutations abrogate spacer-mediated spacer 
acquisition 
We isolated one mutant phage containing each mutation, ΦNM4γ4174-seed and 
ΦNM4γ4174-PAM (Figure 2.4A), and corroborated that indeed they are able to 
propagate in staphylococci harboring pCRISPR(spc174) (Figure 2.4B). Therefore 
these two phages have partially matching sequences with a pre-existing spacer 
but cannot be targeted. We infected cells containing pCRISPR(spc174) and pLR 
plasmids with these two mutant phages, plated the phage-resistant staphylococci 
and analyzed ten colonies for the presence of new spacers via PCR of the pLR 
plasmid. As a control, we infected cells lacking the targeting spacer, harboring 
pCRISPR(SR). We performed this experiment four times and consistently 
observed that only a few colonies acquired new spacers after infection with 
ΦNM4γ4174-PAM (Figure 2.5A), similar to the no-spacer control (Fig. Figure 2.5B). 
In contrast, most of the colonies surviving infection with ΦNM4γ4174-seed acquired 
new spacers (Fig. S3C), many more than the control strain (Fig. S3D). 
Quantification of these data showed a significant increase of the frequency of 
spacer acquisition from the ΦNM4γ4174-seed in the presence of spc174, but not from 
the ΦNM4γ4174-PAM phage (Fig. 2C). Finally, we amplified the expanded pLR loci 
in bulk and subjected the resulting PCR products to next-generation sequencing 
(NGS) to determine both the abundance and the distribution of the newly 
acquired spacers on the phage genome. Similarly to the colony analysis, deep 
sequencing results showed a marked increase in the proportion of ΦNM4γ4174-
seed-derived spacers compared to ΦNM4γ4174-PAM-derived spacers (Fig. 2D). 
Mapping of the reads showed that, similarly to the new spacers generated from 
wild-type ΦNM4γ4, acquired spacers from ΦNM4γ4174-seed cluster around the 
spc174 target (Figure 2.4E). Although qualitatively similar, spacer acquisition 
from wild-type ΦNM4γ4 and ΦNM4γ4174-seed are quantitatively different, with 
approximately a 10-fold increase in the acquisition frequency during infections 
with the wild-type phage. The pattern of spacer capture from the ΦNM4γ4174-PAM 
phage in the presence of spc174, however, is indistinguishable from the pattern of 
a no spacer control (Figure 2.4F); i.e., is not enhanced by the presence of a 
matching spacer. 
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Figure 2.4. PAM, but not seed, target mutations, abrogate new spacer 
acquisition in immune cells.  
(A) ΦNM4γ4 variants containing different tgt174 sequences: wild-type, PAM 
(AGG>ATG) and seed (A-3>G-3). (B) Propagation ability of the three ΦNM4γ4 
variants described in (A) on staphylococci harboring pCRISPR(spc174), measured 
as efficiency of plaquing (EOP). Mean ± StDev values of three independent 
experiments are shown. (C) Spacer acquisition rate after infection with different 
ΦNM4γ4 phages containing mutations in either the PAM or seed of tgt174, 
measured as the fraction of cells [harboring either pCRISPR(spc174) or 
pCRISPR(SR)] that survive infection through the acquisition of a new spacer. 
Mean ± StDev values of three independent experiments are shown. (D) Fraction 
(%) of spacer sequences matching to the genome of phage ΦNM4γ4 detected in 
the PCR product of the expanded CRISPR array of staphylococci harboring either 
pCRISPR(spc174) or pCRISPR(SR) after infection with different ΦNM4γ4 phages 
containing mutations in either the PAM or seed of tgt174. Mean ± StDev values 
of three independent experiments are shown. (E) Distribution of new spacer 
sequences detected in (D) in cells harboring pCRISPR(spc174), measured as 
spacer reads per million of total reads (RPMtot), and mapped to 1 kb bins of the 
ΦNM4γ4 genome (shown in linear form, with tgt174 in the center). Average 
curve of three independent experiments is shown. (F) Same as (E), but after 
analysis of bacteria harboring pCRISPR(SR). 
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Figure 2.5. Analysis of spacer acquisition in bacteriophage-insensitive mutant 
(BIM) colonies.  
S. aureus RN4220 harboring different CRISPR plasmids were infected with 
different variants of ΦNM4γ4 phage, mixed with top agar on plates and 
incubated for 24 hours to isolate BIM colonies. Four independent experiments 
were performed for each host/phage combination. The total number of BIM 
colonies were counted in each plate and ten were selected to detect the 
acquisition of new spacers by PCR. The results of the agarose gel electrophoresis 
are shown. “c” indicates a lane where a PCR product corresponding to the 
CRISPR array uninfected cells was loaded as a negative control. The lane 
immediately to the right of the control lane contains molecular markers. The PCR 
results were used to calculate the fraction of BIM colonies that survived through 
the acquisition of a new spacer (CRISPR BIMs). This fraction was multiplied by 
the total number of BIM colonies per plate and divided by the total number of 
cells infected in the experiment to obtain the spacer acquisition rate. Finally, the 
values obtained in each experiment where used to calculate the mean and 
standard deviation of the spacer acquisition rate for each host/phage 
combination: (A) pCRISPR(spc174)∆L/pSR + ΦNM4γ4PAM , (B) 
pCRISPR(SR)∆L/pSR + ΦNM4γ4PAM , (C) pCRISPR(spc174)∆L/pSR + 
ΦNM4γ4seed , (D) pCRISPR(SR)∆L/pSR + ΦNM4γ4seed.  
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2.2.2 Target orientation does not affect the pattern of spacer acquisition 
 
Our findings resemble the “priming” effect of pre-existing spacers observed 
during the type I CRISPR-Cas immune response (Datsenko et al., 2012). Similarly 
to our results, the presence of a pre-existing spacer enhances the rate of 
acquisition of new spacers, which tend to cluster in the vicinity of the 
protospacer sequence (Staals et al., 2016). An outstanding feature of type I 
priming is the orientation bias of the acquired sequences: most of the 
protospacers that correspond to the new spacers are either located in the same 
DNA strand as the priming protospacer (defined as the strand that anneals to the 
crRNA) (Datsenko et al., 2012; Swarts et al., 2012) or in opposite strands at the 5’ 
or 3’ of the target site (Staals et al., 2016; Westra et al., 2015). Therefore we 
decided to check whether type II priming displays a similar orientation bias. 
Analysis of the new spacers acquired as a result of spc174 priming showed a 
marked strand bias, both during targeting (infection with wild-type ΦNM4γ4, 
Figure 2.6A) and non-targeting (infection with ΦNM4γ4174-seed, Figure 2.6B) 
conditions.  
 
 
Figure 2.6. Strand bias of spc174-mediated spacer acquisition.  
(A) Abundance of the spacer sequences acquired after infection of staphylococci 
carrying pCRISPR(spc174) with ΦNM4γ4, measured as spacer reads per million 
of total reads (RPMtot), mapped to 1 kb bins of either the top or bottom strands 
of the phage genome (shown in linear form, with tgt174 in the center). Average 
curve of three independent experiments is shown. (B) Same as (A) but after 
infection with ΦNM4γ4seed. 
 
If there is orientation bias as in type I priming, relocating the target of spc174 on 
the opposite strand would reverse the observed strand bias. We unsuccessfully 
attempted to introduce the spc174 protospacer in the opposite strand of 
ΦNM4γ4, most likely because the resulting phages are not viable (data not 
shown). Therefore we decided to investigate the orientation bias during priming 
by spc256 (Figure 2.1E), which targets a non-essential region of ΦNM4γ4 that can 
be reversed without loss of viral titers (Figure 2.7A-B). This spacer targets a 
protospacer located in the bottom strand of the ΦNM4γ4 genome. Similarly to 
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spc174, spc256 priming showed a strong strand bias, with most new spacers 
acquired having matching protospacers in the bottom strand (Figure 2.7C). 
When the target was relocated to the top strand in the mutant phage 
ΦNM4γ4256rev, however, the newly acquired spacers still matched bottom-strand 
protospacers (Figure 2.7D). Therefore, as opposed to priming in type I CRISPR-
Cas systems, type II priming lacks an orientation bias. 
 
Figure 2.7. Target orientation does not affect the pattern of spacer acquisition. 
 (A) The sequence of tgt256 on the ΦNM4γ4 genome (orange box, the line marks 
the PAM) was reversed in the ΦNM4γ4256rev mutant virus to allow annealing of 
the crRNA generated by spc256 to the other strand of the phage genome. (B) 
Comparison of the efficiency of plaquing (EOP) of ΦNM4γ4 on staphylococci 
carrying pCRISPR(spc256) of both phages shown in (A). Mean ± StDev values of 
three independent experiments are shown. (C) Distribution of new spacer 
sequences acquired after infection of staphylococci carrying pCRISPR(spc256) 
with ΦNM4γ4, measured as spacer reads per million of total phage reads 
(RPMphage), and mapped to 1 kb bins of either the top or bottom strands of the 
phage genome (shown in linear form, with tgt256 in the center). Average curve of 
three independent experiments is shown. (D) Same as (C) but after infection with 
ΦNM4γ4256rev. 
 
2.3 Target DNA cleavage is required for type II primed spacer acquisition 
The distribution of the new spacers acquired through type II priming, narrowly 
centered at the target site of the priming spacer, suggests that Cas9 binding 
and/or cleavage of the protospacer are important for the process. To investigate 
this, we first tested the ability of spc174 to direct the cleavage of the different 
targets found in ΦNM4γ4, ΦNM4γ4174-seed and ΦNM4γ4174-PAM phages. 
Biochemical characterization of S. pyogenes Cas9 has shown that binding of the 
PAM nucleotides is the fundamental first step in target recognition, which then 
proceeds to the critical pairing of the protospacer DNA and crRNA seed 
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sequences (Sternberg et al., 2014). As a result of this mechanism, PAM mutations 
that prevent its recognition completely abrogate target cleavage, whereas 
mismatches within the seed region can lead to low levels of nuclease activity. 
Indeed, when we tested the cleavage of the different spc174 targets in vitro we 
found strong cleavage of the wild-type target, lower levels of cleavage of the 174-
seed target, and no Cas9 nuclease activity against the 174-PAM target DNA 
(Figure 2.8A-B).  
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Figure 2.8. Target DNA cleavage is required for type II primed spacer 
acquisition. 
 (A) In vitro cleavage assay of a dsDNA oligonucleotide containing the different 
tgt174 sequences shown in Fig. 2A, incubated with increasing concentrations of a 
1:1:1 mix of Cas9:tracrRNA:crRNA174: 0, 6.25, 12.5, 25, 50 and 100 nM. Substrates 
and cleavage products were separated by agarose gel electrophoresis. A 
representative image of three replicates is shown. (B) The bands corresponding 
to the cleavage products in (A) were quantified and plotted against the 
concentration of the Cas9 ribonucleoprotein complex. Mean ± StDev values of 
three independent experiments are shown. (C) In vivo cleavage of phage DNA. 
Cells containing the pCRISPR(spc174) or pCRISPR(SR) plasmids where infected 
with ΦNM4γ4, ΦNM4γ4174-seed or ΦNM4γ4174-PAM phages and the cleavage 
products (marked by the black triangle) of the tgt174 sequence were amplified 
and separated by agarose gel electrophoresis. (D) Distribution of new spacer 
sequences acquired after infection of staphylococci carrying either 
pCRISPR(spc174, wtcas9), pCRISPR(spc174, dcas9) or pCRISPR(SR), with 
ΦNM4γ4, measured as spacer reads per million of total reads (RPMtot), and 
mapped to 1 kb bins of either the top or bottom strands of the phage genome 
(shown in linear form, with tgt174 in the center). Average curve of two 
independent experiments is shown. The inset shows the data from cells 
harboring pCRISPR(spc174, dcas9) or pCRISPR(SR) around the target site, with a 
different RPMtot scale. (E) Same as (D) but after infection with ΦNM4γ4seed. 
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We also tested cleavage of phage DNA in vivo during infection. Cells containing 
the pCRISPR(spc174) or pCRISPR(SR) plasmids where infected with ΦNM4γ4, 
ΦNM4γ4174-seed or ΦNM4γ4174-PAM phages, total DNA extracted after 20 minutes 
and treated with terminal deoxynucleotidyl transferase (TdT) and deoxycytosine 
to add poly-dC extensions to the 3’ ends of DNA breaks (Figure 2.9). The 
modified DNA was used as template for amplification with a polyG primer and 
a second primer annealing upstream of the spc174 target sequence to detect Cas9 
cleavage of the phage genome as a PCR product.  
 
 
 
Figure 2.9. Detection of Cas9 cleavage of the phage genome in vivo  
A schematic depicting assay for detecting cleavage of viral genomes in vivo. In 
brief, total DNA was extracted 30 minutes after infection and treated with 
terminal deoxynucleotidyl transferase (TdT) and deoxycytosine (dC) to add 
poly-dC extensions to the 3’ ends of DNA breaks (black dot). The modified DNA 
was used as template for amplification with a polyG primer (orange arrow) and 
a second specific primer annealing upstream of the spc174 target sequence (blue 
arrow) to detect Cas9 cleavage sites on the phage genome as a PCR product.  
Whereas no amplification was detected in the non-targeting control samples, 
strong and weak products were observed for targeting cells infected with wild-
type ΦNM4γ4 and ΦNM4γ4174-seed phages, respectively (Figure 2.8C). No PCR 
product was detected for targeting cells infected with mutant phages lacking a 
functional PAM in the spc174 target. Cloning and sequencing of these PCR 
products confirmed the specificity of the cleavage (data not shown). Therefore 
both in vitro and in vivo experiments, as expected, showed a strong cleavage of 
the wild-type spc174 target, partial cleavage of the target with the seed mutation, 
and no cleavage of the target with the non-functional PAM. These different levels 
of Cas9 cleavage are correlated with the level of priming mediated by spc174, as 
spacer acquisition was highest during infection with wild-type ΦNM4γ4, 
intermediate with ΦNM4γ4174-seed and very low with ΦNM4γ4174-PAM (Figure 2.1C 
and Figure 2.4D). As mentioned above, this could be due to a requirement for 
binding and/or cleavage of the target site. To determine if binding alone can 
induce type II primed spacer acquisition, we performed short-term infection 
experiments in staphylococci expressing catalytically dead Cas9 (dCas9), which 
can bind but not cleave the target specified by the crRNA guide (Bikard et al., 
2013; Qi et al., 2013), and has been previously shown to be capable of 
 49 
participating in naïve spacer acquisition (Heler et al., 2015; Wei et al., 2015b). 
Next-generation sequencing analysis of the acquired spacers in the presence of 
spc174 targeting showed the reduction of the peak located in the target site to the 
same background levels observed in the absence of targeting, during infection 
with both wild-type ΦNM4γ4 (Figure 2.8D) and ΦNM4γ4174-seed (Figure 2.8E) 
phages. These data demonstrate that target cleavage is fundamental for type II 
CRISPR-Cas primed spacer acquisition. 
 
2.4 Cleavage-mediated spacer acquisition in Streptococcus thermophilus 
In order to confirm our results in a natural experimental system, i.e. as opposed 
to the heterologous plasmid-based system described above, we explored 
cleavage-mediated spacer acquisition in Streptococcus thermophilus, the first 
organism shown to employ CRISPR-Cas systems for anti-phage defense 
(Barrangou et al., 2007). Strain DGCC7710 harbors two type II-A CRISPR loci 
(CRISPR1 and CRISPR3) that function independently from one another (Carte et 
al., 2014) and both are capable of spacer acquisition (Barrangou et al., 2007; Wei 
et al., 2015a). To eliminate the possibility of competition between these two 
CRISPR loci for the same substrates during spacer acquisition that might 
complicate interpretation of our results, we used a mutant containing only 
CRISPR3 (Figure 2.10A), strain CRISPR3-naïve (Varble et al., 2019), since this 
locus encodes the closest relative to the S. pyogenes SF370 type II-A system used 
in our previous experiments (Fonfara et al., 2014). We infected CRISPR3-naïve 
cells with the phage Φ2972 (Figure 2.10B) in soft agar to generate ‘bacteriophage-
insenstive mutants’ (BIMs) colonies as previously described (Hynes et al., 2017). 
The resulting BIMs were screened for spacer acquisition by PCR and three of 
these colonies containing a single, unique spacer targeting Φ2972 were saved for 
subsequent experiments (CRISPR3α, CRISPR3β, and CRISPR3γ, Figure 2.10C). 
First we confirmed the targeting, and thus cleavage, properties of each spacer 
(spc-α, spc-β, and spc-γ, Figure 2.10B) by measuring the ability of Φ2972 to form 
plaques in lawns of CRISPR-adapted streptococci (Fig. 2.10D). We then 
measured cleavage-mediated spacer acquisition after infection of liquid cultures 
with Φ2972 at a MOI of 10 for thirty minutes. Cells were collected for genomic 
DNA extraction, amplification of the CRISPR3 locus and NGS of the obtained 
PCR product. When analyzed quantitatively, sequencing data showed a 
markedly higher number of new anti-viral spacers for the three targeting strains 
relative to the CRISPR3-naïve control (~ 80-fold increase on average, Figure 
2.10D). Finally, qualitative analysis of the distribution pattern of the new spacers 
revealed a clustering around their respective Cas9 target sites (Figure 2.10F). 
Altogether, these results demonstrate the existence of cleavage-mediated spacer 
acquisition in the CRISPR3 locus of S. thermophilus, and also show that it shares 
similar mechanistic features with the S. pyogenes SF370 heterologous system. 
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Figure 2.10. Cleavage-dependent spacer acquisition in Streptococcus 
thermophilus. 
(A) Type II-A CRISPR-cas locus of S. thermophilus DGCC7710. White rectangles, 
CRISPR repeats; colored and numbered rectangles, spacers; “L”, leader sequence; 
blue arrows, protein-coding genes; yellow arrow, tracrRNA gene. (B) 
Streptococcal phage Φ2972 genome and the Cas9 targets analyzed in this study. 
(C) Agarose gel electrophoresis of PCR products after amplification of the 
CRISPR3 array from S. thermophilus CRISPR3-naïve that acquired spacers a, b 
and g upon infection with Φ2972. Grey and black arrows: non-expanded and 
expanded, respectively, CRISPR3 arrays. (D) Comparison of the efficiency of 
plaquing (EOP) of phage Φ2972 on CRISPR3-a, -b or -g streptococci. Mean ± 
StDev values of three independent experiments are shown. (E) Fraction (%) of 
new spacer sequences matching to the genome of phage Φ2972 detected after 
infection of CRISPR3-a, -b or -g streptococci. (-) indicates new spacers acquired in 
the absence of a targeting spacer by CRISPR-naïve cells. Values for a single 
experiment are shown. (F) Distribution of new spacer sequences detected 30 
minutes after infection of streptococci expressing Cas9 programmed to cleave the 
targets shown in (B). Reads per million of phage reads (RPMphage) are mapped to 
1 kb bins of the Φ2972 genome. Values for a single experiment are shown. 
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2.5 Discussion 
 
Our results demonstrate that the presence of pre-existing spacers enhances 
further spacer acquisition during the type II-A CRISPR-Cas immune response 
through a mechanism that requires the cleavage of the target DNA and that 
results in the capture of sequences in the vicinity of the cut site. This 
phenomenon was observed for both a heterologous S. pyogenes SF370 and the 
native CRISPR3 locus of S. thermophilus DGCC7710, suggesting that it is a 
common feature of type 2 CRISPR systems. As a result of this mechanism, the 
abundance of the newly acquired spacers is determined by the efficiency of 
cleavage mediated by the preexisting priming spacer. Spacers with fully 
functional targets lead to the highest level of spacer acquisition, spacers that 
target a protospacer with seed mutations promote an intermediate level of 
priming and those that target a site with a non-functional PAM do not enhance 
spacer acquisition. We believe that the strict correlation between target cleavage 
and primed spacer acquisition is a result of the mechanism behind type II-A 
spacer capture, which displays a marked preference for sequences near free 
double-stranded DNA (dsDNA) ends (Modell et al., 2017). In this model, the 
dsDNA ends generated by Cas9 cleavage become substrates for spacer 
acquisition. The previously reported physical association between Cas9, Csn2 
and the Cas1-Cas2 integrase of the type II-A systems (Heler et al., 2015; 
Wilkinson et al., 2019), could provide an efficient avenue for the recruitment of 
the spacer acquisition machinery to the free dsDNA ends generated by Cas9. A 
previous study showed that when the dsDNA end is either the cos site injected 
by a phage or the product of DNA restriction, processing by the AddAB nuclease 
extends the region of spacer acquisition to the first chi site capable of inhibit 
AddAB (Modell et al., 2017), presumably by generating degradation products 
with new dsDNA ends for the spacer acquisition machinery. In AddAB mutants, 
however, the region of acquisition is narrowed and centered around the dsDNA 
end, lacking the expansion to the chi sites. Interestingly, our data shows an 
acquisition hotspot concentrated at the cleavage site, not limited by chi sites, 
similar to the spacer acquisition pattern in AddAB mutants (Modell et al., 2017). 
This suggests that the dsDNA ends produced by Cas9 cannot be processed by 
AddAB, due to either the tight binding of Cas9 to its cleavage products (Garneau 
et al., 2010; Sternberg et al., 2014) or the expression of an AddAB inhibitor by 
ΦNM4γ4 (Bobay et al., 2013). Alternatively, as a result of the close association 
between the acquisition machinery and Cas9, the Csn2/Cas1-Cas2 complex 
could have preferential access to the dsDNA ends generated after cleavage and 
prevent the loading of AddAB to the ends. 
Although conceptually similar, our results show important differences in 
the mechanism of primed spacer acquisition carried out by type I and type II 
CRISPR-Cas systems. In these systems, the crRNA-guided Cascade complex 
requires both seed and PAM sequences to recognize a protospacer sequence and 
recruit the Cas3 nuclease to destroy the target genome by nicking one DNA 
strand at different length intervals (Dillard et al., 2018; Loeff et al., 2018; Mulepati 
and Bailey, 2013; Sinkunas et al., 2011). The lack of robust priming against perfect 
targets has been explained by two hypotheses in the context of this targeting 
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mechanism. Some studies support the idea that, upon interaction with a 
mutated, but not with a perfect, protospacer, the Cascade complex adopts a 
“priming” conformation that enables the recruitment of Cas1/Cas2 to initiate 
spacer acquisition from the target genome (Blosser et al., 2015; Redding et al., 
2015). Other work has shown that target cleavage is required for type I priming, 
but perfect protospacers lead to the rapid degradation of the target genome and 
prevent Cas1/Cas2 from extracting additional spacers from it (Musharova et al., 
2019; Semenova et al., 2016). Indeed, only when an anti-CRISPR Cascade 
inhibitor is over-expressed in hosts to impair target destruction, high levels of 
“interference-driven acquisition” can be detected (Staals et al., 2016). Mutated 
protospacers, on the other hand, lead to the recruitment by Cascade of both Cas3 
and Cas1/Cas2, which promote slow degradation of the target genome and 
primed spacer acquisition, respectively (Musharova et al., 2019; Semenova et al., 
2016; Staals et al., 2016). Moreover, in type I-F systems that encode a Cas2-Cas3 
fusion protein, Cas1 recruitment to the mutated target site, an essential step for 
primed acquisition, inhibits the nuclease activity (within Cas3) of the fusion 
(Rollins et al., 2017), supporting the idea that slow target degradation is 
important for primed spacer acquisition. In contrast to the results reported for 
type I priming, where acquisition mediated by targeted protospacers can only be 
detected when target degradation is artificially decreased, we observed the 
highest levels of type II primed spacer acquisition in the presence of a perfect 
protospacer that can be rapidly cleaved. We believe that this difference could be 
related to the lack of processive degradation after target cleavage by Cas9 
compared with Cas3 (Sternberg et al., 2014); i.e. the rapid degradation of DNA 
containing a perfect target for Cas3 prevents the acquisition of new spacers from 
sequences that surround the target site. Alternatively, even if the Cas1/Cas2 
complex interacts with both the Cas3 and Cas9 nucleases, the integration 
substrates (also known as pre-spacers) could be more immediately accessible to 
the integrase complex in the vicinity of the target site after Cas9 cleavage versus 
Cas3 nicking.  
Another difference is the influence of the protospacer location in the 
orientation of the new spacers. Whereas during type I priming the acquired 
spacers match the same strand as the priming protospacer (Datsenko et al., 2012; 
Staals et al., 2016; Swarts et al., 2012), this is not the case for the spacers acquired 
through type II primed spacer acquisition. This dissimilitude could be related to 
the disparities in DNA cleavage between Cas3 and Cas9. The recognition of a 
mutated protospacer by Cascade leads to the recruitment of Cas3 and the 
Cas1/Cas2 integrase to the target DNA. This priming complex moves 
unidirectionally along one of the DNA strands (Dillard et al., 2018; Redding et 
al., 2015), a process that could cause the observed polarity of spacer acquisition 
during type I priming. In contrast, Cas9 remains bound to the cleaved DNA ends 
(Sternberg et al., 2014); i.e. the lack of strand-specific or directional movement of 
this nuclease prevents any influence on the extraction of spacers by Cas1/Cas2. 
Finally, the wide use of Cas9 as a tool for genome engineering of the 
human genome (Doudna and Charpentier, 2014) have revealed the existence of 
“off-target” sites. These are not simply mutated targets, but sequences with 
random and imperfect complementarity to the crRNA guide of Cas9 that can 
nevertheless be recognized and cleaved by the nuclease at low rates (Fu et al., 
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2013; Hsu et al., 2013). Limiting Cas9 off-target effects represents a fundamental 
obstacle for the continued improvement of CRISPR-Cas9 biotechnology. 
According to our results, these off-target cleavage events should lead to primed 
spacer acquisition, and therefore it is interesting to speculate that this “defect” of 
Cas9 targeting has been selected through evolution to boost the otherwise naïve 
type II CRISPR-Cas immune response and to achieve immunization against 
phages for which a priori there are no partially matching pre-existing spacers.  
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CHAPTER 3: TYPE II PRIMED SPACER ACQUISTION MEDIATES A 
ROBUTS ANTI-VIRAL IMMUNE RESPONSE  
 
3.1 Introduction 
A hallmark of CRISPR immunity is the generation of a heterogenous bacterial 
population with thousands of different spacer sequences, each of them in a 
different cell (Barrangou et al., 2007; Heler et al., 2015; Paez-Espino et al., 2013). 
This prevents the rise of phage escapers containing mutations that can avoid the 
immunity mediated by one of the acquired spacers (van Houte et al., 2016). These 
phages can kill the cells in the population harboring that particular spacer but 
will be eliminated upon infection of other host cells that contain different spacers 
for which they do not have escape mutations. In addition, the expansion of the 
spacer repertoire defends the host population from infection with related phages 
that share target sequences with the previous phage that triggered spacer 
acquisition. Therefore, the enhancement of spacer acquisition promoted by Cas9 
cleavage should mediate a more robust type II-A CRISPR-Cas immune response. 
On one hand, the cleavage of targets with seed escape mutations would allow 
the host to contain the rise of such escapers after they appear in the population. 
On the other, the acquisition of additional spacers that occurs after cleavage of 
perfect targets within immune hosts would enable to anticipate the occurrence of 
phage (seed and PAM) escapers or related phages; i.e. it would equip the host 
with a different spacer sequence for defense against phages that cannot be 
cleaved by the first spacer. 
 
3.2 Primed spacer acquisition occurs during long-term phage infections 
 
To investigate these scenarios, we first determined whether primed spacer 
acquisition occurs during infection of staphylococci harboring a naïve pCRISPR, 
without spacers matching ΦNM4γ4; i.e whether cleavage-mediated spacer 
acquisition can happen after naïve cells capture their first spacers. We infected 
naïve cells with ΦNM4γ4 at a multiplicity of infection (MOI) of 1 and allowed 
the cultures to grow in the presence of phage for 24 hours before amplifying the 
CRISPR arrays and submitting the resulting PCR products to next-generation 
sequencing. We then selected reads that contained two new anti-viral spacers 
and calculated the genomic distance between the first and second acquired 
sequences (located at the 5’ end of the array (Barrangou et al., 2007; McGinn and 
Marraffini, 2016)). Consistent with a previous bioinformatic analysis (Nicholson 
et al., 2018), the histogram of these distances revealed that the majority of the 
second spacers map within 1 kb of the protospacer targeted by the first spacer 
(Figure 3.1A and Figure 3.1C-G), without any noticeable strand bias (Figure 
3.1B). This spacer distribution is similar to that obtained in the spc174 priming 
experiments (Figure 2-1C and Figure 2.4E), and thus the data strongly suggests 
primed spacer acquisition follows the naïve type II-A CRISPR-Cas immune 
response.  
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Figure 3.1. Cleavage-dependent spacer acquisition occurs during long-term 
infection 
(A) Distance between the targets in the ΦNM4γ4 genome specified by the first 
and second spacers acquired after 24-hour infection of naïve staphylococci 
carrying the type II-A CRISPR-Cas system of S. pyogenes with ΦNM4γ4. The 
number of different spacers within 1-kb bins of the ΦNM4γ4 genome are shown; 
the position of first spacer acquired in each array is set as 0 kb. (B) Same as (A) 
but analyzed according to whether spacer targets the same or the opposite DNA 
strand as the first acquired spacer. (C) Location within the ΦNM4γ4 genome of 
the targets specified by the four first spacers analyzed in (tgtA, tgtB, tgtC, and 
tgtD) (D-E)  Distribution of distances between the targets specified by the second 
spacers integrated after the acquisition of the spacers A, B, C and D, respectively; 
the target sequence specified by the first spacer acquired, which is given a 0 kb 
position, is shown.  
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3.3 Primed spacer acquisition limits the propagation of existing escaper viruses 
 
 
To determine if primed spacer acquisition can limit the propagation of phage 
escapers, we selected colonies that acquired a second spacer after priming with 
spc174 (Figure 3.2C) and infected them with wild-type ΦNM4γ4 phage. Whereas 
the phage population contained a significant number of mutants that were able 
to propagate in staphylococci equipped with pCRISPR(spc174), we were unable 
to detect plaques on cultures harboring an additional spacer acquired through 
priming (Figure 3.2A). We then tested our first prediction; i.e. that Cas9 partial 
cleavage would promote the acquisition of new spacers to neutralize seed 
escaper phages. We infected exponentially-growing staphylococci harboring 
pCRISPR(spc174) with ΦNM4γ4, ΦNM4γ4174-seed or ΦNM4γ4174-PAM phages (or a 
mock infection as a control) at a MOI of 10 and we measured the optical density 
of the culture to monitor cell survival (Figure 3.2B). Due to spc174 targeting, 
cultures infected with wild-type ΦNM4γ4 continue growing, similarly to the 
control where no phage was added. In contrast, cultures infected with both 
escaper phages succumbed to infection and stopped growing, and the cells that 
received ΦNM4γ4174-PAM were not able to recover. Cells infected with ΦNM4γ4174-
seed, however, regained growth at 13 hours post-infection. PCR analysis of the 
three replicas showed that in all cases a second new spacer was acquired (Figure 
3.2C). Spacer acquisition was absolutely required for the recovery of the culture, 
as cells expressing the catalytically dead version of Cas1 (dCas1) were incapable 
of recovery (Figure 3.2D-E). In addition, the spacer acquisition that enabled the 
survival was primed by spc174, since cells harboring pCRISPR(SR) failed to 
regrow (Figure 3.2F-G). Altogether, the results presented in Figure 3.2 
demonstrate that primed spacer acquisition occurs during the type II-A CRISPR-
Cas immune response, enabling the containment of seed escaper phages. 
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Figure 3.2: Cleavage-dependent spacer acquisition mediates a robust immune 
response against escaper viruses 
(A) Quantification of phage escapers as PFU/ml after the plating of different 
dilutions of phage ΦNM4γ4 stock onto plates seeded with different 
staphylococcal strains that harbor pCRISPR either lacking a targeting spacer (-) 
or programmed with spc174 or spc174 and additional spacer acquired in the 
experiment of Fig. S3C. Mean ± StDev values of three independent experiments 
are shown. (B) Cell survival measured as OD600 after infection of cultures 
carrying pCRISPR(spc174) with different phages at MOI 10 or none as a control. 
The average curves of three different replicates are shown, with +/- StDev values 
shown in lighter colors. (C) Agarose gel electrophoresis of PCR products after 
amplification of the CRISPR array of cells obtained after the experiment in (B) to 
detect the integration of new spacers. Grey and black arrows: non-expanded and 
expanded, respectively, CRISPR arrays. (D) Cell survival measured as OD600 
after infection of cultures carrying either the wild-type or the nuclease deficient 
cas1 gene (wtcas1 or dcas1, respectively) on pCRISPR(spc174) with ΦNM4γ4 at 
MOI 10 or no phage as a control. The average curves of three different replicates 
are shown, with +/- StDev values shown in lighter colors. (E) Agarose gel 
electrophoresis of PCR products after amplification of the CRISPR array of cells 
obtained after the experiment in (D) to detect the integration of new spacers. 
Grey and black arrows: non-expanded and expanded, respectively, CRISPR 
arrays. (F) Same as (D) but after infection of staphylococci carrying either 
pCRISPR(SR) or pCRISPR(spc174). The average curves of three different 
replicates are shown, with +/- StDev values shown in lighter colors. (G) Same as 
(E) but for the cells obtained after the experiment in (F).  
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3.4. Primed spacer acquisition anticipates infection by emergent viruses 
 
Finally, we tested the second prediction; that Cas9 cleavage within fully immune 
hosts prepares the cell for future escaper or related phages. First, we infected 
cells carrying pCRISPR(spc174) with ΦNM4γ4 at a high MOI (100), which 
increases the concentration of escapers present in the experiment. After the initial 
decimation of the culture, presumably by escaper phages, resistant cells that 
acquired new spacers were able to recover (Figs. 6D-E). Cells harboring 
pCRISPR(SR), lacking the priming spacer, or pCas9(spc174), lacking the Cas1-
Cas2-Csn2 acquisition machinery, both failed to re-grow (Figure 3.3A) or acquire 
new spacers (Figure 3.3B), demonstrating that the survival of staphylococci 
carrying pCRISPR(spc174) depended on the expansion of the spacer repertoire 
mediated by spc174-mediated cleavage of wild-type viruses. 
Second, we infected cells carrying pCRISPR(spc174) with ΦNM4γ4 for 30 
minutes and then added the related phage ΦNM1γ6PAM, which shares 73.5 % of 
sequence identity with ΦNM4γ4 and contains a PAM mutation in tgt174 that 
prevents Cas9 cleavage. As controls, we also infected staphylococci with either 
ΦNM4γ4 or ΦNM1γ6PAM alone. Analysis of data from Figures 2.1C and Figure 
2.4D indicated that, from the 346 different spacer sequences acquired during the 
first 30 minutes of infection with ΦNM4γ4 in all three replicates, 343 have perfect 
matches on the ΦNM1γ6PAM genome, and the remaining 3 have imperfect 
matches that could still enable some level of Cas9 targeting (Figure 3.3E  and 
Table 3.1). Therefore, it is expected that staphylococci carrying pCRISPR(spc174) 
will use the targeting spacer not only to destroy ΦNM4γ4, but also to prepare the 
host population with spacers against ΦNM1γ6PAM and thus ensure survival after 
infection with this phage. As expected, the culture resisted infection with 
ΦNM4γ4 but not with ΦNM1γ6PAM (Figure 3.3C). The latter eventually recovered 
after about 17 hours, due to the naïve acquisition of spacers (Figure 3.3D). In 
contrast, the culture pre-infected with ΦNM4γ4 recovered from infection with 
ΦNM1γ6PAM significantly faster, at about 13 hours (Figure 3.3C) through the 
acquisition of new spacers (Figure 3.3D). Next generation sequencing of the new 
spacers showed that, in addition to spacers acquired from the ΦNM1γ6PAM 
genome, all 346 spacer sequences that were acquired from the ΦNM4γ4 genome 
after 30 minutes of infection were present at least in one replicate population that 
survived infection by both phages for 24 hours, including the three spacers that 
partially match the ΦNM1γ6PAM genome (Table 3.1). The presence of these 
sequences, resulting from spacer acquisition from ΦNM4γ4 DNA following 
cleavage of this phage by Cas9 loaded with the spc174 crRNA guide, and which 
are not required to provide immunity against this ΦNM4γ4, demonstrates that 
these spacers indeed can be used for the targeting of ΦNM1γ6PAM. Priming 
within already-immune cells therefore allows a pre-emptive strike against future 
infection by escaper phages and/or related viruses. 
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Figure 3.3. Cleavage-dependent spacer acquisition provides pre-emptive 
immunity against viruses 
(A) Cell survival measured as OD600 after infection with ΦNM4γ4 at MOI 100 of 
staphylococci carrying different plasmids. The average curves of three different 
replicates are shown, with +/- StDev values shown in lighter colors. (C) Agarose 
gel electrophoresis of PCR products after amplification of the CRISPR array of 
cells obtained after the experiment in (A) to detect the integration of new spacers. 
(D) Cell survival measured as OD600 after infection of cultures carrying 
pCRISPR(spc174) with different phages at MOI 1 or none as a control. 
“ΦNM4γ4/ΦNM1” indicates infection with ΦNM1γ6PAM 30 minutes of addition 
of ΦNM4γ4 at MOI 10. “ΦNM1” is an abbreviation for ΦNM1γ6PAM. The average 
curves of three different replicates are shown, with +/- StDev values shown in 
lighter colors. (E) Same as (C) but for the cells obtained after the experiment in 
(D). 
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Table 3.1. Spacers acquired from ΦNM4γ4 present in ΦNM1γ6PAM 
 
Spacer in NM4  NM4 
PAM 
NM4  
position 
Replicate 
of Figure 
2-1C 
Normalized 
Reads (30 
min) 
Spacer 
Present 
in 
NM1? 
(Y/N) 
Position 
in NM1 
or NM4 
Reads at 
24 hour 
of co-
infection 
(rep #1) 
Reads at 
24 hour 
of co-
infection 
(rep #2) 
Reads at 
24 hour 
of co-
infection 
(rep #3) 
TGAACGACACAAATGATTTA GGG 107 1 38.98152805 Y 40912 0 2 0 
TGAACGACACAAATGATTTA GGG 107 2 30.77489057 Y 40912 0 2 0 
TGAACGACACAAATGATTTA GGG 107 3 8.206637484 Y 40912 0 2 0 
CACAAATGATTTAGGGTAGG TGG 114 1 119.0665571 Y 40919 0 0 4 
CACAAATGATTTAGGGTAGG TGG 114 2 77.65210248 Y 40919 0 0 4 
CACAAATGATTTAGGGTAGG TGG 114 3 72.47529565 Y 40919 0 0 4 
GAAATCCATACCAACCATCT GGG 190 1 165.442976 Y 40995 0 5 0 
GAAATCCATACCAACCATCT GGG 190 2 170.1699181 Y 40995 0 5 0 
GAAATCCATACCAACCATCT GGG 190 3 86.66060645 Y 40995 0 5 0 
AACAATTCAACCCAGATGGT TGG 196 1 600.3216556 Y 41001 0 2 0 
AACAATTCAACCCAGATGGT TGG 196 2 560.9304708 Y 41001 0 2 0 
AACAATTCAACCCAGATGGT TGG 196 3 379.731021 Y 41001 0 2 0 
CGCTAACATAAAGAACATAT TGG 228 1 18.90776868 Y 41033 0 0 4 
CGCTAACATAAAGAACATAT TGG 228 2 39.39118475 Y 41033 0 0 4 
CGCTAACATAAAGAACATAT TGG 228 3 14.18082651 Y 41033 0 0 4 
ATGTTCTTTATGTTAGCGAC AGG 249 1 200.6640952 Y 41054 0 0 2 
ATGTTCTTTATGTTAGCGAC AGG 249 2 278.5105988 Y 41054 0 0 2 
ATGTTCTTTATGTTAGCGAC AGG 249 3 106.0697381 Y 41054 0 0 2 
ACGACAATATCCAACTTTTG CGG 356 1 165.6578186 Y 41161 2 2 5 
ACGACAATATCCAACTTTTG CGG 356 2 103.5361366 Y 41161 2 2 5 
ACGACAATATCCAACTTTTG CGG 356 3 62.12168198 Y 41161 2 2 5 
GTTTTCCCGTCAAAGTATGG TGG 393 1 274.3707621 Y 41198 2 2 16 
GTTTTCCCGTCAAAGTATGG TGG 393 2 232.9563074 Y 41198 2 2 16 
GTTTTCCCGTCAAAGTATGG TGG 393 3 139.7737845 Y 41198 2 2 16 
TCAAAGTATGGTGGCGGAGC TGG 402 1 304.8729606 Y 41207 0 4 0 
TCAAAGTATGGTGGCGGAGC TGG 402 2 530.038545 Y 41207 0 4 0 
TCAAAGTATGGTGGCGGAGC TGG 402 3 217.722094 Y 41207 0 4 0 
TTAAATACTTTCACATCATT TGG 453 1 75.63107472 Y 41258 0 0 2 
TTAAATACTTTCACATCATT TGG 453 2 124.4761438 Y 41258 0 0 2 
TTAAATACTTTCACATCATT TGG 453 3 59.87460082 Y 41258 0 0 2 
GGTCAAAACTGGAACGGTAA AGG 474 1 28.72323119 Y 41279 0 0 3 
GGTCAAAACTGGAACGGTAA AGG 474 2 131.3061997 Y 41279 0 0 3 
GGTCAAAACTGGAACGGTAA AGG 474 3 12.30995623 Y 41279 0 0 3 
ATGGCGTTGCGCAACCTGGT TGG 505 1 846.1226484 Y 41310 0 4 0 
ATGGCGTTGCGCAACCTGGT TGG 505 2 1251.064028 Y 41310 0 4 0 
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ATGGCGTTGCGCAACCTGGT TGG 505 3 438.0299744 Y 41310 0 4 0 
TGGCGTTGCGCAACCTGGTT GGG 506 1 497.9045752 Y 41311 4 0 0 
TGGCGTTGCGCAACCTGGTT GGG 506 2 765.7646315 Y 41311 4 0 0 
TGGCGTTGCGCAACCTGGTT GGG 506 3 313.5538306 Y 41311 4 0 0 
ACATGTCTTGTCACAGTTTC AGG 515 1 362.2498657 Y 41320 0 3 0 
ACATGTCTTGTCACAGTTTC AGG 515 2 350.1541939 Y 41320 0 3 0 
ACATGTCTTGTCACAGTTTC AGG 515 3 176.7828968 Y 41320 0 3 0 
TTTAACCTAATAAAATACAT TGG 554 1 15.7564739 Y 41359 0 0 2 
TTTAACCTAATAAAATACAT TGG 554 2 25.21035824 Y 41359 0 0 2 
TTTAACCTAATAAAATACAT TGG 554 3 6.30258956 Y 41359 0 0 2 
ACAATCCAATGTATTTTATT AGG 565 1 12.60517912 Y 41370 3 0 0 
ACAATCCAATGTATTTTATT AGG 565 2 17.33212129 Y 41370 3 0 0 
ACAATCCAATGTATTTTATT AGG 565 3 9.45388434 Y 41370 3 0 0 
AGCGTTGGCAATAAAGCTAA AGG 609 1 61.54978113 Y 41414 0 3 0 
AGCGTTGGCAATAAAGCTAA AGG 609 2 86.16969358 Y 41414 0 3 0 
AGCGTTGGCAATAAAGCTAA AGG 609 3 6.154978113 Y 41414 0 3 0 
GTTCCGTTTCCTACTGCTCC AGG 701 1 3236.367593 Y 41506 0 0 3 
GTTCCGTTTCCTACTGCTCC AGG 701 2 4197.198145 Y 41506 0 0 3 
GTTCCGTTTCCTACTGCTCC AGG 701 3 2094.412109 Y 41506 0 0 3 
CTTAAATACTTAGCGATATT AGG 758 1 81.93366428 Y 41563 0 0 2 
CTTAAATACTTAGCGATATT AGG 758 2 64.60154299 Y 41563 0 0 2 
CTTAAATACTTAGCGATATT AGG 758 3 34.66424258 Y 41563 0 0 2 
AAAAAGATTATGGCTTATAT TGG 889 1 77.20672211 Y 41694 0 0 3 
AAAAAGATTATGGCTTATAT TGG 889 2 26.78600563 Y 41694 0 0 3 
AAAAAGATTATGGCTTATAT TGG 889 3 23.63471085 Y 41694 0 0 3 
CAGGAGAAAGCGCAAGTGGT GGG 961 1 2366.62238 Y 41766 0 0 2 
CAGGAGAAAGCGCAAGTGGT GGG 961 2 3502.664148 Y 41766 0 0 2 
CAGGAGAAAGCGCAAGTGGT GGG 961 3 1797.813672 Y 41766 0 0 2 
TATTACTAATAAAAATGATA TGG 1154 1 2.051659371 Y 41959 0 0 2 
TATTACTAATAAAAATGATA TGG 1154 3 4.103318742 Y 41959 0 0 2 
CCAGCTACCAAACCACCTAT AGG 1223 1 527.8418757 Y 42028 0 2 0 
CCAGCTACCAAACCACCTAT AGG 1223 2 589.2921239 Y 42028 0 2 0 
CCAGCTACCAAACCACCTAT AGG 1223 3 305.6755937 Y 42028 0 2 0 
GCGATTCATGGTAAGCCTAT AGG 1224 1 516.8123439 Y 42029 0 6 0 
GCGATTCATGGTAAGCCTAT AGG 1224 2 779.9454581 Y 42029 0 6 0 
GCGATTCATGGTAAGCCTAT AGG 1224 3 354.5206628 Y 42029 0 6 0 
TGGTAAGCCTATAGGTGGTT TGG 1232 1 1635.521991 Y 42037 5 0 0 
TGGTAAGCCTATAGGTGGTT TGG 1232 2 2075.127613 Y 42037 5 0 0 
TGGTAAGCCTATAGGTGGTT TGG 1232 3 1022.595156 Y 42037 5 0 0 
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CCTATAGGTGGTTTGGTAGC TGG 1239 1 882.6739023 Y 42044 5 0 0 
CCTATAGGTGGTTTGGTAGC TGG 1239 2 1021.619056 Y 42044 5 0 0 
CCTATAGGTGGTTTGGTAGC TGG 1239 3 494.6819656 Y 42044 5 0 0 
AGTGTATAACCTGCTGGCAC TGG 1283 1 15613.34139 Y 42088 7 4 1 
AGTGTATAACCTGCTGGCAC TGG 1283 2 26265.59643 Y 42088 7 4 1 
AGTGTATAACCTGCTGGCAC TGG 1283 3 11487.47669 Y 42088 7 4 1 
TCAACTAATTCAAGAATTAC AGG 1407 1 35.35657936 Y 42212 0 1 2 
TCAACTAATTCAAGAATTAC AGG 1407 2 63.57981377 Y 42212 0 1 2 
TCAACTAATTCAAGAATTAC AGG 1407 3 22.64061661 Y 42212 0 1 2 
ATTACTTATATTGCTAATAG TGG 1494 1 25.88403416 Y 42299 0 3 0 
ATTACTTATATTGCTAATAG TGG 1494 2 10.35361366 Y 42299 0 3 0 
TCGTTATATAGCGACAGGAG AGG 1523 1 471.0894217 Y 42328 0 2 2 
TCGTTATATAGCGACAGGAG AGG 1523 2 243.3099211 Y 42328 0 2 2 
TCGTTATATAGCGACAGGAG AGG 1523 3 269.1939553 Y 42328 0 2 2 
AGCGACAGGAGAGGTAGACA AGG 1532 1 404.1768961 Y 42337 2 0 3 
AGCGACAGGAGAGGTAGACA AGG 1532 2 619.60113 Y 42337 2 0 3 
AGCGACAGGAGAGGTAGACA AGG 1532 3 211.3209152 Y 42337 2 0 3 
ACAGGAGAGGTAGACAAGGC AGG 1536 1 597.9603948 Y 42341 9 0 0 
ACAGGAGAGGTAGACAAGGC AGG 1536 2 540.2733443 Y 42341 9 0 0 
ACAGGAGAGGTAGACAAGGC AGG 1536 3 157.8640254 Y 42341 9 0 0 
ACAGTTATTAAATAACTATT TGG 1646 1 29.93730041 Y 42451 0 2 2 
ACAGTTATTAAATAACTATT TGG 1646 2 23.63471085 Y 42451 0 2 2 
ACAGTTATTAAATAACTATT TGG 1646 3 14.18082651 Y 42451 0 2 2 
AGAAATGTTAAAAAGTGTAT AGG 1668 1 36.23988997 Y 42473 0 3 0 
AGAAATGTTAAAAAGTGTAT AGG 1668 2 33.08859519 Y 42473 0 3 0 
AGAAATGTTAAAAAGTGTAT AGG 1668 3 28.36165302 Y 42473 0 3 0 
TAGATAACAGGCAGGTACTT CGG 1722 1 113.4466121 Y 42527 4 0 0 
TAGATAACAGGCAGGTACTT CGG 1722 2 129.203086 Y 42527 4 0 0 
TAGATAACAGGCAGGTACTT CGG 1722 3 94.5388434 Y 42527 4 0 0 
GTGACATGCTTGGGTGAACA AGG 1817 1 326.21384 Y 42622 0 0 2 
GTGACATGCTTGGGTGAACA AGG 1817 2 894.5234858 Y 42622 0 0 2 
GTGACATGCTTGGGTGAACA AGG 1817 3 254.405762 Y 42622 0 0 2 
AAAACATCCAGTGACATGCT TGG 1827 1 91.38754862 Y 42632 0 4 0 
AAAACATCCAGTGACATGCT TGG 1827 2 97.69013818 Y 42632 0 4 0 
AAAACATCCAGTGACATGCT TGG 1827 3 72.47977994 Y 42632 0 4 0 
TGCTAAAGTCATATATACTA CGG 1886 1 6.154978113 Y 42691 0 1 2 
TGCTAAAGTCATATATACTA CGG 1886 2 20.51659371 Y 42691 0 1 2 
TGCTAAAGTCATATATACTA CGG 1886 3 20.51659371 Y 42691 0 1 2 
CATTCCCGTATAACAGTTTA CGG 1923 1 63.6014405 Y 42728 6 0 2 
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CATTCCCGTATAACAGTTTA CGG 1923 2 123.0995623 Y 42728 6 0 2 
CATTCCCGTATAACAGTTTA CGG 1923 3 104.6346279 Y 42728 6 0 2 
TCAGATACATGGCCTCTGCC CGG 1980 1 1930.965466 Y 42785 0 0 2 
TCAGATACATGGCCTCTGCC CGG 1980 2 3023.917972 Y 42785 0 0 2 
TCAGATACATGGCCTCTGCC CGG 1980 3 958.9696788 Y 42785 0 0 2 
GGGACCAACAGTCAGATACA TGG 1991 1 45.13650616 Y 42796 0 6 0 
GGGACCAACAGTCAGATACA TGG 1991 2 59.49812176 Y 42796 0 6 0 
GGGACCAACAGTCAGATACA TGG 1991 3 22.56825308 Y 42796 0 6 0 
TAACCGTATCTTAATCGATA CGG 2099 1 2.051659371 Y 42904 0 1 0 
TAACCGTATCTTAATCGATA CGG 2099 2 26.67157182 Y 42904 0 1 0 
TAACCGTATCTTAATCGATA CGG 2099 3 10.25829686 Y 42904 0 1 0 
ACTAAGACATCAATTTTAGT TGG 4576 1 47.2694217 Y 4974 0 0 1 
ACTAAGACATCAATTTTAGT TGG 4576 2 47.2694217 Y 4974 0 0 1 
ACTAAGACATCAATTTTAGT TGG 4576 3 18.90776868 Y 4974 0 0 1 
AACAAAACGGTATAAACATC GGG 4619 1 55.82617794 Y 5017 3 0 0 
AACAAAACGGTATAAACATC GGG 4619 2 120.9567189 Y 5017 3 0 0 
AACAAAACGGTATAAACATC GGG 4619 3 46.21166952 Y 5017 3 0 0 
GGATTCCTTATTAAACGCAA GGG 4675 1 36.92986868 Y 5073 0 0 3 
GGATTCCTTATTAAACGCAA GGG 4675 2 55.39480302 Y 5073 0 0 3 
GGATTCCTTATTAAACGCAA GGG 4675 3 38.98152805 Y 5073 0 0 3 
CGTTCCATTGAATACTGTGT AGG 4698 1 794.1262846 Y 5096 1100731 12 8 
CGTTCCATTGAATACTGTGT AGG 4698 2 885.5138332 Y 5096 1100731 12 8 
CGTTCCATTGAATACTGTGT AGG 4698 3 392.3362001 Y 5096 1100731 12 8 
CATGCCTACACAGTATTCAA TGG 4710 1 45.13650616 Y 5108 0 5 0 
CATGCCTACACAGTATTCAA TGG 4710 2 143.616156 Y 5108 0 5 0 
CATGCCTACACAGTATTCAA TGG 4710 3 24.61991245 Y 5108 0 5 0 
AGAAACATCAATCACACATT CGG 4755 1 7.87823695 Y 5153 6 0 0 
AGAAACATCAATCACACATT CGG 4755 2 9.45388434 Y 5153 6 0 0 
AGAAACATCAATCACACATT CGG 4755 3 17.33212129 Y 5153 6 0 0 
ACATCAATCACACATTCGGA CGG 4759 1 137.4611779 Y 5157 0 5 0 
ACATCAATCACACATTCGGA CGG 4759 2 164.1327497 Y 5157 0 5 0 
ACATCAATCACACATTCGGA CGG 4759 3 67.70475924 Y 5157 0 5 0 
AGTAAGACGCCAAAAGTAAC AGG 4795 1 125.2987549 Y 5193 0 0 1 
AGTAAGACGCCAAAAGTAAC AGG 4795 2 234.7800928 Y 5193 0 0 1 
AGTAAGACGCCAAAAGTAAC AGG 4795 3 89.63203014 Y 5193 0 0 1 
CAACTGCCATTGTGATGAGG AGG 4895 3 25.88403416 Y 5293 7 0 0 
TCACAACTGCCATTGTGATG AGG 4898 1 150.1273981 Y 5296 8 11 0 
TCACAACTGCCATTGTGATG AGG 4898 2 181.1882391 Y 5296 8 11 0 
TCACAACTGCCATTGTGATG AGG 4898 3 113.8897503 Y 5296 8 11 0 
 67 
AATGGCAGTTGTGACGTGGA AGG 4923 1 129.2545404 Y 5321 9 37 626632 
AATGGCAGTTGTGACGTGGA AGG 4923 2 373.4020055 Y 5321 9 37 626632 
AATGGCAGTTGTGACGTGGA AGG 4923 3 55.39480302 Y 5321 9 37 626632 
TGAAGCATAATACTGCTACT AGG 5418 1 672.8014355 Y 5959 8 0 4 
TGAAGCATAATACTGCTACT AGG 5418 2 842.9713537 Y 5959 8 0 4 
TGAAGCATAATACTGCTACT AGG 5418 3 414.3952636 Y 5959 8 0 4 
GCTGTAGTGAAGTATAGAAA CGG 5464 1 34.87820931 Y 6005 0 2 0 
GCTGTAGTGAAGTATAGAAA CGG 5464 2 4.103318742 Y 6005 0 2 0 
GCTGTAGTGAAGTATAGAAA CGG 5464 3 8.206637484 Y 6005 0 2 0 
TTCTATACTTCACTACAGCA TGG 5484 1 369.2986868 Y 6025 0 0 3 
TTCTATACTTCACTACAGCA TGG 5484 2 373.4020055 Y 6025 0 0 3 
TTCTATACTTCACTACAGCA TGG 5484 3 178.4943653 Y 6025 0 0 3 
ATAAAAAAACTGCTACTTGT TGG 5569 1 286.767825 Y 6110 4 11 239434 
ATAAAAAAACTGCTACTTGT TGG 5569 2 300.9486515 Y 6110 4 11 239434 
ATAAAAAAACTGCTACTTGT TGG 5569 3 209.5611029 Y 6110 4 11 239434 
GTCAAGATGTATTACGAAAT AGG 5658 1 29.93730041 Y 6199 0 3 0 
GTCAAGATGTATTACGAAAT AGG 5658 2 31.5129478 Y 6199 0 3 0 
GTCAAGATGTATTACGAAAT AGG 5658 3 23.63471085 Y 6199 0 3 0 
ATTCATTTTAAAAGGTCATA TGG 5729 1 2.051659371 Y 6270 0 2 0 
ATTCATTTTAAAAGGTCATA TGG 5729 2 6.154978113 Y 6270 0 2 0 
ATTCATTTTAAAAGGTCATA TGG 5729 3 2.051659371 Y 6270 0 2 0 
TTCATTTTAAAAGGTCATAT GGG 5730 1 6.30258956 Y 6271 0 0 1 
TTCATTTTAAAAGGTCATAT GGG 5730 2 22.05906346 Y 6271 0 0 1 
TTCATTTTAAAAGGTCATAT GGG 5730 3 6.30258956 Y 6271 0 0 1 
ACGACATAAGCATGTTTAAT TGG 5771 1 99.26578557 Y 6312 0 0 8 
ACGACATAAGCATGTTTAAT TGG 5771 2 86.66060645 Y 6312 0 0 8 
ACGACATAAGCATGTTTAAT TGG 5771 3 34.66424258 Y 6312 0 0 8 
AGATGAGAATGACTTAGATA TGG 5810 1 30.77489057 Y 6351 2 0 0 
AGATGAGAATGACTTAGATA TGG 5810 2 75.91139673 Y 6351 2 0 0 
AGATGAGAATGACTTAGATA TGG 5810 3 26.67157182 Y 6351 2 0 0 
CAATCCATTCATCTATTGCT TGG 5833 1 406.5170266 Y 6374 26 744762 6 
CAATCCATTCATCTATTGCT TGG 5833 2 477.4211592 Y 6374 26 744762 6 
CAATCCATTCATCTATTGCT TGG 5833 3 263.1331141 Y 6374 26 744762 6 
TGAAGAGAACACAGACGAAC AGG 5870 1 181.4350783 Y 6411 6 0 0 
TGAAGAGAACACAGACGAAC AGG 5870 2 412.1832805 Y 6411 6 0 0 
TGAAGAGAACACAGACGAAC AGG 5870 3 186.7075507 Y 6411 6 0 0 
ATATCTGAATTGTTATCAGT TGG 5981 1 132.3543808 Y 6522 0 0 4 
ATATCTGAATTGTTATCAGT TGG 5981 2 138.6569703 Y 6522 0 0 4 
ATATCTGAATTGTTATCAGT TGG 5981 3 47.2694217 Y 6522 0 0 4 
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AATAGAGCTAGGGAGTTTAA CGG 6039 1 63.6014405 Y 6580 188 0 0 
AATAGAGCTAGGGAGTTTAA CGG 6039 2 106.6862873 Y 6580 188 0 0 
AATAGAGCTAGGGAGTTTAA CGG 6039 3 32.82654994 Y 6580 188 0 0 
GACAGAAACTATTGAGTACG AGG 6116 1 176.0114323 Y 6657 8 0 6 
GACAGAAACTATTGAGTACG AGG 6116 2 253.6635348 Y 6657 8 0 6 
GACAGAAACTATTGAGTACG AGG 6116 3 144.9505913 Y 6657 8 0 6 
AGAAACTATTGAGTACGAGG AGG 6119 1 274.3707621 Y 6660 51483 2 6 
AGAAACTATTGAGTACGAGG AGG 6119 2 238.1331143 Y 6660 51483 2 6 
AGAAACTATTGAGTACGAGG AGG 6119 3 124.243364 Y 6660 51483 2 6 
AGTATGCTTACTTTTTCTTG TGG 6153 1 429.6749671 Y 6694 3 0 0 
AGTATGCTTACTTTTTCTTG TGG 6153 2 647.100854 Y 6694 3 0 0 
AGTATGCTTACTTTTTCTTG TGG 6153 3 393.4373192 Y 6694 3 0 0 
TTTGCAGTATACGGAAAAAT TGG 6247 1 3.15129478 Y 6788 0 0 2 
TTTGCAGTATACGGAAAAAT TGG 6247 2 14.18082651 Y 6788 0 0 2 
GTCATTGACATTAACGAAGG TGG 6313 1 25.88403416 Y 6854 0 7 1 
GTCATTGACATTAACGAAGG TGG 6313 2 31.06084099 Y 6854 0 7 1 
CATTAACGAAGGTGGAACAA CGG 6321 1 55.39480302 Y 6862 0 4 0 
CATTAACGAAGGTGGAACAA CGG 6321 2 149.7711341 Y 6862 0 4 0 
CATTAACGAAGGTGGAACAA CGG 6321 3 51.29148428 Y 6862 0 4 0 
TTTTTTACCTCAAATTTTAC AGG 6405 1 42.48992432 Y 6946 0 0 1 
TTTTTTACCTCAAATTTTAC AGG 6405 2 41.55948802 Y 6946 0 0 1 
TTTTTTACCTCAAATTTTAC AGG 6405 3 21.71018031 Y 6946 0 0 1 
TCTCCCCAATCATTAAACGT TGG 6516 1 23.63471085 Y 7057 0 8 4 
TCTCCCCAATCATTAAACGT TGG 6516 2 70.90413255 Y 7057 0 8 4 
TCTCCCCAATCATTAAACGT TGG 6516 3 34.66424258 Y 7057 0 8 4 
AAAAACCAACGTTTAATGAT TGG 6527 1 12.60517912 Y 7068 0 1 0 
AAAAACCAACGTTTAATGAT TGG 6527 2 11.02953173 Y 7068 0 1 0 
AAAAACCAACGTTTAATGAT TGG 6527 3 7.87823695 Y 7068 0 1 0 
GTCAGTATGTACAGATTAAT AGG 6571 1 91.38754862 Y 7112 9 0 1 
GTCAGTATGTACAGATTAAT AGG 6571 2 96.11449079 Y 7112 9 0 1 
GTCAGTATGTACAGATTAAT AGG 6571 3 66.17719038 Y 7112 9 0 1 
CATGACCTGTAATAACAAAG TGG 6602 1 15.5304205 Y 7143 0 2 0 
CATGACCTGTAATAACAAAG TGG 6602 2 10.35361366 Y 7143 0 2 0 
CATGACCTGTAATAACAAAG TGG 6602 3 10.35361366 Y 7143 0 2 0 
GCGCTTCAATAGTGATAGTA GGG 6668 1 244.1474651 Y 7209 0 0 2 
GCGCTTCAATAGTGATAGTA GGG 6668 2 352.8854118 Y 7209 0 0 2 
GCGCTTCAATAGTGATAGTA GGG 6668 3 157.9777716 Y 7209 0 0 2 
TGCGCTTCAATAGTGATAGT AGG 6669 1 61.45024821 Y 7210 0 0 8 
TGCGCTTCAATAGTGATAGT AGG 6669 2 69.32848516 Y 7210 0 0 8 
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TGCGCTTCAATAGTGATAGT AGG 6669 3 29.93730041 Y 7210 0 0 8 
TCTACTACGTCCGTAATGCT AGG 6876 1 477.4211592 Y 7417 37028 6 12 
TCTACTACGTCCGTAATGCT AGG 6876 2 475.8455118 Y 7417 37028 6 12 
TCTACTACGTCCGTAATGCT AGG 6876 3 278.889588 Y 7417 37028 6 12 
ATTTGCAAATCCTAGCATTA CGG 6882 1 67.70475924 Y 7423 0 3 3 
ATTTGCAAATCCTAGCATTA CGG 6882 2 86.16969358 Y 7423 0 3 3 
ATTTGCAAATCCTAGCATTA CGG 6882 3 28.72323119 Y 7423 0 3 3 
GTAGTAGAAGCAATTAGAAA TGG 6907 1 14.3616156 Y 7448 4 2 0 
GTAGTAGAAGCAATTAGAAA TGG 6907 2 12.30995623 Y 7448 4 2 0 
GTAGTAGAAGCAATTAGAAA TGG 6907 3 2.051659371 Y 7448 4 2 0 
AGTTTTATAACGGCTCAGCA GGG 7014 1 377.5053243 Y 7555 45282 18 165780 
AGTTTTATAACGGCTCAGCA GGG 7014 2 315.9555431 Y 7555 45282 18 165780 
AGTTTTATAACGGCTCAGCA GGG 7014 3 80.01471547 Y 7555 45282 18 165780 
GGCTCAGCAGGGTTTCAAGC TGG 7025 1 96.14508423 Y 7566 0 0 6 
GGCTCAGCAGGGTTTCAAGC TGG 7025 2 161.895916 Y 7566 0 0 6 
GGCTCAGCAGGGTTTCAAGC TGG 7025 3 73.19432219 Y 7566 0 0 6 
ATCGTATTTGAAAATGATGA AGG 7109 1 4.103318742 Y 7650 0 0 1 
ATCGTATTTGAAAATGATGA AGG 7109 2 4.103318742 Y 7650 0 0 1 
ATCGTATTTGAAAATGATGA AGG 7109 3 8.206637484 Y 7650 0 0 1 
TCTTGGAAATCATATTTATA CGG 7147 1 2.051659371 Y 7688 177817 5 64548 
TCTTGGAAATCATATTTATA CGG 7147 2 16.41327497 Y 7688 177817 5 64548 
TCTTGGAAATCATATTTATA CGG 7147 3 8.206637484 Y 7688 177817 5 64548 
ATTCAATCAATTGTTTTTCT TGG 7164 1 9.45388434 Y 7705 0 5 0 
ATTCAATCAATTGTTTTTCT TGG 7164 2 11.02953173 Y 7705 0 5 0 
ATTCAATCAATTGTTTTTCT TGG 7164 3 7.87823695 Y 7705 0 5 0 
TTGGTATCAAAATCTAAGCT AGG 7219 1 1.57564739 Y 7760 0 4 0 
TTGGTATCAAAATCTAAGCT AGG 7219 2 12.60517912 Y 7760 0 4 0 
AAACTTACCAATAAGATCAT TGG 7238 1 45.69377431 Y 7779 0 0 2 
AAACTTACCAATAAGATCAT TGG 7238 2 63.0258956 Y 7779 0 0 2 
AAACTTACCAATAAGATCAT TGG 7238 3 15.7564739 Y 7779 0 0 2 
TTTGATACCAATGATCTTAT TGG 7247 1 66.17719038 Y 7788 4 0 0 
TTTGATACCAATGATCTTAT TGG 7247 2 85.08495906 Y 7788 4 0 0 
TTTGATACCAATGATCTTAT TGG 7247 3 36.23988997 Y 7788 4 0 0 
TATTGGTAAGTTTTGTCACT TGG 7264 1 72.47977994 Y 7805 18995 55709 3 
TATTGGTAAGTTTTGTCACT TGG 7264 2 61.45024821 Y 7805 18995 55709 3 
TATTGGTAAGTTTTGTCACT TGG 7264 3 34.66424258 Y 7805 18995 55709 3 
TGGAAATTCAATGAAGATGA AGG 7295 1 90.27301232 Y 7836 60971 0 0 
TGGAAATTCAATGAAGATGA AGG 7295 2 38.98152805 Y 7836 60971 0 0 
TGGAAATTCAATGAAGATGA AGG 7295 3 16.41327497 Y 7836 60971 0 0 
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ACATCATCGCCCTTTTTGTA AGG 7333 1 221.5792121 Y 7874 27 0 3 
ACATCATCGCCCTTTTTGTA AGG 7333 2 644.2210425 Y 7874 27 0 3 
ACATCATCGCCCTTTTTGTA AGG 7333 3 285.1806526 Y 7874 27 0 3 
TTTATTAAACCTTACAAAAA GGG 7340 1 2.051659371 Y 7881 3 0 0 
TTTATTAAACCTTACAAAAA GGG 7340 2 6.154978113 Y 7881 3 0 0 
GCTTTTTGCTTATCTGTCTT CGG 7372 1 228.4688716 Y 7913 1 1 3 
GCTTTTTGCTTATCTGTCTT CGG 7372 2 299.3730041 Y 7913 1 1 3 
GCTTTTTGCTTATCTGTCTT CGG 7372 3 127.6274386 Y 7913 1 1 3 
AGCAATCCATTTGAAAGCAG TGG 7457 1 15.5304205 Y 7998 0 3 0 
AGCAATCCATTTGAAAGCAG TGG 7457 2 20.70722733 Y 7998 0 3 0 
CTTGGTCGTCATATCCAAAT TGG 7464 1 1.57564739 Y 8005 0 2 3 
TTTGAAAGCAGTGGCCAATT TGG 7466 1 31.5129478 Y 8007 6 0 0 
TTTGAAAGCAGTGGCCAATT TGG 7466 2 15.7564739 Y 8007 6 0 0 
TTTGAAAGCAGTGGCCAATT TGG 7466 3 3.15129478 Y 8007 6 0 0 
CACCTTAAAACGCTAAATCT TGG 7482 1 12.60517912 Y 8023 4 0 3 
CACCTTAAAACGCTAAATCT TGG 7482 2 15.7564739 Y 8023 4 0 3 
CACCTTAAAACGCTAAATCT TGG 7482 3 11.02953173 Y 8023 4 0 3 
GACCAAGATTTAGCGTTTTA AGG 7496 1 110.789606 Y 8037 0 5 0 
GACCAAGATTTAGCGTTTTA AGG 7496 2 145.6678153 Y 8037 0 5 0 
GACCAAGATTTAGCGTTTTA AGG 7496 3 59.49812176 Y 8037 0 5 0 
AAGTACCGTCGTTATCTTTC TGG 7533 1 314.7976145 Y 8074 0 5 0 
AAGTACCGTCGTTATCTTTC TGG 7533 2 548.647271 Y 8074 0 5 0 
AAGTACCGTCGTTATCTTTC TGG 7533 3 219.893112 Y 8074 0 5 0 
ACTTATTCCGTCGTTGCTAC TGG 7568 1 739.3867123 Y 8109 0 7 0 
ACTTATTCCGTCGTTGCTAC TGG 7568 2 2208.235483 Y 8109 0 7 0 
ACTTATTCCGTCGTTGCTAC TGG 7568 3 791.491145 Y 8109 0 7 0 
ACCTCTACTTCTGCTTTTAG TGG 7621 1 150.1273981 Y 8162 0 0 2 
ACCTCTACTTCTGCTTTTAG TGG 7621 2 103.5361366 Y 8162 0 0 2 
ACCTCTACTTCTGCTTTTAG TGG 7621 3 98.35932981 Y 8162 0 0 2 
AAAAGCAGAAGTAGAGGTTC CGG 7642 1 138.6350086 Y 8183 1 0 0 
AAAAGCAGAAGTAGAGGTTC CGG 7642 2 232.6090748 Y 8183 1 0 0 
AAAAGCAGAAGTAGAGGTTC CGG 7642 3 123.4378823 Y 8183 1 0 0 
TAGAGATATAGAACTTCACT GGG 7714 1 148.1108547 Y 8255 0 6130 5171 
TAGAGATATAGAACTTCACT GGG 7714 2 242.6496981 Y 8255 0 6130 5171 
TAGAGATATAGAACTTCACT GGG 7714 3 75.63107472 Y 8255 0 6130 5171 
AGAGATATAGAACTTCACTG GGG 7715 1 56.94487515 Y 8256 0 3 0 
AGAGATATAGAACTTCACTG GGG 7715 2 31.06084099 Y 8256 0 3 0 
AGAGATATAGAACTTCACTG GGG 7715 3 51.76806832 Y 8256 0 3 0 
AATTTTCTAGTTGATTCTAC TGG 7726 1 115.9943919 Y 8267 0 2 0 
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AATTTTCTAGTTGATTCTAC TGG 7726 2 72.26388589 Y 8267 0 2 0 
AATTTTCTAGTTGATTCTAC TGG 7726 3 86.84072124 Y 8267 0 2 0 
ACTGTTCTATGAAAGTTGCA AGG 7818 1 162.0810903 Y 8359 0 7 0 
ACTGTTCTATGAAAGTTGCA AGG 7818 2 223.6308714 Y 8359 0 7 0 
ACTGTTCTATGAAAGTTGCA AGG 7818 3 102.5829686 Y 8359 0 7 0 
CTGTTCTATGAAAGTTGCAA GGG 7819 1 205.1659371 Y 8360 0 0 1 
CTGTTCTATGAAAGTTGCAA GGG 7819 2 240.0441464 Y 8360 0 0 1 
CTGTTCTATGAAAGTTGCAA GGG 7819 3 141.5644966 Y 8360 0 0 1 
TTACTCGTTTCTACACTCAT AGG 7870 1 97.69013818 Y 8411 0 0 1 
TTACTCGTTTCTACACTCAT AGG 7870 2 77.20672211 Y 8411 0 0 1 
TTACTCGTTTCTACACTCAT AGG 7870 3 47.2694217 Y 8411 0 0 1 
AACCGCAACTGTGTAATATG CGG 7952 1 10.35361366 Y 8493 6 0 0 
AACCGCAACTGTGTAATATG CGG 7952 2 10.35361366 Y 8493 6 0 0 
CGGAAAGCCTCACGCAGACC TGG 7972 1 832.1201967 Y 8513 25592 6 4 
CGGAAAGCCTCACGCAGACC TGG 7972 2 1130.480103 Y 8513 25592 6 4 
CGGAAAGCCTCACGCAGACC TGG 7972 3 499.0240017 Y 8513 25592 6 4 
CTGGCACATTATGAAGCAGT CGG 7991 1 189.0776868 Y 8532 8 0 4 
CTGGCACATTATGAAGCAGT CGG 7991 2 237.9227559 Y 8532 8 0 4 
CTGGCACATTATGAAGCAGT CGG 7991 3 72.47977994 Y 8532 8 0 4 
CTAATACATGTTTGTCATAG TGG 8025 1 170.8346255 Y 8566 0 3 0 
CTAATACATGTTTGTCATAG TGG 8025 2 186.365046 Y 8566 0 3 0 
CTAATACATGTTTGTCATAG TGG 8025 3 93.18252298 Y 8566 0 3 0 
CACAACGAGCAACATGCGAT TGG 8081 1 182.7750972 Y 8622 0 2 0 
CACAACGAGCAACATGCGAT TGG 8081 2 181.1994499 Y 8622 0 2 0 
CACAACGAGCAACATGCGAT TGG 8081 3 102.4170804 Y 8622 0 2 0 
AATACCACTTGCATGACTCG TGG 8124 1 253.6635348 Y 8665 0 0 1 
AATACCACTTGCATGACTCG TGG 8124 2 310.6084099 Y 8665 0 0 1 
AATACCACTTGCATGACTCG TGG 8124 3 93.18252298 Y 8665 0 0 1 
CTTCCGCCAAGATGACGATT AGG 8213 1 17.33212129 Y 8754 2181 0 0 
CTTCCGCCAAGATGACGATT AGG 8213 2 22.05906346 Y 8754 2181 0 0 
CTTCCGCCAAGATGACGATT AGG 8213 3 9.45388434 Y 8754 2181 0 0 
AGCACTCCTAATCGTCATCT TGG 8223 1 167.0186233 Y 8764 0 1 2 
AGCACTCCTAATCGTCATCT TGG 8223 2 189.0776868 Y 8764 0 1 2 
AGCACTCCTAATCGTCATCT TGG 8223 3 107.1440225 Y 8764 0 1 2 
ACTCCTAATCGTCATCTTGG CGG 8226 1 165.6578186 Y 8767 1 489 0 
ACTCCTAATCGTCATCTTGG CGG 8226 2 238.1331143 Y 8767 1 489 0 
ACTCCTAATCGTCATCTTGG CGG 8226 3 72.47529565 Y 8767 1 489 0 
AAAAACCTGTATTAACTAAA CGG 8286 2 6.154978113 Y 8827 0 1 0 
AAAAACCTGTATTAACTAAA CGG 8286 3 2.051659371 Y 8827 0 1 0 
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AATCTCCGTTTAGTTAATAC AGG 8297 1 8.373926691 Y 8838 0 5 0 
AATCTCCGTTTAGTTAATAC AGG 8297 2 35.97687023 Y 8838 0 5 0 
AATCTCCGTTTAGTTAATAC AGG 8297 3 5.582617794 Y 8838 0 5 0 
TTTTACAAAAGCTTTACCAT AGG 8321 1 83.50931167 Y 8862 15 24 215581 
TCAATTAGTTTGTCCGCCTA TGG 8321 1 1025.829686 Y 8862 0 7 7 
TTTTACAAAAGCTTTACCAT AGG 8321 2 81.93366428 Y 8862 15 24 215581 
TCAATTAGTTTGTCCGCCTA TGG 8321 2 1489.504703 Y 8862 0 7 7 
TTTTACAAAAGCTTTACCAT AGG 8321 3 26.78600563 Y 8862 15 24 215581 
TCAATTAGTTTGTCCGCCTA TGG 8321 3 841.1803421 Y 8862 0 7 7 
TTTTTTGATGTCTATTACCC AGG 8363 1 82.80883061 Y 8904 0 5 0 
TTTTTTGATGTCTATTACCC AGG 8363 2 113.5132285 Y 8904 0 5 0 
TTTTTTGATGTCTATTACCC AGG 8363 3 33.8058522 Y 8904 0 5 0 
AAAGTTACATTACAGCCCCT GGG 8364 1 419.1222057 Y 8905 3 0 2 
AAAGTTACATTACAGCCCCT GGG 8364 2 564.0817656 Y 8905 3 0 2 
AAAGTTACATTACAGCCCCT GGG 8364 3 173.3212129 Y 8905 3 0 2 
GAAACAATAAGTAAACTTTC TGG 8405 1 18.60872598 Y 8946 0 1 5 
GAAACAATAAGTAAACTTTC TGG 8405 2 44.66094235 Y 8946 0 1 5 
GAAACAATAAGTAAACTTTC TGG 8405 3 23.57105291 Y 8946 0 1 5 
AAAGTTTACTTATTGTTTCT AGG 8425 1 45.69377431 Y 8966 0 6 11 
AAAGTTTACTTATTGTTTCT AGG 8425 2 55.14765865 Y 8966 0 6 11 
AAAGTTTACTTATTGTTTCT AGG 8425 3 33.08859519 Y 8966 0 6 11 
GTTAAAAGAATGTTAAAGTC AGG 8438 1 20.46959858 Y 8979 0 6 0 
GTTAAAAGAATGTTAAAGTC AGG 8438 2 24.81163464 Y 8979 0 6 0 
GTTAAAAGAATGTTAAAGTC AGG 8438 3 25.74207094 Y 8979 0 6 0 
GAAAAACAAAGATTTGTTTC GGG 8471 1 37.21745196 Y 9012 0 0 2 
GAAAAACAAAGATTTGTTTC GGG 8471 2 30.084107 Y 9012 0 0 2 
GAAAAACAAAGATTTGTTTC GGG 8471 3 19.84930771 Y 9012 0 0 2 
ATTAATAACCTAGTAAGGTT AGG 8594 1 14.18082651 Y 9135 0 0 1 
ATTAATAACCTAGTAAGGTT AGG 8594 2 29.93730041 Y 9135 0 0 1 
ATTAATAACCTAGTAAGGTT AGG 8594 3 11.02953173 Y 9135 0 0 1 
TTAAAACCCCTAACCTTACT AGG 8602 1 85.08495906 Y 9143 3 15 158780 
TTAAAACCCCTAACCTTACT AGG 8602 2 34.66424258 Y 9143 3 15 158780 
TTAAAACCCCTAACCTTACT AGG 8602 3 25.21035824 Y 9143 3 15 158780 
TCGGTTGATTCTATATCTAA CGG 8640 1 53.34314365 Y 9181 0 4 2 
TCGGTTGATTCTATATCTAA CGG 8640 2 149.7711341 Y 9181 0 4 2 
TCGGTTGATTCTATATCTAA CGG 8640 3 51.29148428 Y 9181 0 4 2 
GAATGACGGTATGAATATAT CGG 8667 1 9.45388434 Y 9208 0 0 6 
GAATGACGGTATGAATATAT CGG 8667 2 29.93730041 Y 9208 0 0 6 
GAATGACGGTATGAATATAT CGG 8667 3 17.33212129 Y 9208 0 0 6 
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GTTTTAAACCCAAAGAATGA CGG 8681 1 32.82654994 Y 9222 0 0 64 
GTTTTAAACCCAAAGAATGA CGG 8681 2 125.1512216 Y 9222 0 0 64 
GTTTTAAACCCAAAGAATGA CGG 8681 3 28.72323119 Y 9222 0 0 64 
ATATTCATACCGTCATTCTT TGG 8688 1 160.7160338 Y 9229 0 1 0 
ATATTCATACCGTCATTCTT TGG 8688 2 159.1403864 Y 9229 0 1 0 
ATATTCATACCGTCATTCTT TGG 8688 3 53.57201126 Y 9229 0 1 0 
TTAAAAGAATAGCATCATTT GGG 8767 1 3.15129478 Y 9308 0 0 2 
TTAAAAGAATAGCATCATTT GGG 8767 2 11.02953173 Y 9308 0 0 2 
TTAAAAGAATAGCATCATTT GGG 8767 3 1.57564739 Y 9308 0 0 2 
TTATTTCAACAAATGAATGG TGG 8803 1 10.35361366 Y 9344 1 0 5049 
TTATTTCAACAAATGAATGG TGG 8803 2 5.176806832 Y 9344 1 0 5049 
TTATTTCAACAAATGAATGG TGG 8803 3 10.35361366 Y 9344 1 0 5049 
TGGGAAATTCCACCTTTATG TGG 9030 1 10.35361366 Y 9571 0 0 3 
TGGGAAATTCCACCTTTATG TGG 9030 2 82.82890931 Y 9571 0 0 3 
TGGGAAATTCCACCTTTATG TGG 9030 3 20.70722733 Y 9571 0 0 3 
AAATAACTTTATCCACATAA AGG 9034 1 34.87820931 Y 9575 8 0 1 
AAATAACTTTATCCACATAA AGG 9034 2 28.72323119 Y 9575 8 0 1 
AAATAACTTTATCCACATAA AGG 9034 3 43.08484679 Y 9575 8 0 1 
AAACTTGGGAACTTGTCTTT GGG 9049 1 12.60517912 Y 9590 0 2 0 
AAACTTGGGAACTTGTCTTT GGG 9049 2 9.45388434 Y 9590 0 2 0 
AAACTTGGGAACTTGTCTTT GGG 9049 3 15.7564739 Y 9590 0 2 0 
TTATTGAAGGCGCATCAAAA GGG 9091 2 12.30995623 Y 9632 4 0 0 
ATTATTGAAGGCGCATCAAA AGG 9092 1 2.051659371 Y 9633 0 1 0 
ATTATTGAAGGCGCATCAAA AGG 9092 2 4.103318742 Y 9633 0 1 0 
TCAATACCTTTACCTAAAAT AGG 9135 1 3.15129478 Y 9676 0 10 0 
TCAATACCTTTACCTAAAAT AGG 9135 2 1.57564739 Y 9676 0 10 0 
TCAATACCTTTACCTAAAAT AGG 9135 3 3.15129478 Y 9676 0 10 0 
CCATTTCGTTATCTCCTTTC TGG 9193 1 342.400558 Y 9734 8 32 6895 
CCATTTCGTTATCTCCTTTC TGG 9193 2 357.9078297 Y 9734 8 32 6895 
CCATTTCGTTATCTCCTTTC TGG 9193 3 130.5712273 Y 9734 8 32 6895 
ATTTAAGTGCTAAAGCTAAA GGG 9301 1 26.67157182 Y 9842 0 0 4 
ATTTAAGTGCTAAAGCTAAA GGG 9301 2 26.67157182 Y 9842 0 0 4 
ATTTAAGTGCTAAAGCTAAA GGG 9301 3 12.30995623 Y 9842 0 0 4 
GTGTATATTTGCCAATTGTC AGG 9332 1 586.7951592 Y 9873 0 2 0 
GTGTATATTTGCCAATTGTC AGG 9332 2 744.6591846 Y 9873 0 2 0 
GTGTATATTTGCCAATTGTC AGG 9332 3 238.1916925 Y 9873 0 2 0 
TCCTAAGTCGTCCTGACAAT TGG 9337 1 53.57201126 Y 9878 5 0 0 
TCCTAAGTCGTCCTGACAAT TGG 9337 2 92.96319601 Y 9878 5 0 0 
TCCTAAGTCGTCCTGACAAT TGG 9337 3 37.81553736 Y 9878 5 0 0 
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ACCAACCGAAATGCCATTTT CGG 9518 1 7.87823695 Y 10059 0 4 0 
ACCAACCGAAATGCCATTTT CGG 9518 2 45.69377431 Y 10059 0 4 0 
ACCAACCGAAATGCCATTTT CGG 9518 3 1.57564739 Y 10059 0 4 0 
AAAACGGATTATCGGCAAAC GGG 9541 1 41.55948802 Y 10082 0 0 1 
AAAACGGATTATCGGCAAAC GGG 9541 2 49.00297841 Y 10082 0 0 1 
AAAACGGATTATCGGCAAAC GGG 9541 3 10.23479929 Y 10082 0 0 1 
GGAAAAACGGAAAACCGAAA AGG 9576 2 6.154978113 Y 10117 0 0 4 
GAAAAACGGAAAACCGAAAA GGG 9577 1 2.051659371 Y 10118 0 0 2 
GAAAAACGGAAAACCGAAAA GGG 9577 2 2.051659371 Y 10118 0 0 2 
TAATGATGGAAGTATATTGT CGG 9656 1 7.87823695 Y 10197 0 12 0 
TAATGATGGAAGTATATTGT CGG 9656 2 25.21035824 Y 10197 0 12 0 
AGGGAATGGAATACACAGTC GGG 9667 1 115.3741011 Y 10208 0 2 0 
AGGGAATGGAATACACAGTC GGG 9667 2 191.980023 Y 10208 0 2 0 
AGGGAATGGAATACACAGTC GGG 9667 3 92.42333903 Y 10208 0 2 0 
GTATTCGATAATTTCTTTAT AGG 9687 3 1.57564739 Y 10228 0 3 0 
ATGGAATCAAGATTTTAGGT TGG 9794 1 14.18082651 Y 10335 18 784259 5 
ATGGAATCAAGATTTTAGGT TGG 9794 2 15.7564739 Y 10335 18 784259 5 
ATGGAATCAAGATTTTAGGT TGG 9794 3 17.33212129 Y 10335 18 784259 5 
CAAAAAGTGTTTCTGGTCTA AGG 9865 1 36.92986868 Y 10406 0 1 0 
CAAAAAGTGTTTCTGGTCTA AGG 9865 2 86.16969358 Y 10406 0 1 0 
CAAAAAGTGTTTCTGGTCTA AGG 9865 3 51.29148428 Y 10406 0 1 0 
ACTTTTTGGCAGTAAATTTG AGG 9896 2 20.70722733 Y 10437 0 7 0 
ACTTTTTGGCAGTAAATTTG AGG 9896 3 10.35361366 Y 10437 0 7 0 
TCCAATTGATCCGTGCCAGT TGG 9926 1 918.6024284 Y 10467 26467 9 5 
TCCAATTGATCCGTGCCAGT TGG 9926 2 1435.414772 Y 10467 26467 9 5 
TCCAATTGATCCGTGCCAGT TGG 9926 3 502.6315174 Y 10467 26467 9 5 
ACCAACTGGCACGGATCAAT TGG 9941 1 283.6165302 Y 10482 3 12 0 
ACCAACTGGCACGGATCAAT TGG 9941 2 267.8600563 Y 10482 3 12 0 
ACCAACTGGCACGGATCAAT TGG 9941 3 215.8636924 Y 10482 3 12 0 
GAAGTACGACGAAAGTTATT GGG 9971 1 28.36165302 Y 10512 0 0 1 
GAAGTACGACGAAAGTTATT GGG 9971 2 23.63471085 Y 10512 0 0 1 
GAAGTACGACGAAAGTTATT GGG 9971 3 9.45388434 Y 10512 0 0 1 
TTTATCTTTTCGCTGAATAG TGG 9998 1 36.23764782 Y 10539 0 8 0 
TTTATCTTTTCGCTGAATAG TGG 9998 2 25.88403416 Y 10539 0 8 0 
TTTATCTTTTCGCTGAATAG TGG 9998 3 41.41445466 Y 10539 0 8 0 
AATCCTTTTTCGACATGAGT AGG 10043 1 163.8673286 Y 10584 7 1 0 
AATCCTTTTTCGACATGAGT AGG 10043 2 162.2916812 Y 10584 7 1 0 
AATCCTTTTTCGACATGAGT AGG 10043 3 86.66060645 Y 10584 7 1 0 
GGATTGAAATGTGAGAGATG TGG 10077 1 72.47529565 Y 10618 0 4 0 
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GGATTGAAATGTGAGAGATG TGG 10077 2 62.12168198 Y 10618 0 4 0 
GGATTGAAATGTGAGAGATG TGG 10077 3 25.88403416 Y 10618 0 4 0 
CTTTATACTCGTAACCATTC GGG 10126 1 119.7161371 Y 10667 2 1 2 
CTTTATACTCGTAACCATTC GGG 10126 2 357.9078297 Y 10667 2 1 2 
CTTTATACTCGTAACCATTC GGG 10126 3 52.10443274 Y 10667 2 1 2 
TCTTTATACTCGTAACCATT CGG 10127 1 154.4134442 Y 10668 7 0 0 
TCTTTATACTCGTAACCATT CGG 10127 2 151.2621494 Y 10668 7 0 0 
TCTTTATACTCGTAACCATT CGG 10127 3 78.7823695 Y 10668 7 0 0 
CCTACTAAAAAACACCCGAA TGG 10128 1 65.65309987 Y 10669 2 0 0 
CCTACTAAAAAACACCCGAA TGG 10128 2 71.80807799 Y 10669 2 0 0 
CCTACTAAAAAACACCCGAA TGG 10128 3 2.051659371 Y 10669 2 0 0 
ACAGCAATAGAGTACGTACA AGG 10320 1 184.6493434 Y 10861 0 9 0 
ACAGCAATAGAGTACGTACA AGG 10320 2 441.1067648 Y 10861 0 9 0 
ACAGCAATAGAGTACGTACA AGG 10320 3 100.5313092 Y 10861 0 9 0 
TTGCAAGGTTCATACGGAAC TGG 10374 1 49.62326928 Y 10915 0 0 2 
TTGCAAGGTTCATACGGAAC TGG 10374 2 61.0986503 Y 10915 0 0 2 
TTGCAAGGTTCATACGGAAC TGG 10374 3 57.99719597 Y 10915 0 0 2 
CTTTTGCGATAGCGTATGCT AGG 10390 1 223.7419294 Y 10931 0 0 6 
CTTTTGCGATAGCGTATGCT AGG 10390 2 316.7051254 Y 10931 0 0 6 
CTTTTGCGATAGCGTATGCT AGG 10390 3 168.5942707 Y 10931 0 0 6 
TTGATACGATCCATCAACAT TGG 10454 1 195.3802764 Y 10995 11 1 7 
TTGATACGATCCATCAACAT TGG 10454 2 253.6792298 Y 10995 11 1 7 
TTGATACGATCCATCAACAT TGG 10454 3 116.5979069 Y 10995 11 1 7 
TATGCACATACCAATGTTGA TGG 10460 1 172.3393872 Y 11001 0 0 4 
TATGCACATACCAATGTTGA TGG 10460 2 260.5607401 Y 11001 0 0 4 
TATGCACATACCAATGTTGA TGG 10460 3 149.7711341 Y 11001 0 0 4 
TTTACTTGTACTAGATGATA TGG 10559 1 73.85973736 Y 11100 4 0 0 
TTTACTTGTACTAGATGATA TGG 10559 2 96.42799044 Y 11100 4 0 0 
TTTACTTGTACTAGATGATA TGG 10559 3 69.75641861 Y 11100 4 0 0 
TTACTTGTACTAGATGATAT GGG 10560 1 70.90413255 Y 11101 1 0 7 
TTACTTGTACTAGATGATAT GGG 10560 2 80.35801689 Y 11101 1 0 7 
TTACTTGTACTAGATGATAT GGG 10560 3 56.72330604 Y 11101 1 0 7 
AGCATTGTTGATAACAGAGT AGG 10620 1 55.14765865 Y 11161 7 0 0 
AGCATTGTTGATAACAGAGT AGG 10620 2 69.32848516 Y 11161 7 0 0 
AGCATTGTTGATAACAGAGT AGG 10620 3 75.63107472 Y 11161 7 0 0 
AACTAAATCAAAATATGAAC TGG 10681 1 11.16523559 Y 11222 0 0 1 
AACTAAATCAAAATATGAAC TGG 10681 2 36.59716109 Y 11222 0 0 1 
AACTAAATCAAAATATGAAC TGG 10681 3 12.71596275 Y 11222 0 0 1 
GCGAGAAAAGTAAGAGTAAT CGG 10734 1 77.20672211 Y 11275 9 0 0 
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GCGAGAAAAGTAAGAGTAAT CGG 10734 2 91.38754862 Y 11275 9 0 0 
GCGAGAAAAGTAAGAGTAAT CGG 10734 3 42.54247953 Y 11275 9 0 0 
TTTAGTTTTTAAAAATTCTT TGG 10772 1 4.72694217 Y 11313 0 2 0 
TTTAGTTTTTAAAAATTCTT TGG 10772 2 4.72694217 Y 11313 0 2 0 
TTTAGTTTTTAAAAATTCTT TGG 10772 3 1.57564739 Y 11313 0 2 0 
GAAACTCATAGATGAGGCAC AGG 10837 1 295.5685976 Y 11378 0 11 0 
GAAACTCATAGATGAGGCAC AGG 10837 2 494.3718202 Y 11378 0 11 0 
GAAACTCATAGATGAGGCAC AGG 10837 3 228.2670387 Y 11378 0 11 0 
CCTTAATATTCGACGATAGC GGG 10903 1 102.6581383 Y 11444 0 0 2 
CCTTAATATTCGACGATAGC GGG 10903 2 131.1915182 Y 11444 0 0 2 
CCTTAATATTCGACGATAGC GGG 10903 3 76.60592195 Y 11444 0 0 2 
TATCTTCCGTGCCATCTTCT CGG 10962 1 623.9563664 Y 11503 7 15 166 
TATCTTCCGTGCCATCTTCT CGG 10962 2 1011.565624 Y 11503 7 15 166 
TATCTTCCGTGCCATCTTCT CGG 10962 3 504.2071648 Y 11503 7 15 166 
TATTACTTATACCGAGAAGA TGG 10967 1 8.206637484 Y 11508 0 10 0 
TATTACTTATACCGAGAAGA TGG 10967 2 24.61991245 Y 11508 0 10 0 
TATTACTTATACCGAGAAGA TGG 10967 3 8.206637484 Y 11508 0 10 0 
AGATGGCACGGAAGATATTA AGG 10984 1 10.25829686 Y 11525 0 3 0 
AGATGGCACGGAAGATATTA AGG 10984 2 10.25829686 Y 11525 0 3 0 
AGATGGCACGGAAGATATTA AGG 10984 3 12.30995623 Y 11525 0 3 0 
AATGAAGTTTATTCGCTCAC AGG 11030 1 693.4851882 Y 11571 0 0 5 
AATGAAGTTTATTCGCTCAC AGG 11030 2 1286.793402 Y 11571 0 0 5 
AATGAAGTTTATTCGCTCAC AGG 11030 3 390.7832456 Y 11571 0 0 5 
TTTCTTTTCGTCGCTGAAAT GGG 11039 1 3.15129478 Y 11580 0 4 0 
TTTCTTTTCGTCGCTGAAAT GGG 11039 3 9.45388434 Y 11580 0 4 0 
CTTTTATATGAGCAAGAGCT AGG 11123 1 14.18082651 Y 11664 0 3 0 
CTTTTATATGAGCAAGAGCT AGG 11123 2 25.21035824 Y 11664 0 3 0 
CTTTTATATGAGCAAGAGCT AGG 11123 3 48.84506909 Y 11664 0 3 0 
CGTGGACGAGGCGAGCCCAT AGG 11206 1 182.7750972 Y 11747 0 0 3 
CGTGGACGAGGCGAGCCCAT AGG 11206 2 277.3139406 Y 11747 0 0 3 
CGTGGACGAGGCGAGCCCAT AGG 11206 3 64.60154299 Y 11747 0 0 3 
GAAACGTTCGAGGCACCTAT GGG 11207 1 167.0186233 Y 11748 0 5 0 
GAAACGTTCGAGGCACCTAT GGG 11207 2 130.7787334 Y 11748 0 5 0 
GAAACGTTCGAGGCACCTAT GGG 11207 3 88.23625384 Y 11748 0 5 0 
GTATTACGAAAGCGTGGACG AGG 11218 1 170.8346255 Y 11759 0 5 0 
GTATTACGAAAGCGTGGACG AGG 11218 2 77.65210248 Y 11759 0 5 0 
GTATTACGAAAGCGTGGACG AGG 11218 3 82.82890931 Y 11759 0 5 0 
ATCATAAAGCGTATATACAA GGG 11298 1 16.41327497 Y 11839 0 2 1 
ATCATAAAGCGTATATACAA GGG 11298 2 38.98152805 Y 11839 0 2 1 
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ATCATAAAGCGTATATACAA GGG 11298 3 2.051659371 Y 11839 0 2 1 
TTCGACCATGATTTAAGTAA TGG 11362 1 34.87820931 Y 11903 0 0 2 
TTCGACCATGATTTAAGTAA TGG 11362 2 71.80807799 Y 11903 0 0 2 
TTCGACCATGATTTAAGTAA TGG 11362 3 34.87820931 Y 11903 0 0 2 
ACTTTCCATTACTTAAATCA TGG 11373 1 184.6493434 Y 11914 6 177225 1 
ACTTTCCATTACTTAAATCA TGG 11373 2 155.9261122 Y 11914 6 177225 1 
ACTTTCCATTACTTAAATCA TGG 11373 3 38.98152805 Y 11914 6 177225 1 
TTAATTAAGTTATCGATATC CGG 11428 1 54.27545078 Y 11969 0 6 1 
TTAATTAAGTTATCGATATC CGG 11428 2 78.15664912 Y 11969 0 6 1 
TTAATTAAGTTATCGATATC CGG 11428 3 41.86963346 Y 11969 0 6 1 
ACAGTATTAGACGCATGTAA TGG 11468 1 102.5829686 Y 12009 0 3 0 
ACAGTATTAGACGCATGTAA TGG 11468 2 160.0294309 Y 12009 0 3 0 
ACAGTATTAGACGCATGTAA TGG 11468 3 92.3246717 Y 12009 0 3 0 
AGCTAGTTATTTCTGTAATT TGG 11496 1 20.48341607 Y 12037 0 3 0 
AGCTAGTTATTTCTGTAATT TGG 11496 2 29.93730041 Y 12037 0 3 0 
AGCTAGTTATTTCTGTAATT TGG 11496 3 3.15129478 Y 12037 0 3 0 
TACTGATATTCAACTTCTGT AGG 11619 1 154.4134442 Y 12160 0 1 0 
TACTGATATTCAACTTCTGT AGG 11619 2 196.9559238 Y 12160 0 1 0 
TACTGATATTCAACTTCTGT AGG 11619 3 72.47977994 Y 12160 0 1 0 
GGATATCGAAAAAGAAGCGC TGG 11670 1 570.3574513 Y 12211 0 2 0 
GGATATCGAAAAAGAAGCGC TGG 11670 2 928.265281 Y 12211 0 2 0 
GGATATCGAAAAAGAAGCGC TGG 11670 3 375.8962648 Y 12211 0 2 0 
TCATACTCTAGTAATTCGTC TGG 11697 1 648.5141004 Y 12238 2 8 10 
TCATACTCTAGTAATTCGTC TGG 11697 2 867.4767761 Y 12238 2 8 10 
TCATACTCTAGTAATTCGTC TGG 11697 3 417.4557528 Y 12238 2 8 10 
AAAAAGAACGGGTTAACTCC TGG 11839 1 42.17977889 Y 12380 0 10 0 
AAAAAGAACGGGTTAACTCC TGG 11839 2 32.8754159 Y 12380 0 10 0 
AAAAAGAACGGGTTAACTCC TGG 11839 3 26.67250724 Y 12380 0 10 0 
ACTCTTTTTGCAACCATTCC AGG 11841 1 461.1862589 Y 12382 17 0 1 
ACTCTTTTTGCAACCATTCC AGG 11841 2 789.0099816 Y 12382 17 0 1 
ACTCTTTTTGCAACCATTCC AGG 11841 3 220.8235483 Y 12382 17 0 1 
GAACGGGTTAACTCCTGGAA TGG 11844 1 141.5644966 Y 12385 0 7 0 
GAACGGGTTAACTCCTGGAA TGG 11844 2 184.6493434 Y 12385 0 7 0 
GAACGGGTTAACTCCTGGAA TGG 11844 3 22.56825308 Y 12385 0 7 0 
ATGGTTGCAAAAAGAGTACG TGG 11863 1 20.70722733 Y 12404 4 0 0 
ATGGTTGCAAAAAGAGTACG TGG 11863 2 20.70722733 Y 12404 4 0 0 
ATGGTTGCAAAAAGAGTACG TGG 11863 3 15.5304205 Y 12404 4 0 0 
AAAAAGAGTACGTGGTGGCT GGG 11871 1 269.4357037 Y 12412 0 0 4 
AAAAAGAGTACGTGGTGGCT GGG 11871 2 438.0299744 Y 12412 0 0 4 
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AAAAAGAGTACGTGGTGGCT GGG 11871 3 173.3212129 Y 12412 0 0 4 
GAAGCCTTAAACGCACCTTA TGG 11902 1 240.0441464 Y 12443 0 2 0 
GAAGCCTTAAACGCACCTTA TGG 11902 2 878.1102108 Y 12443 0 2 0 
GAAGCCTTAAACGCACCTTA TGG 11902 3 320.0588619 Y 12443 0 2 0 
GCAAAGAACGTGAAATAGCT AGG 11981 1 33.08859519 Y 12522 0 4 0 
GCAAAGAACGTGAAATAGCT AGG 11981 2 33.08859519 Y 12522 0 4 0 
GCAAAGAACGTGAAATAGCT AGG 11981 3 11.02953173 Y 12522 0 4 0 
AGCTAGGCAACGACGTAAAG AGG 11997 2 15.5304205 Y 12538 0 0 8 
AAGAGGTTGAACTACGTAAG AGG 12014 1 181.1882391 Y 12555 0 3 0 
AAGAGGTTGAACTACGTAAG AGG 12014 2 165.6578186 Y 12555 0 3 0 
AAGAGGTTGAACTACGTAAG AGG 12014 3 36.23764782 Y 12555 0 3 0 
AACATTCACGTGATCCGTAC TGG 12065 1 731.0127856 Y 12606 2 3 0 
AACATTCACGTGATCCGTAC TGG 12065 2 915.2391728 Y 12606 2 3 0 
AACATTCACGTGATCCGTAC TGG 12065 3 467.699313 Y 12606 2 3 0 
CACTCCATTTCTTGAACATT TGG 12089 1 20.48341607 Y 12630 0 1 0 
CACTCCATTTCTTGAACATT TGG 12089 2 25.21035824 Y 12630 0 1 0 
CACTCCATTTCTTGAACATT TGG 12089 3 14.18082651 Y 12630 0 1 0 
TCGCCGTATGTGTAATGTGC TGG 12179 1 1674.165047 Y 12720 0 1 12 
TCGCCGTATGTGTAATGTGC TGG 12179 2 2046.029422 Y 12720 0 1 12 
TCGCCGTATGTGTAATGTGC TGG 12179 3 1027.201674 Y 12720 0 1 12 
CCACAATTAGCATTTGCAAT AGG 12264 1 63.0258956 Y 12805 10 0 1 
CCACAATTAGCATTTGCAAT AGG 12264 2 58.29895343 Y 12805 10 0 1 
CCACAATTAGCATTTGCAAT AGG 12264 3 42.54247953 Y 12805 10 0 1 
TCCTCATGACCATTCTTTAA CGG 12299 1 88.22135295 Y 12840 0 0 5 
TCCTCATGACCATTCTTTAA CGG 12299 2 182.597684 Y 12840 0 0 5 
TCCTCATGACCATTCTTTAA CGG 12299 3 65.65309987 Y 12840 0 0 5 
TTTACGCGCGTTATCTGTCA TGG 12377 1 328.2654994 Y 12918 0 1 0 
TTTACGCGCGTTATCTGTCA TGG 12377 2 309.800565 Y 12918 0 1 0 
TTTACGCGCGTTATCTGTCA TGG 12377 3 131.3061997 Y 12918 0 1 0 
GTATCAGGATAACGAGCGAG TGG 12454 1 243.3099211 Y 12995 12 0 0 
GTATCAGGATAACGAGCGAG TGG 12454 2 129.4201708 Y 12995 12 0 0 
GTATCAGGATAACGAGCGAG TGG 12454 3 93.18252298 Y 12995 12 0 0 
AATAAGCGCCATTCACTACA TGG 12468 1 147.7194747 Y 13009 0 4 1 
AATAAGCGCCATTCACTACA TGG 12468 2 326.21384 Y 13009 0 4 1 
AATAAGCGCCATTCACTACA TGG 12468 3 59.49812176 Y 13009 0 4 1 
GCACATATCCATGTAGTGAA TGG 12476 1 500.6048865 Y 13017 0 0 16 
GCACATATCCATGTAGTGAA TGG 12476 2 900.6784639 Y 13017 0 0 16 
GCACATATCCATGTAGTGAA TGG 12476 3 451.3650616 Y 13017 0 0 16 
ATGGCGCTTATTACTTTCAC GGG 12495 1 123.1277369 Y 13036 0 9 0 
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ATGGCGCTTATTACTTTCAC GGG 12495 2 308.9048513 Y 13036 0 9 0 
ATGGCGCTTATTACTTTCAC GGG 12495 3 25.74207094 Y 13036 0 9 0 
TTTTTCACACCTTGCCAATC TGG 12511 1 127.469773 Y 13052 0 4 0 
TTTTTCACACCTTGCCAATC TGG 12511 2 299.6004883 Y 13052 0 4 0 
TTTTTCACACCTTGCCAATC TGG 12511 3 118.4755554 Y 13052 0 4 0 
ACGGGCATATCGTACCAGAT TGG 12513 1 124.4761438 Y 13054 1 1 0 
ACGGGCATATCGTACCAGAT TGG 12513 2 334.0372467 Y 13054 1 1 0 
ACGGGCATATCGTACCAGAT TGG 12513 3 132.3543808 Y 13054 1 1 0 
CATATCGTACCAGATTGGCA AGG 12518 1 668.8409549 Y 13059 8 4 1 
CATATCGTACCAGATTGGCA AGG 12518 2 1009.416411 Y 13059 8 4 1 
CATATCGTACCAGATTGGCA AGG 12518 3 262.6123995 Y 13059 8 4 1 
ATTAGACGAGTTAATTAAAT GGG 12681 1 4.72694217 Y 13222 4 0 3 
ATTAGACGAGTTAATTAAAT GGG 12681 2 9.45388434 Y 13222 4 0 3 
ATTAGACGAGTTAATTAAAT GGG 12681 3 4.72694217 Y 13222 4 0 3 
TTTCAATATCAACTATGAAG GGG 12812 1 10.35361366 Y 13353 0 9 0 
TTTCAATATCAACTATGAAG GGG 12812 2 31.06084099 Y 13353 0 9 0 
CTTATCAAATACCGTGTCTT TGG 12844 1 187.5020394 Y 13385 0 12 0 
CTTATCAAATACCGTGTCTT TGG 12844 2 248.9522876 Y 13385 0 12 0 
CTTATCAAATACCGTGTCTT TGG 12844 3 85.08495906 Y 13385 0 12 0 
AAAAGAAGTAACCAAAGACA CGG 12849 1 30.77489057 Y 13390 3 5 0 
AAAAGAAGTAACCAAAGACA CGG 12849 2 90.27301232 Y 13390 3 5 0 
AAAAGAAGTAACCAAAGACA CGG 12849 3 61.54978113 Y 13390 3 5 0 
TTTGAAATGTACGAGATGGA AGG 12886 1 434.9517867 Y 13427 0 6 0 
TTTGAAATGTACGAGATGGA AGG 12886 2 869.9035733 Y 13427 0 6 0 
TTTGAAATGTACGAGATGGA AGG 12886 3 473.9333147 Y 13427 0 6 0 
AGTATAAAAGAATGTTTATA TGG 12943 1 4.103318742 Y 13484 4 0 3 
AGTATAAAAGAATGTTTATA TGG 12943 2 36.92986868 Y 13484 4 0 3 
AGTATAAAAGAATGTTTATA TGG 12943 3 4.103318742 Y 13484 4 0 3 
GTTTAAGATATAGAATGCTT TGG 12964 1 69.32848516 Y 13505 4 0 988 
GTTTAAGATATAGAATGCTT TGG 12964 2 130.7787334 Y 13505 4 0 988 
GTTTAAGATATAGAATGCTT TGG 12964 3 48.84506909 Y 13505 4 0 988 
ATATGACGATGACGTTAATC TGG 13007 1 50.24356015 Y 13548 0 2 0 
ATATGACGATGACGTTAATC TGG 13007 2 35.35657936 Y 13548 0 2 0 
ATATGACGATGACGTTAATC TGG 13007 3 33.8058522 Y 13548 0 2 0 
AATCTGGAAAGATGGGGAGT TGG 13023 1 99.26578557 Y 13564 0 0 2 
AATCTGGAAAGATGGGGAGT TGG 13023 2 88.23625384 Y 13564 0 0 2 
AATCTGGAAAGATGGGGAGT TGG 13023 3 25.21035824 Y 13564 0 0 2 
GATACAAAGACTTACTTTAT AGG 13044 1 17.33212129 Y 13585 0 9 0 
GATACAAAGACTTACTTTAT AGG 13044 2 37.81553736 Y 13585 0 9 0 
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GATACAAAGACTTACTTTAT AGG 13044 3 18.90776868 Y 13585 0 9 0 
TTTTGTGCAAAGTACGAATG AGG 13127 2 5.176806832 Y 13668 1 0 0 
CAGTTTTAATACCGTATTCG TGG 13140 1 93.18252298 Y 13681 15816 2 12974 
CAGTTTTAATACCGTATTCG TGG 13140 2 82.82890931 Y 13681 15816 2 12974 
CAGTTTTAATACCGTATTCG TGG 13140 3 41.41445466 Y 13681 15816 2 12974 
CGACCTCTATGCTTGCAGTT TGG 13183 1 115.0222595 Y 13724 0 8 2 
CGACCTCTATGCTTGCAGTT TGG 13183 2 55.14765865 Y 13724 0 8 2 
CGACCTCTATGCTTGCAGTT TGG 13183 3 36.23988997 Y 13724 0 8 2 
GTTCCAAACTGCAAGCATAG AGG 13196 1 15.5304205 Y 13737 0 1 0 
GTTCCAAACTGCAAGCATAG AGG 13196 2 51.76806832 Y 13737 0 1 0 
GTTCCAAACTGCAAGCATAG AGG 13196 3 5.176806832 Y 13737 0 1 0 
TCGTCCCACACTCGATATTT CGG 13231 1 26.78600563 Y 13772 1 0 1 
TCGTCCCACACTCGATATTT CGG 13231 2 37.81553736 Y 13772 1 0 1 
TCGTCCCACACTCGATATTT CGG 13231 3 33.08859519 Y 13772 1 0 1 
CGAGTGTGGGACGAATATAC AGG 13256 1 180.8147874 Y 13797 0 9 0 
CGAGTGTGGGACGAATATAC AGG 13256 2 231.9887839 Y 13797 0 9 0 
CGAGTGTGGGACGAATATAC AGG 13256 3 110.1016287 Y 13797 0 9 0 
GGAAGAATACACGATGTTGT AGG 13277 1 672.8014355 Y 13818 40 24899 2 
GGAAGAATACACGATGTTGT AGG 13277 2 761.0376894 Y 13818 40 24899 2 
GGAAGAATACACGATGTTGT AGG 13277 3 340.3398362 Y 13818 40 24899 2 
AGTTCACTATGAAAACTACG CGG 13321 1 108.7129435 Y 13862 14 0 5 
AGTTCACTATGAAAACTACG CGG 13321 2 82.82890931 Y 13862 14 0 5 
AGTTCACTATGAAAACTACG CGG 13321 3 82.82890931 Y 13862 14 0 5 
GTAGAACTTATGCAAAGTAC AGG 13382 1 215.2409305 Y 13923 10 3 0 
GTAGAACTTATGCAAAGTAC AGG 13382 2 375.2759739 Y 13923 10 3 0 
GTAGAACTTATGCAAAGTAC AGG 13382 3 277.2700171 Y 13923 10 3 0 
CCTATTACAGATTCATCGTC TGG 13462 1 571.9081785 Y 14003 11 98 4 
CCTATTACAGATTCATCGTC TGG 13462 2 829.9491787 Y 14003 11 98 4 
CCTATTACAGATTCATCGTC TGG 13462 3 350.7744847 Y 14003 11 98 4 
TTAAAAGATTTTATGTTTGA GGG 13550 1 24.61991245 Y 14091 1 0 0 
TTAAAAGATTTTATGTTTGA GGG 13550 2 24.61991245 Y 14091 1 0 0 
TTAAAAGATTTTATGTTTGA GGG 13550 3 6.154978113 Y 14091 1 0 0 
AGATATGACTGTGAGGTTAA AGG 13625 1 123.0995623 Y 14166 0 6 0 
AGATATGACTGTGAGGTTAA AGG 13625 2 367.2470274 Y 14166 0 6 0 
AGATATGACTGTGAGGTTAA AGG 13625 3 75.91139673 Y 14166 0 6 0 
ATTTGAATCATCACATTTAT TGG 13654 1 15.7564739 Y 14195 0 0 3 
ATTTGAATCATCACATTTAT TGG 13654 2 18.90776868 Y 14195 0 0 3 
ATTTGAATCATCACATTTAT TGG 13654 3 14.18082651 Y 14195 0 0 3 
TGAATCATCACATTTATTGG AGG 13657 1 51.76806832 Y 14198 0 0 10 
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TGAATCATCACATTTATTGG AGG 13657 2 36.23764782 Y 14198 0 0 10 
TGAATCATCACATTTATTGG AGG 13657 3 5.176806832 Y 14198 0 0 10 
TAGCGTCCATTACACCTAGT TGG 13691 1 297.7973567 Y 14232 0 2 0 
TAGCGTCCATTACACCTAGT TGG 13691 2 431.7273849 Y 14232 0 2 0 
TAGCGTCCATTACACCTAGT TGG 13691 3 234.7714611 Y 14232 0 2 0 
AAGAGAACGCAACAAAGAGC TGG 13806 1 101.1074112 Y 14347 5 0 0 
AAGAGAACGCAACAAAGAGC TGG 13806 2 231.368493 Y 14347 5 0 0 
AAGAGAACGCAACAAAGAGC TGG 13806 3 76.29577652 Y 14347 5 0 0 
AAAGATTTAATAAACGAATT TGG 13873 1 4.72694217 Y 14414 0 0 6 
AAAGATTTAATAAACGAATT TGG 13873 2 1.57564739 Y 14414 0 0 6 
AAAGATTTAATAAACGAATT TGG 13873 3 9.45388434 Y 14414 0 0 6 
CGGATTGTTCTATTTGTTCA CGG 13956 1 498.5532272 Y 14497 0 12 0 
CGGATTGTTCTATTTGTTCA CGG 13956 2 718.0807799 Y 14497 0 12 0 
CGGATTGTTCTATTTGTTCA CGG 13956 3 432.9001273 Y 14497 0 12 0 
ATACGCACTAGCACTTATAA CGG 13976 1 84.11803421 Y 14517 0 0 2 
ATACGCACTAGCACTTATAA CGG 13976 2 147.7194747 Y 14517 0 0 2 
ATACGCACTAGCACTTATAA CGG 13976 3 22.56825308 Y 14517 0 0 2 
GCGTTTGATGAAATACTTGA GGG 14075 1 129.2545404 Y 14616 0 4 0 
GCGTTTGATGAAATACTTGA GGG 14075 2 203.1142777 Y 14616 0 4 0 
GCGTTTGATGAAATACTTGA GGG 14075 3 102.5829686 Y 14616 0 4 0 
ATTCAACATTCAGTTAAAGA AGG 14111 1 22.56825308 Y 14652 0 13479 0 
ATTCAACATTCAGTTAAAGA AGG 14111 2 20.51659371 Y 14652 0 13479 0 
ATTCAACATTCAGTTAAAGA AGG 14111 3 12.30995623 Y 14652 0 13479 0 
AGTTGTCTATAAATATGAGG AGG 14173 1 77.65210248 Y 14714 0 8 1 
AGTTGTCTATAAATATGAGG AGG 14173 2 36.23764782 Y 14714 0 8 1 
AGTTGTCTATAAATATGAGG AGG 14173 3 5.176806832 Y 14714 0 8 1 
CTATCTCGTAAGTTCAGCGT TGG 14261 1 816.185348 Y 14802 0 18 0 
CTATCTCGTAAGTTCAGCGT TGG 14261 2 800.4288741 Y 14802 0 18 0 
CTATCTCGTAAGTTCAGCGT TGG 14261 3 346.6424258 Y 14802 0 18 0 
CTTTGAATGGTTTAATACAT TGG 14324 1 53.57201126 Y 14865 0 7756 0 
CTTTGAATGGTTTAATACAT TGG 14324 2 29.93730041 Y 14865 0 7756 0 
CTTTGAATGGTTTAATACAT TGG 14324 3 14.18082651 Y 14865 0 7756 0 
TGTACGTCTAACGGCTTACC TGG 14357 1 291.2265616 Y 14898 1 0 0 
TGTACGTCTAACGGCTTACC TGG 14357 2 564.4646881 Y 14898 1 0 0 
TGTACGTCTAACGGCTTACC TGG 14357 3 136.774136 Y 14898 1 0 0 
TCATCAAGTTGTACGTCTAA CGG 14366 1 164.1327497 Y 14907 0 3 0 
TCATCAAGTTGTACGTCTAA CGG 14366 2 330.3171587 Y 14907 0 3 0 
TCATCAAGTTGTACGTCTAA CGG 14366 3 131.3061997 Y 14907 0 3 0 
TGATGAATTAGCTGACATGT TGG 14399 1 215.8636924 Y 14940 42 10 0 
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TGATGAATTAGCTGACATGT TGG 14399 2 315.129478 Y 14940 42 10 0 
TGATGAATTAGCTGACATGT TGG 14399 3 92.96319601 Y 14940 42 10 0 
TTGAGTATTGCGAATCAAGT AGG 14430 1 75.63107472 Y 14971 0 2 0 
TTGAGTATTGCGAATCAAGT AGG 14430 2 127.6274386 Y 14971 0 2 0 
TTGAGTATTGCGAATCAAGT AGG 14430 3 64.60154299 Y 14971 0 2 0 
ATAACAATTGCTTGTTGGTC GGG 14579 1 159.724898 Y 15120 0 2 0 
ATAACAATTGCTTGTTGGTC GGG 14579 2 352.3252119 Y 15120 0 2 0 
ATAACAATTGCTTGTTGGTC GGG 14579 3 152.9016985 Y 15120 0 2 0 
TCACTATAACAATTGCTTGT TGG 14584 1 584.5651817 Y 15125 14 0 0 
TCACTATAACAATTGCTTGT TGG 14584 2 606.6242452 Y 15125 14 0 0 
TCACTATAACAATTGCTTGT TGG 14584 3 321.4320676 Y 15125 14 0 0 
TTTTGTATGCGTCAATGAGT TGG 14638 1 294.6460619 Y 15179 0 3 3 
TTTTGTATGCGTCAATGAGT TGG 14638 2 311.9781832 Y 15179 0 3 3 
TTTTGTATGCGTCAATGAGT TGG 14638 3 135.5056755 Y 15179 0 3 3 
CAAGATGGAACAGCAGACGC AGG 14703 1 250.2873644 Y 15244 0 0 3 
CAAGATGGAACAGCAGACGC AGG 14703 2 538.4124717 Y 15244 0 0 3 
CAAGATGGAACAGCAGACGC AGG 14703 3 104.2088655 Y 15244 0 0 3 
AGATCGAGTCAAGGAGGTTT TGG 14751 1 29.93730041 Y 15292 0 0 2 
AGATCGAGTCAAGGAGGTTT TGG 14751 2 53.57201126 Y 15292 0 0 2 
AGATCGAGTCAAGGAGGTTT TGG 14751 3 17.33212129 Y 15292 0 0 2 
GACGGCTAATGATGATGTAG AGG 16066 1 31.06084099 Y 15771 0 0 6 
GACGGCTAATGATGATGTAG AGG 16066 2 134.5969776 Y 15771 0 0 6 
GACGGCTAATGATGATGTAG AGG 16066 3 119.0665571 Y 15771 0 0 6 
CGATCAGTCTGATTTGATGA GGG 16114 1 18.46493434 Y 15819 8 0 0 
CGATCAGTCTGATTTGATGA GGG 16114 2 88.22135295 Y 15819 8 0 0 
AAGTTAAGAAGTAACGCGCT AGG 21588 1 59.87460082 N 21588 8 0 0 
AAGTTAAGAAGTAACGCGCT AGG 21588 2 129.203086 N 21588 8 0 0 
AAGTTAAGAAGTAACGCGCT AGG 21588 3 113.4466121 N 21588 8 0 0 
GGAGACCTAATCATATTACA AGG 31489 1 36.92986868 Y 31867 0 2 0 
GGAGACCTAATCATATTACA AGG 31489 2 49.2398249 Y 31867 0 2 0 
GGAGACCTAATCATATTACA AGG 31489 3 4.103318742 Y 31867 0 2 0 
TCCGTTTTATCAGTGCCTAT CGG 31536 1 565.657413 Y 31914 0 5 0 
TCCGTTTTATCAGTGCCTAT CGG 31536 2 962.7205553 Y 31914 0 5 0 
TCCGTTTTATCAGTGCCTAT CGG 31536 3 397.0631423 Y 31914 0 5 0 
AACTTCAATTGCAGAACAAA AGG 31579 1 14.3616156 Y 31957 0 3 0 
AACTTCAATTGCAGAACAAA AGG 31579 2 18.46493434 Y 31957 0 3 0 
AACTTCAATTGCAGAACAAA AGG 31579 3 22.56825308 Y 31957 0 3 0 
ATATAAATAATTTTCGTTCT AGG 32433 1 25.21035824 Y 32825 0 0 4 
ATATAAATAATTTTCGTTCT AGG 32433 2 6.30258956 Y 32825 0 0 4 
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ATATAAATAATTTTCGTTCT AGG 32433 3 20.48341607 Y 32825 0 0 4 
TATATGACGCAAGCTCGTCC AGG 32467 1 1179.172936 Y 32859 0 7 6 
TATATGACGCAAGCTCGTCC AGG 32467 2 1712.312936 Y 32859 0 7 6 
TATATGACGCAAGCTCGTCC AGG 32467 3 800.1752171 Y 32859 0 7 6 
CTATCAATAAATTGTCCGTT GGG 32502 1 42.54247953 Y 32894 0 0 4 
CTATCAATAAATTGTCCGTT GGG 32502 2 66.17719038 Y 32894 0 0 4 
CTATCAATAAATTGTCCGTT GGG 32502 3 50.42071648 Y 32894 0 0 4 
CTTGTTAAAAACGGCGGTCA CGG 32545 1 1460.781472 Y 32937 0 1 8 
CTTGTTAAAAACGGCGGTCA CGG 32545 2 1920.353171 Y 32937 0 1 8 
CTTGTTAAAAACGGCGGTCA CGG 32545 3 699.6158455 Y 32937 0 1 8 
TTATTTCTCCAGTTCTATAT TGG 32642 1 111.8709647 Y 33034 0 12 0 
TTATTTCTCCAGTTCTATAT TGG 32642 2 77.20672211 Y 33034 0 12 0 
TTATTTCTCCAGTTCTATAT TGG 32642 3 48.84506909 Y 33034 0 12 0 
TATCTGTCGTTAAATATATT CGG 32694 1 25.21035824 Y 33086 0 10 0 
TATCTGTCGTTAAATATATT CGG 32694 2 31.5129478 Y 33086 0 10 0 
TATCTGTCGTTAAATATATT CGG 32694 3 12.60517912 Y 33086 0 10 0 
GTATCTGAAGTGTATTCCAT AGG 32877 1 174.8968603 Y 33269 0 6 0 
GTATCTGAAGTGTATTCCAT AGG 32877 2 116.5979069 Y 33269 0 6 0 
GTATCTGAAGTGTATTCCAT AGG 32877 3 80.35801689 Y 33269 0 6 0 
TCAGATACACAACCTATGCA AGG 32908 1 1760.32374 Y 33300 0 4 0 
TCAGATACACAACCTATGCA AGG 32908 2 2168.603955 Y 33300 0 4 0 
TCAGATACACAACCTATGCA AGG 32908 3 1520.279594 Y 33300 0 4 0 
GCCAACCCTAACTACTTACA AGG 32983 1 94.37633107 Y 33375 0 3 0 
GCCAACCCTAACTACTTACA AGG 32983 2 162.0810903 Y 33375 0 3 0 
GCCAACCCTAACTACTTACA AGG 32983 3 49.2398249 Y 33375 0 3 0 
TTTAAACGACGTATCGATAT TGG 33034 1 144.9595599 Y 33426 0 0 2 
TTTAAACGACGTATCGATAT TGG 33034 2 124.4761438 Y 33426 0 0 2 
TTTAAACGACGTATCGATAT TGG 33034 3 61.45024821 Y 33426 0 0 2 
GGTGTGAATAATAACTTTAA AGG 33058 2 2.051659371 Y 33450 0 3 0 
AGAATTGGTTAACACCTCTT TGG 33188 1 185.926392 Y 33580 0 4 4 
AGAATTGGTTAACACCTCTT TGG 33188 2 518.3879913 Y 33580 0 4 4 
AGAATTGGTTAACACCTCTT TGG 33188 3 85.08495906 Y 33580 0 4 4 
AGATATGCTGGGTTCTGTAT TGG 33270 1 764.1889842 Y 33662 0 0 3 
AGATATGCTGGGTTCTGTAT TGG 33270 2 540.4470548 Y 33662 0 0 3 
AGATATGCTGGGTTCTGTAT TGG 33270 3 248.9522876 Y 33662 0 0 3 
TAATATCACTTAGATATGCT GGG 33281 1 48.84506909 Y 33673 0 1 0 
TAATATCACTTAGATATGCT GGG 33281 2 116.5979069 Y 33673 0 1 0 
TAATATCACTTAGATATGCT GGG 33281 3 33.08859519 Y 33673 0 1 0 
ATTTCTACCTGTGCTGTTTC TGG 33445 1 316.9686325 Y 33837 0 6 0 
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ATTTCTACCTGTGCTGTTTC TGG 33445 2 347.0527395 Y 33837 0 6 0 
ATTTCTACCTGTGCTGTTTC TGG 33445 3 326.5831409 Y 33837 0 6 0 
GTACTTACCAGAAACAGCAC AGG 33454 1 123.7480278 Y 33846 13 0 2 
GTACTTACCAGAAACAGCAC AGG 33454 2 204.3858403 Y 33846 13 0 2 
GTACTTACCAGAAACAGCAC AGG 33454 3 148.8698078 Y 33846 13 0 2 
AGGGATATGTTCCCAATAAC CGG 33544 1 59.85806857 Y 33936 0 4 0 
AGGGATATGTTCCCAATAAC CGG 33544 2 144.5277718 Y 33936 0 4 0 
AGGGATATGTTCCCAATAAC CGG 33544 3 52.72472361 Y 33936 0 4 0 
GTCCGCAAAACGCCGGTTAT TGG 33548 1 100.841433 Y 33940 0 0 2 
GTCCGCAAAACGCCGGTTAT TGG 33548 2 155.9890916 Y 33940 0 0 2 
GTCCGCAAAACGCCGGTTAT TGG 33548 3 75.63107472 Y 33940 0 0 2 
TCCGCAAAACGCCGGTTATT GGG 33549 1 214.288045 Y 33941 0 0 2 
TCCGCAAAACGCCGGTTATT GGG 33549 2 178.0481551 Y 33941 0 0 2 
TCCGCAAAACGCCGGTTATT GGG 33549 3 66.17719038 Y 33941 0 0 2 
TTATCAGATTTAAAAATCGT TGG 33598 1 20.48341607 Y 33990 0 3 1 
TTATCAGATTTAAAAATCGT TGG 33598 2 15.7564739 Y 33990 0 3 1 
TTATCAGATTTAAAAATCGT TGG 33598 3 7.87823695 Y 33990 0 3 1 
GCAATACCTTTAAAGTCTTT AGG 33654 1 28.36165302 Y 34046 0 0 5 
GCAATACCTTTAAAGTCTTT AGG 33654 2 74.05542733 Y 34046 0 0 5 
GCAATACCTTTAAAGTCTTT AGG 33654 3 17.33212129 Y 34046 0 0 5 
ACTTTAAAGGTATTGCAGGT TGG 33677 1 119.7492016 Y 34069 0 4 0 
ACTTTAAAGGTATTGCAGGT TGG 33677 2 115.0222595 Y 34069 0 4 0 
ACTTTAAAGGTATTGCAGGT TGG 33677 3 51.99636387 Y 34069 0 4 0 
AATACTTGTGTTGTGTTACC CGG 33708 1 810.7201619 Y 34100 0 0 6 
AATACTTGTGTTGTGTTACC CGG 33708 2 1213.288934 Y 34100 0 0 6 
AATACTTGTGTTGTGTTACC CGG 33708 3 829.6390333 Y 34100 0 0 6 
AACTTTGGTACTGGTGGCGT TGG 33790 1 1002.11174 Y 34182 3 0 0 
AACTTTGGTACTGGTGGCGT TGG 33790 2 720.0708572 Y 34182 3 0 0 
AACTTTGGTACTGGTGGCGT TGG 33790 3 348.2180732 Y 34182 3 0 0 
GAGTTTATTCGAGGGAAAGG TGG 33819 1 72.47529565 Y 34211 0 0 4 
GAGTTTATTCGAGGGAAAGG TGG 33819 2 88.00571614 Y 34211 0 0 4 
GAGTTTATTCGAGGGAAAGG TGG 33819 3 51.76806832 Y 34211 0 0 4 
CGATAGTAGACGCAATTAAT GGG 34096 1 39.39118475 Y 34488 2 0 0 
CGATAGTAGACGCAATTAAT GGG 34096 2 61.45024821 Y 34488 2 0 0 
CGATAGTAGACGCAATTAAT GGG 34096 3 61.45024821 Y 34488 2 0 0 
ATTTTTAAAACATTCAGGCA AGG 34145 1 217.4758933 Y 34537 16 0 0 
ATTTTTAAAACATTCAGGCA AGG 34145 2 26.67157182 Y 34537 16 0 0 
ATTTTTAAAACATTCAGGCA AGG 34145 3 121.0479029 Y 34537 16 0 0 
CAAGATACTATCGAAGCTGT CGG 34302 1 244.2253455 Y 34694 0 1 1 
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CAAGATACTATCGAAGCTGT CGG 34302 2 300.9486515 Y 34694 0 1 1 
CAAGATACTATCGAAGCTGT CGG 34302 3 154.4134442 Y 34694 0 1 1 
GAAGTTGAACAACAAATCAA TGG 34542 1 59.49812176 Y 34934 3 3 0 
GAAGTTGAACAACAAATCAA TGG 34542 2 92.3246717 Y 34934 3 3 0 
GAAGTTGAACAACAAATCAA TGG 34542 3 34.87820931 Y 34934 3 3 0 
TCTAAACTTACAGATGATTA CGG 34608 1 77.9630561 Y 35000 0 0 1 
TCTAAACTTACAGATGATTA CGG 34608 2 203.1142777 Y 35000 0 0 1 
TCTAAACTTACAGATGATTA CGG 34608 3 88.22135295 Y 35000 0 0 1 
TAAATCTTTTTAGAGTTATA AGG 35231 1 28.72323119 Y 35623 0 4 3 
TAAATCTTTTTAGAGTTATA AGG 35231 2 75.91139673 Y 35623 0 4 3 
TAAATCTTTTTAGAGTTATA AGG 35231 3 36.92986868 Y 35623 0 4 3 
TACACACGATCAATCACAAA CGG 35268 1 24.61991245 Y 35660 0 0 3 
TACACACGATCAATCACAAA CGG 35268 2 108.7379467 Y 35660 0 0 3 
TACACACGATCAATCACAAA CGG 35268 3 26.67157182 Y 35660 0 0 3 
CACAAACTATTCTATTTTGT TGG 35396 1 64.60154299 Y 35788 0 3 0 
CACAAACTATTCTATTTTGT TGG 35396 2 53.57201126 Y 35788 0 3 0 
CACAAACTATTCTATTTTGT TGG 35396 3 17.33212129 Y 35788 0 3 0 
TTGGTAAGTGGAACTTATCC AGG 35415 1 271.6873993 Y 35807 0 7 0 
TTGGTAAGTGGAACTTATCC AGG 35415 2 428.6209884 Y 35807 0 7 0 
TTGGTAAGTGGAACTTATCC AGG 35415 3 202.2148223 Y 35807 0 7 0 
AATCCCTCAATAACGCCACC TGG 35417 1 98.31610226 Y 35809 0 13 0 
AATCCCTCAATAACGCCACC TGG 35417 2 243.7743103 Y 35809 0 13 0 
AATCCCTCAATAACGCCACC TGG 35417 3 130.2610819 Y 35809 0 13 0 
TTACTCAATTGAATCGCGTT AGG 35456 1 138.6569703 Y 35848 12 0 0 
TTACTCAATTGAATCGCGTT AGG 35456 2 151.2621494 Y 35848 12 0 0 
TTACTCAATTGAATCGCGTT AGG 35456 3 78.7823695 Y 35848 12 0 0 
GTTGACTCAGACGGCAACGG TGG 35505 1 88.00571614 Y 35897 0 0 3 
GTTGACTCAGACGGCAACGG TGG 35505 2 62.12168198 Y 35897 0 0 3 
GTTGACTCAGACGGCAACGG TGG 35505 3 15.5304205 Y 35897 0 0 3 
AACGATGTGTACTTTGATTT AGG 35583 1 140.2326177 Y 35975 0 0 1 
AACGATGTGTACTTTGATTT AGG 35583 2 143.3839125 Y 35975 0 0 1 
AACGATGTGTACTTTGATTT AGG 35583 3 67.75283777 Y 35975 0 0 1 
TTTAGTTATAGTAACTTTGT TGG 35616 1 66.17719038 Y 36008 0 3 0 
TTTAGTTATAGTAACTTTGT TGG 35616 2 80.35801689 Y 36008 0 3 0 
TTTAGTTATAGTAACTTTGT TGG 35616 3 33.08859519 Y 36008 0 3 0 
GTTACTATAACTAAAATTAT GGG 35640 1 1.57564739 Y 36032 0 0 1 
GTTACTATAACTAAAATTAT GGG 35640 2 4.72694217 Y 36032 0 0 1 
GTTACTATAACTAAAATTAT GGG 35640 3 1.57564739 Y 36032 0 0 1 
CTTTGTTGGTTTGATGCATT CGG 35842 1 209.5611029 Y 36234 0 0 2 
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CTTTGTTGGTTTGATGCATT CGG 35842 2 318.2807728 Y 36234 0 0 2 
CTTTGTTGGTTTGATGCATT CGG 35842 3 155.9890916 Y 36234 0 0 2 
AACTAACAAAACAAATACTG AGG 36016 2 5.176806832 Y 36408 3 0 0 
AACTAACAAAACAAATACTG AGG 36016 3 5.176806832 Y 36408 3 0 0 
CATTAAAACTTTTTATGTGT GGG 36082 1 25.21035824 Y 36474 0 0 1 
CATTAAAACTTTTTATGTGT GGG 36082 2 23.63471085 Y 36474 0 0 1 
CATTAAAACTTTTTATGTGT GGG 36082 3 1.57564739 Y 36474 0 0 1 
ATTAAGTGGTACGTAGACAT GGG 36125 1 132.3543808 Y 36517 9 0 0 
ATTAAGTGGTACGTAGACAT GGG 36125 2 88.23625384 Y 36517 9 0 0 
ATTAAGTGGTACGTAGACAT GGG 36125 3 20.48341607 Y 36517 9 0 0 
ATGTGGATTCTCGGTTTGAT AGG 36489 1 29.93730041 Y 36881 0 0 5 
ATGTGGATTCTCGGTTTGAT AGG 36489 2 39.39118475 Y 36881 0 0 5 
ATGTGGATTCTCGGTTTGAT AGG 36489 3 59.87460082 Y 36881 0 0 5 
TCCTAAAATCCCTTTAAGCA TGG 36563 1 432.9001273 Y 36955 0 4 0 
TCCTAAAATCCCTTTAAGCA TGG 36563 2 572.4129645 Y 36955 0 4 0 
TCCTAAAATCCCTTTAAGCA TGG 36563 3 240.0441464 Y 36955 0 4 0 
GATTTTAGGATATAGCTTCT GGG 36592 1 185.926392 Y 36984 0 5 0 
GATTTTAGGATATAGCTTCT GGG 36592 2 160.7160338 Y 36984 0 5 0 
GATTTTAGGATATAGCTTCT GGG 36592 3 81.93366428 Y 36984 0 5 0 
ATAGCTTCTGGGCGTGCTTC TGG 36603 1 144.2176263 Y 36995 0 0 1 
ATAGCTTCTGGGCGTGCTTC TGG 36603 2 520.1138911 Y 36995 0 0 1 
ATAGCTTCTGGGCGTGCTTC TGG 36603 3 303.3222335 Y 36995 0 0 1 
TTCTGGGCGTGCTTCTGGTT TGG 36608 1 304.0999463 Y 37000 0 0 5 
TTCTGGGCGTGCTTCTGGTT TGG 36608 2 467.9672748 Y 37000 0 0 5 
TTCTGGGCGTGCTTCTGGTT TGG 36608 3 283.6165302 Y 37000 0 0 5 
GCCAATGACTCAACAATTAC TGG 37201 1 59.85806857 N 37201 0 9 0 
GCCAATGACTCAACAATTAC TGG 37201 2 77.53635825 N 37201 0 9 0 
GCCAATGACTCAACAATTAC TGG 37201 3 19.84930771 N 37201 0 9 0 
CCGCCCATGATTGCTTTTGC TGG 38337 1 714.8852231 Y 38756 1 0 0 
CCGCCCATGATTGCTTTTGC TGG 38337 2 1022.549493 Y 38756 1 0 0 
CCGCCCATGATTGCTTTTGC TGG 38337 3 644.1720643 Y 38756 1 0 0 
TCTTAGGATTCCATCTAATT CGG 38411 1 7.87823695 Y 38830 5 0 0 
TCTTAGGATTCCATCTAATT CGG 38411 2 18.90776868 Y 38830 5 0 0 
TCTTAGGATTCCATCTAATT CGG 38411 3 4.72694217 Y 38830 5 0 0 
CGATTGTACTTGCTTGATGT TGG 38453 1 699.5874412 Y 38893 0 0 12 
CGATTGTACTTGCTTGATGT TGG 38453 2 715.3439151 Y 38893 0 0 12 
CGATTGTACTTGCTTGATGT TGG 38453 3 499.4802226 Y 38893 0 0 12 
TAAAAGGTATCTACTTCACA AGG 38516 1 75.91139673 Y 38956 8 0 0 
TAAAAGGTATCTACTTCACA AGG 38516 2 43.08484679 Y 38956 8 0 0 
 87 
TAAAAGGTATCTACTTCACA AGG 38516 3 61.54978113 Y 38956 8 0 0 
AAAAGGTATCTACTTCACAA GGG 38517 1 36.92986868 Y 38957 9 0 0 
AAAAGGTATCTACTTCACAA GGG 38517 2 192.8559809 Y 38957 9 0 0 
AAAAGGTATCTACTTCACAA GGG 38517 3 61.54978113 Y 38957 9 0 0 
TCCATAAACAAATGTAATCT AGG 38712 1 12.60517912 Y 39152 0 4 0 
TCCATAAACAAATGTAATCT AGG 38712 2 18.90776868 Y 39152 0 4 0 
TCCATAAACAAATGTAATCT AGG 38712 3 1.57564739 Y 39152 0 4 0 
ACCTAGATTACATTTGTTTA TGG 38727 1 182.597684 Y 39167 5 0 3 
ACCTAGATTACATTTGTTTA TGG 38727 2 262.6123995 Y 39167 5 0 3 
ACCTAGATTACATTTGTTTA TGG 38727 3 65.65309987 Y 39167 5 0 3 
TACAACATCGTCGATAATAA GGG 38761 1 14.3616156 Y 39201 0 0 4 
TACAACATCGTCGATAATAA GGG 38761 2 34.87820931 Y 39201 0 0 4 
TACAACATCGTCGATAATAA GGG 38761 3 18.46493434 Y 39201 0 0 4 
TCTTTCAATATCGTTGATAG TGG 38911 1 139.7737845 Y 39351 0 0 2 
TCTTTCAATATCGTTGATAG TGG 38911 2 103.5361366 Y 39351 0 0 2 
TCTTTCAATATCGTTGATAG TGG 38911 3 93.18252298 Y 39351 0 0 2 
ACTACAGTACCGTTTTTACC GGG 39159 1 256.1801277 Y 39599 0 7 1 
ACTACAGTACCGTTTTTACC GGG 39159 2 258.0410003 Y 39599 0 7 1 
ACTACAGTACCGTTTTTACC GGG 39159 3 177.4031877 Y 39599 0 7 1 
ATTTGCCACATTTTAGTGTC AGG 39192 1 184.5365326 Y 39632 0 4 0 
ATTTGCCACATTTTAGTGTC AGG 39192 2 174.9220242 Y 39632 0 4 0 
TCAATCCTGACACTAAAATG TGG 39203 2 10.35361366 Y 39643 0 0 1 
TCAATCCTGACACTAAAATG TGG 39203 3 15.5304205 Y 39643 0 0 1 
ACTAAAATGTGGCAAATTGA TGG 39214 1 151.8227935 Y 39654 0 2 2 
ACTAAAATGTGGCAAATTGA TGG 39214 2 320.0588619 Y 39654 0 2 2 
ACTAAAATGTGGCAAATTGA TGG 39214 3 75.91139673 Y 39654 0 2 2 
TCGTCATGATTATGATTTTT TGG 39534 1 63.0258956 Y 39974 0 5 1 
TCGTCATGATTATGATTTTT TGG 39534 2 45.69377431 Y 39974 0 5 1 
TCGTCATGATTATGATTTTT TGG 39534 3 33.08859519 Y 39974 0 5 1 
AAAATCATAATCATGACGAG CGG 39554 1 62.12168198 Y 39994 0 0 1 
AAAATCATAATCATGACGAG CGG 39554 2 41.41445466 Y 39994 0 0 1 
AAAATCATAATCATGACGAG CGG 39554 3 31.06084099 Y 39994 0 0 1 
CCTGTCCAAATTTTAACCGT CGG 39633 1 77.20672211 Y 40073 3 0 0 
CCTGTCCAAATTTTAACCGT CGG 39633 2 36.23988997 Y 40073 3 0 0 
CCTGTCCAAATTTTAACCGT CGG 39633 3 31.5129478 Y 40073 3 0 0 
CTCAACCGACGGTTAAAATT TGG 39644 1 3.15129478 Y 40084 10 0 0 
GGTTTTATTACAAAAGATGA AGG 39821 1 47.18816553 Y 40261 0 0 5 
GGTTTTATTACAAAAGATGA AGG 39821 2 86.16969358 Y 40261 0 0 5 
GGTTTTATTACAAAAGATGA AGG 39821 3 18.46493434 Y 40261 0 0 5 
 88 
CTATCCGGATATTTATTTTT AGG 39848 1 29.93730041 Y 40288 0 6 301 
CTATCCGGATATTTATTTTT AGG 39848 2 22.05906346 Y 40288 0 6 301 
CTATCCGGATATTTATTTTT AGG 39848 3 25.21035824 Y 40288 0 6 301 
GTTGATTCTTCTATGCTATC CGG 39863 1 519.1834548 Y 40303 0 0 8 
GTTGATTCTTCTATGCTATC CGG 39863 2 829.6390333 Y 40303 0 0 8 
GTTGATTCTTCTATGCTATC CGG 39863 3 345.5020124 Y 40303 0 0 8 
TGAACCTAATAAAAGTTATC AGG 39926 1 49.00297841 Y 40366 53 0 3 
TGAACCTAATAAAAGTTATC AGG 39926 2 70.71315872 Y 40366 53 0 3 
TGAACCTAATAAAAGTTATC AGG 39926 3 16.74785338 Y 40366 53 0 3 
ACAATAGAAAATGTACGTAG CGG 39951 1 103.5361366 Y 40391 0 4 0 
ACAATAGAAAATGTACGTAG CGG 39951 2 93.18252298 Y 40391 0 4 0 
ACAATAGAAAATGTACGTAG CGG 39951 3 103.5361366 Y 40391 0 4 0 
TCAAGTGATTTAGGAATATC AGG 40005 1 70.71315872 Y 40445 11 0 0 
TCAAGTGATTTAGGAATATC AGG 40005 2 84.97984864 Y 40445 11 0 0 
TCAAGTGATTTAGGAATATC AGG 40005 3 62.64937747 Y 40445 11 0 0 
GTGACATACAACATCCCTGA AGG 40055 1 379.5569836 Y 40495 0 2 0 
GTGACATACAACATCCCTGA AGG 40055 2 379.5569836 Y 40495 0 2 0 
GTGACATACAACATCCCTGA AGG 40055 3 162.0810903 Y 40495 0 2 0 
ATCAACTTTAGTAATCCTTC AGG 40056 1 17.98843511 N 40056 0 0 3 
ATCAACTTTAGTAATCCTTC AGG 40056 2 42.48992432 N 40056 0 0 3 
ATCAACTTTAGTAATCCTTC AGG 40056 3 13.95654449 N 40056 0 0 3 
ACTATAAGTGATGTTTATTC AGG 40092 1 61.71894117 Y 40532 0 0 2 
ACTATAAGTGATGTTTATTC AGG 40092 2 77.84650368 Y 40532 0 0 2 
ACTATAAGTGATGTTTATTC AGG 40092 3 49.93341471 Y 40532 0 0 2 
GGAAAAAAGGAGCAAACAAA TGG 40176 1 32.82654994 Y 40616 0 1 1 
GGAAAAAAGGAGCAAACAAA TGG 40176 2 45.13650616 Y 40616 0 1 1 
GGAAAAAAGGAGCAAACAAA TGG 40176 3 16.41327497 Y 40616 0 1 1 
GAAACACTTTCTTCATCTAC TGG 40266 1 1017.587166 Y 40706 4 0 0 
GAAACACTTTCTTCATCTAC TGG 40266 2 1563.132982 Y 40706 4 0 0 
GAAACACTTTCTTCATCTAC TGG 40266 3 678.9083528 Y 40706 4 0 0 
AACATCTCAAGAAGGGAAAT GGG 40356 1 7.87823695 Y 40796 3 0 0 
AACATCTCAAGAAGGGAAAT GGG 40356 2 7.87823695 Y 40796 3 0 0 
AACATCTCAAGAAGGGAAAT GGG 40356 3 1.57564739 Y 40796 3 0 0 
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3.5 Discussion 
 
 
 
 
Figure 3.4. A model for type II-A CRISPR-Cas primed immunity against 
bacteriophages 
A schematic for II-A primed spacer acquisition in pre-immune cells. Following 
phage infection, Cas9 utilizes a pre-existing spacer (red) to produce a dsDNA 
DNA break (DSB) that is used a substrate to generate new spacers for acquisition. 
The newly acquired spacer (green) can then be used provide immunity against 
the original, parental virus as well as related escaper phages. 
 
Primed spacer acquisition has clear advantages for the bacterial population: it 
increases the diversity of spacer sequences to prevent the raise of escaper phages 
(van Houte et al., 2016) and to generate new immunity against related viruses. In 
type I systems, the presence of a target mutation would trigger additional spacer 
acquisition from other regions of the escaper or related phage to neutralize these 
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threats. In type II systems, however, given the strong priming effect of fully 
targeting spacers, spacer diversity is generated not only after, but also before the 
cell is infected with an escaper or a related phage. This is a unique feature of type 
II primed spacer acquisition that allows “preventive” immunity against future 
threats that could overcome the defense provided by the initial spacer acquired. 
We believe that cleavage-mediated spacer acquisition is an integral part of the 
type II-A CRISPR-Cas immune response that immediately follows the acquisition 
of the first spacers by naïve cells (an argument supported by the data in Figure 
2.11A) and leads to a more rapid increase in the diversity and abundance of 
spacers in the population that limits the rise of escapers. Phage escapers, 
however, are only one of the many threats that bacteria face in their natural 
habitats. How cleavage-mediated spacer acquisition impacts the dynamics of the 
virus-host co-evolution in ecological contexts remains largely unknown. In 
Figure 2.13C we explored conditions in which the host is exposed to two phages 
and showed that this mechanism can immunize the host against both infections 
if the viral genomes are related. In more complex environments, the number of 
co-existing phages, their genetic divergence and their relative frequencies will 
most likely affect the benefits of type II priming. Finally, since the strength of the 
immunity provided by type II spacers decreases as their positions within the 
CRISPR array upon new integration events (McGinn and Marraffini, 2016), the 
accelerated acquisition mediated by Cas9 cleavage will also “downgrade” the 
previously acquired spacers. How this potential cost of priming affects the 
overall type II CRISPR-Cas immune response is not known. 
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CHAPTER 4: PERSEPCTIVES 
 
 The ever-present competition between bacteria and bacteriophages has 
given rise to an “evolutionary arms race”, known as Red Queen interactions 
(McLaughlin and Malik, 2017), that has led to the development of diverse anti-
phage mechanisms (Rostol and Marraffini, 2019a). A key driver in the 
diversification of these systems is the inherent ability of phages to eventually 
escape these defenses, thus forcing further bacterial innovation (Fernandez et al., 
2018). By acquiring spacers, CRISPR-Cas immune systems are therefore unique 
among prokaryotic defense strategies in that they are able to adapt to the viruses 
that challenge them without fundamentally altering their molecular machinery 
(Barrangou et al., 2007). Once added to the CRISPR array, spacers function as 
molecular memories that can be repeatedly utilized upon subsequent infections 
to guide CRISPR-associated (Cas) nucleases to execute sequence-specific nucleic 
acid cleavage (Barrangou et al., 2007; Marraffini and Sontheimer, 2008). Yet, 
despite the potency of this immune response, viruses rapidly and readily escape 
CRISPR by mutating their genomes, thereby precluding spacer-mediated 
recognition (Deveau et al., 2010; Pyenson et al., 2017; Semenova et al., 2011). This 
problem of CRISPR-escape by viruses is particularly acute for type II CRISPR 
systems because the Cas9 immunity can be abrogated with single nucleotide 
polymorphisms (SNPs) in the target’s PAM or seed sequence (Deveau et al., 
2008; Pyenson et al., 2017). 
 In my thesis work, I have explored how type II-A CRISPR-Cas9 systems 
combat rapidly evolving bacteriophages that readily escape initial Cas9 
targeting. By studying the CRISPR-Cas loci from Streptococcus pyogenes and 
Streptococcus thermophilus, I have identified a previously unidentified phase of the 
CRISPR-Cas9 immune response known as primed spacer acquisition or 
“priming”. This primed immune response equips these systems with a means of 
combating phage escapers by using their preexisting spacers to direct additional 
spacer acquisition at an enhanced rate. I demonstrated that the mechanism that 
mediates primed acquisition requires CRISPR RNA (crRNA) mediated 
recognition of the viral genome and subsequent Cas9-generated dsDNA breaks 
(DSBs). This mechanism allows CRISPR immune cells to acquire additional 
spacers at the same time as they destroy the infecting virus. A consequence of 
Cas9-mediated priming is that the spacers acquired through this mechanism are 
located within the immediate vicinity of the target site cleaved by Cas9. I have 
shown these newly acquired spacers are capable of combating existing escaper 
phages as well as preemptively immunizing against escapers and related viruses 
that would otherwise prove lethal to them in the absence of priming.  
 During our study a complementary bioinformatic study was published 
corroborating our in vivo findings (Nicholson et al., 2018). Nicholson et al (2018) 
analyzed the genomes of 35,240 individual archaea and bacterial strains and 
examined strains with one CRISPR locus containing spacers matching targets in 
archaeal viruses, bacteriophages and prophages. From this group of CRISPR loci 
they identified 1,488 systems with arrays containing two or more spacers against 
the same viral genome. Similar to our own analysis of type II-A CRISPR-Cas 
system of S. pyogenes with two anti-viral spacers after 24 hour infections with 
ΦNM4γ4 (Figure 3.1), Nicholson et al (2018) then compared the position of each 
spacer target relative to the first targeting spacer acquired in the array (ie the 
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most leader-distal anti-viral spacer). In agreement with our findings in Figure 
3.1A-B, this analysis revealed that more recently acquired anti-viral spacers 
tended to be located in close proximity to the original targeting spacer, 
suggesting that Cas9-priming is occurring against these viruses. Together with 
our work on the S. pyogenes and S. thermophilus loci, this suggests that Cas9-
priming is a widespread phenomenon among type II-A CRISPR-Cas systems. In 
addition, the presence of multiple spacers targeting the same virus in these 
strains suggests that, in agreement with our own data (Figure 3.2A) as well as 
the work of others (Pyenson et al., 2017; van Houte et al., 2016), having multiple 
targeting spacers is fundamental to mounting a successful anti-viral CRISPR 
immune response. Intriguingly, Nicholson et al (2018) also identified a similar 
number of type II-C CRISPR arrays that appeared to have also undergone anti-
viral priming. Altogether, these results, in combination with the work presented 
in this thesis, provides evidence for a model in which priming is a hallmark 
feature of all type II CRISPR-Cas immune responses. 
 While the genetic basis for Cas9-directed primed spacer acquisition is now 
established, the precise mechanistic basis of how Cas9-generated dsDNA breaks 
(DSBs) lead to the recruitment of the type II spacer acquisition machinery is less 
clear. As discussed in Chapter 1.5 and Chapter 2.7, Cas9 has been shown to 
physically associate with Csn2 and the Cas1-Cas2 complex (Heler et al., 2015; 
Wilkinson et al., 2019). In addition, it is well established from work in our own 
lab as well as others that DSBs serve as “hotspots” where spacer acquisition is 
highly active (Levy et al., 2015; Modell et al., 2017). Given this data as well as 
results presented here, we propose a mechanistic model of spacer acquisition in 
which the creation of free DNA ends generated either during the injection of a 
phage genome (Modell et al., 2017), the replication of a plasmid (Levy et al., 
2015), or in our case the cleavage of a viral genome by Cas9 acts as a universal 
signal for the recruitment of the acquisition machinery in all type I and II 
CRISPRs. In the case of type II priming (Figure 4.1), after Cas9 produces a DSB it 
remains firmly bound to its target (Sternberg et al., 2014) allowing sufficient time 
for Cas1-Cas2-Csn2 complex (Wilkinson et al., 2019) recruitment to the viral 
genome. As has been previously reported, Cas9 in association with Cas1-Cas2-
Csn2 proceeds to select functional viral targets (pre-spacers) (Heler et al., 2015) in 
the proximity of the Cas9 cut site. Cas9 and Csn2 then dissociate following Cas1-
Cas2 binding of the pre-spacer forming the integration complex (Wright et al., 
2017; Xiao et al., 2017b) that coordinates spacer placement in the CRISPR array 
following LAS recognition (McGinn and Marraffini, 2016; Wei et al., 2015a). 
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Figure 4.1. A model for the mechanism of Cas9-primed spacer acquisition. 
In the type II-A system, Cas9 binds PAM-containing targets and introduces 
dsDNA breaks. The spacer acquisition complex (Cas1-Cas2-Csn2) is recruited to 
the free DNA ends generated by Cas9 and pre-spacers (colored squares) are 
captured from both DNA strands. The abundance of pre-spacers allows for 
enhanced rate of integration and spacer acquisition. 
 
 This model (summarized above in Figure 4.1) possess many questions for 
future experimentation both in vivo and in vitro. In particular, after DNA 
cleavage, does Cas9 directly recruit Cas1-Cas2 and Csn2 or is the complex 
innately attracted to the DSB itself? Experiments in which type II-A spacer 
acquisition against bacterial genome is monitored after cutting with the 
restriction enzyme I-sceI (Modell et al., 2017) suggest that DSB are sufficient to 
generate hotspots for Cas1-Cas2 recruitment, but whether this is true for Cas9 
priming has yet to be tested. Alternatively, Cas9 primed spacer acquisition may 
be more efficient than naive or “I-sceI-assisted” spacer acquisition because Cas9 
is able to physically associate with (Heler et al., 2015) and therefore recruit Cas1-
Cas2-Csn2. It is has been reported that cleavage of phage 2972 with LlaDCHI 
restriction endonuclease system can increase the rate of spacer acquisition in 
Streptococcus thermophilus DGCC7710 (Hynes et al., 2014) but the mechanistic 
basis for this phenomenon is unknown. Whether cleavage of viral genomes by 
restriction modification systems (R-Ms) can phenocopy Cas9’s role in priming 
requires further study. Of particular interest will be investigating if phages cut 
by R-Ms can generate the same pattern of spacer acquisition seen during Cas9 
targeting with new spacers clustered within 1 kb of the cut site (Figure 2.1D-H, 
Figure 2.10F, and Figure 3.1A). Cas9 participates in spacer acquisition at two 
stages: (1) directing primed spacer acquisition and (2) selecting pre-spacers for 
integration (Heler et al., 2015; Wei et al., 2015b) but how these two processes are 
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coordinated in the cell is unknown. Does the same Cas9 responsible for DNA 
cleavage also participate in spacer selection in cis or are multiple Cas9s required 
in trans? Single-molecule studies utilizing DNA curtains, like those performed on 
the type I-E systems (Dillard et al., 2018; Redding et al., 2015), would be highly 
informative. In addition, the question of how pre-spacers are produced within 
the 1 kb region around the Cas9 cut site is fundamental. During naive spacer 
acquisition our lab has shown that the functional analog of RecBCD, AddAB 
processes free DNA ends to generate substrates for the type II-A spacer 
acquisition machinery (Modell et al., 2017). The hotspots of spacer acquisition 
generated from Cas9-directed priming in both S. pyogenes and S. thermophilus 
however showed no evidence of AddAB activity (Figure 2.1D-H and Figure 
2.10F). This implies that there is an AddAB-independent means of generating 
pre-spacers. In type I systems it is believed that Cas3 in concert with Cas1-Cas2 
and Cascade can generate pre-spacers (Künne et al., 2016; Shiriaeva et al., 2019) 
(reviewed in Chapter 1.6). Whether the type II-A spacer acquisition machinery 
has a role in producing pre-spacers has yet to be investigated. Of particular 
interest is Csn2, whose role in spacer acquisition is currently unknown. Although 
required for spacer acquisition in vivo (Heler et al.; Wei et al., 2015b), Csn2 is not 
need for spacer integration in vitro (Wright and Doudna, 2016). In addition, it has 
been shown that Csn2 associates with Cas1-Cas2 and forms a central channel 
capable of threading dsDNA ends (Arslan et al., 2013; Bernheim et al., 2017; 
Wilkinson et al., 2019) suggesting that Csn2 may be important in the potential 
translocation of Cas1-Cas2 in a manner analogous to Cas3’s hypothesized role in 
the type I primed acquisition complex (PAC) (Dillard et al., 2018; Redding et al., 
2015) (Figure 1.7). Altogether the work presented in this thesis provides a 
platform for additional mechanistic studies that will clarify the molecular events 
that coordinate type II priming. 
 Prokaryotes commonly carry multiple CRISPR loci both of the same and 
different type (Makarova et al., 2020; Nicholson et al., 2018). The potential 
interplay between the systems and its functional consequences have only begun 
to be explored. In the Marinomonas mediterranea, the type I-F and III-B systems 
can exchange and successful deploy each other’s crRNAs during CRISPR 
targeting (Silas et al., 2017). If CRISPR loci can synergize during spacer 
acquisition is unknown. One possibility, in line with work presented here, is that 
Cas nucleases from one CRISPR system can generate dsDNA breaks that could 
be recognized by the Cas1-Cas2 machinery derived from another locus. In this 
scenario, CRISPR targeting by one system enhances the acquisition of spacers by 
another, thereby imparting the host with two targeting spacers and enhanced 
immunity. Cas1-Cas2 complexes from different loci may also compete for the 
same substrates. Future work will be needed to determine the costs and benefits 
of carrying multiple CRISPRs. The S. thermophilus DGCC710 strain presented in 
this work, that naturally contains two type II-A CRISPR loci as well as a III-A 
and I-E locus (Carte et al., 2014), provides a potential model for answering these 
question.  
The acquisition of spacers provides CRISPR-containing hosts with a 
multitude of advantages especially during the context of infection with genetic 
parasites but, unlike CRISPR targeting (reviewed in Chapter 1.4.3), appears to 
have no dedicated mechanism for distinguishing between self from non-self 
nucleic acids (Levy et al., 2015). This is particularly striking given that spurious 
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acquisition of spacers derived from the host chromosome often leads to the 
generation of lethal DSBs that cannot be repaired in many prokaryotes 
(Bernheim et al., 2017; Jiang et al., 2013). While cells that undergo self-acquisition 
are likely rapidly removed from the population, these auto-immune events likely 
impose a heavy fitness cost to hosts carrying active CRISPR systems. The data 
presented here provide a mechanism by which type II-A systems can prioritize 
the acquisition non-self spacers. By utilizing base-pairing between the crRNA 
and its targets, Cas9 preferentially localizes the spacer acquisition machinery to 
foreign DNA elements. Future studies will be needed to further investigate if 
self-acquisition is limited by active priming. 
CRISPR-Cas9 systems have been widely adopted for a variety of genome 
editing and biotechnologies (Doudna and Charpentier, 2014). In addition, spacer 
acquisition has recently been repurposed as a technology that can be used as a 
memory storage system (Sheth et al., 2017) and more recently as a means of 
generating comprehensive crRNA libraries that can be used to perturb bacterial 
genomes of interest (Jiang et al., 2020). The observation that Cas9 cleavage can 
specify 1 kb regions of DNA to be acquired may therefore be leveraged as a 
means of controlling which DNA sequences are preferentially utilized by these 
technologies. Thus, the continued study of the fundamental biology of CRISPR-
Cas9 will undoubtably lead to further biotechnological advances.  
 The type II primed spacer acquisition response presented here provides 
prokaryotes with potent solutions to the problem posed by the Red Queen 
hypothesis (Figure 1.1). Firstly, by continually updating their immune repertoire, 
priming allows the host to maintain its fitness in the face of rapidly evolving 
viruses that threaten it. This aspect of priming is particularly useful when 
confronting bacteriophages that have escaped full CRISPR targeting but can still 
be recognized by Cas9 (ie seed sequence escapers shown in Figure 2.3B). While 
such escapers can be partially cleaved by Cas9, this level of DNA cleavage is not 
sufficient on its own to protect the population from phage infection (Figure 2.4A-
B and Figure 3.2A-E). Primed spacer acquisition however allows the host to 
rapidly counteract this class of escapers by rapidly immunizing the hosts with 
secondary targeting spacers, and in doing so allowing the population to recover 
from the infection (Figure 3.2B-C). This therefore perfectly fits in the existing 
paradigm of Red Queen interactions where viral escape compels the host to 
update is anti-viral defense strategy (Figure 1.1). Priming against viral escapers 
requires base-paring between the crRNA and the target (Figure 2.4 and Figure 
3.2G-F). As a result, spacers that are no longer useful for anti-viral targeting still 
retain vital functionality. This lies in sharp contrast to many Red Queen 
interactions where the emergence of virulent escapers renders the existing host 
defenses completely obsolete, thereby forcing de novo adaptation and 
replacement of the exiting defense mechanism (Figure 1.1). Additionally, the 
strong priming effect observed with fully targeting spacers means that the host 
can acquire secondary immunity prior to infection with an escaper or related 
phage. As a result, rather than responding to the evolution of viral populations, 
the immune system anticipates viruses’ evolution. This novel form of 
“anticipatory immunity” inverts the traditional reading of the Red Queen 
hypothesis, allowing the host rather than the pathogen to drive the evolutionary 
arms race. A limitation of our current study is that our experiments are carried 
out on relatively short evolutionary timescales. More long-term passaging 
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experiments will be needed to determine how priming influences the 
coevolution of bacteria and phages. Furthermore, this study exclusively 
examines Cas9-priming in the context of lytic phage infection but in the 
environment, bacteria are thought to commonly encounter lysogenic viruses that 
frequently integrate into their genomes as prophages (Canchaya et al., 2004) 
(Figure 1.3). Such prophages can provide their host with protection against 
related phages through superinfection exclusion in a CRISPR-independent 
manner (Zinder, 1958). If priming affects the rates of phage lysogenization and 
conversely if presence of lysogens affect the stability of type II CRISPRs systems, 
as is the case for type I systems (Rollie et al., 2020), requires further exploration. 
 The microbial world has provided us with endless innovation as a 
consequence of the interplay between prokaryotes and their viruses. The 
discovery of type II priming and the novel anticipatory immunity it provides 
represents only one of an ever-growing list of sophisticated innovations 
developed by these organisms. Continued exploration of the microbial world 
will undoubtably lie at the vanguard of science and further our own 
advancement. 
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CHAPTER 5: MATERIALS AND METHODS 
 
5.1 Bacterial strains and growth conditions  
Cultivation of S. aureus RN4220 (Kreiswirth et al., 1983) was carried out in brain-
heart infusion (BHI) broth medium or tryptic soy broth (TSB) at 37°C with 
shaking. Wherever applicable, media were supplemented with chloramphenicol 
at 10 &g/ml and or erythromycin at 10 &g/ml to ensure pC194-derived and 
pE194-derived plasmid maintenance respectively. Cultivation of S. thermophilus 
DG7710 (Horvath et al., 2008) was carried out in M17 broth supplemented with 
10% lactose (LM17) at 42 °C without shaking. Wherever applicable, media were 
supplemented with 200 &g/ml spectinomycin. Strains and plasmids used in this 
study are listed in Table 4.1 and Table 4.2. 
 
5.2 Plasmid Construction 
All cloning was performed with electrocompetent S. aureus RN4220 cells as 
described previously (Goldberg et al., 2014). The sequences and oligonucleotides 
used in this study are listed in Supplementary Data File 2. To construct pPN86, 
pE194 was amplified with oPN283 and oPN284, pGG32 (Goldberg et al., 2014) 
was amplified with oPN285 and oPN286, and a two-piece Gibson assembly was 
preformed. To construct pPN249, pC194 was amplified with oPN548 and 
oPN549, φNM4γ4 genomic DNA was amplified with oPN550 and oPN551, and a 
two-piece Gibson assembly was preformed. pPN250 was then constructed by 
amplifying pPN249 with AV186 and oPN565 as well as AV187 and oPN564 and a 
two-piece Gibson assembly was preformed. pPN23 was constructed by 
amplifying pJM62 (Modell et al., 2017) with H237 and H238 (Heler et al., 2015) 
and preforming a one-piece Gibson assembly. BsaI cloning was used to make 
pPN183 by inserting spacer174 (annealed primers RH486-RH487) into the BsaI 
site of pPN23. pPN77 was constructed by amplifying pJM62 with JM110 and 
JM115 (McGinn and Marraffini, 2016) and preforming a one piece Gibson 
assembly. pPN91 then was constructed in a two-piece Gibson by amplifying 
pPN77 with JM90 and oPN280 as well as JM91 and oPN279 and a two-piece 
Gibson assembly was preformed. BsaI cloning was used to make pPN174 and 
pPN256 by inserting spacer174 (annealed primers RH486-RH487) and spacer256 
(annealed oPN91-oPN92) into the BsaI site of pPN91. The E220A mutation was 
introduced into pPN174 to generate pPN285 by amplifying pPN174 with PS285 
and H293 as well as PS284 and H294 and then preforming a two-piece Gibson 
assembly as described previously (Heler et al., 2015). pPN136 was constructed by 
amplying pGG32 (Heler et al., 2015) with JM91 and oGG140 and JM90 and JM115 
and preforming a two piece Gibson assembly (McGinn and Marraffini, 2016). 
pPN290 was constructed by replacing the wild-type Cas9 with the nuclease-dead 
form of Cas9 (D10A, H840A mutations) by amplying pPN91 with H294 and 
H295 (Heler et al., 2015), amplyfing pDB182 (Bikard et al., 2014) with H293 and 
H296 (Heler et al., 2015), and preforming a two-piece Gibson assembly. pPN294 
was then made by inserting spacer174 (annealed primers RH486-RH487) into the 
BsaI site of pPN290. pPN92 was constructed by amplifying pJM62 (Modell et al., 
2017) with JM90 and oPN280, amplifying pPN77 with JM91 and oPN279, and 
preforming a two piece Gibson assembly (McGinn and Marraffini, 2016). BsaI 
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cloning was used to make pPN182 by inserting spacer174 (annealed primers 
RH486-RH487) into the BsaI site of pPN92. 
 
5.3 Strain Construction 
To create the S. thermophilus strain JAV25 we employed the method described 
previously (Varble et al., 2019). Briefly, deletions were made by transforming 
PCR amplicons with 2-kb homology arms flanking an spectinomycin resistance 
cassette into wild-type strains. The sequences and oligonucleotides used in this 
study are listed in Supplementary Data File 2. To delete CRISPR1, DG7710 
genomic DNA was amplified with AV664 and AV665 as well as AV666-AV667  
(Varble et al., 2019)and pLZ12spec55 was amplified with AV672 and AV673 
(Varble et al., 2019) followed by a thee-piece Gibson assembly to create the final 
PCR amplicon for transformation.  
 
5.4 Isolation of JAV25 CRISPR BIMs 
BIMs derived from JAV25 (CRISPR3-naïve in the text) were isolated using a 
previously described method (Hynes et al., 2017) with minor modification. 
Overnight cultures of JAV25 were infected with Φ2972 at a MOI of 0.1 and mixed 
with with LM17 media soft agar supplemented with 10 mM CaCl2 and then 
plated LM17 agar plates supplements on 10 mM CaCl2. Plates were incubated at 
42 °C overnight after drying at room temperature from 30 minutes. The resulting 
colonies were then screened for spacer acquisition by TopTaq PCR amplification 
(Qiagen) with the primers oPN737 with oPN738 and three of these colonies 
containing a single, unique spacer targeting Φ2972 were saved for subsequent 
study (CRISPR3α, CRISPR3β, and CRISPR3γ). 
 
5.5 Plaque formation assay in S. aureus 
Serial dilutions of phage stock were prepared in triplicate, spotted on fresh top 
agar lawns of RN4220 in BHI agar supplemented with appropriate antibiotic and 
5 mM CaCl2. Plates were incubated at 37 °C overnight after drying at room 
temperature from 30 minutes. 
 
5.6 Plaque formation assay in S. thermophilus 
Plaque formation of was measured as described previously (Hynes et al., 2017) 
with minor variations. Briefly, overnight cultures were launched from single 
colonies, infected with serials dilutions of phage stock Φ2972 were prepared in 
triplicate, and mixed with with LM17 media soft agar supplemented with 10 mM 
CaCl2 and then plated LM17 agar plates supplements on 10 mM CaCl2. Plates 
were incubated at 42 °C overnight after drying at room temperature from 30 
minutes. 
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5.7 Quantifying CRISPR phage escapers  
Thirty escaper plaques were isolated from soft agar lawns of RN4220 harboring a 
type II-A CRISPR plasmid targeting φNM4γ4 in BHI soft agar supplemented 
with the appropriate antibiotic, 5 mM CaCl2, and resuspended in 20 &L BHI. 2 &L 
of the phage mixture was added to 30 &L of Colony Lysis Buffer (Pyenson et al., 
2017) and boiled at 98 °C degrees for 10 minutes. 1 &L of the resulting phage 
lysate was then used as template for PCR amplification. For escapers of 
CRISPR174, oPN246 and oPN247 (all oligonucleotides used in this study are 
listed in Supplementary Data File 2) were used to amplify a portion of φNM4γ4 
amidase gene (gp68) (Bae et al., 2006). PCR products were purified with the 
QIAquick PCR Purification Kit (Qiagen) and submitted for Sanger sequencing. 
 
5.8 Isolation of spontaneous CRISPR escaper phage  
φNM4γ4PAM, φNM4γ4Seed, and φNM1γ6PAM were isolated from spontaneous 
escaper plaques following infection of φNM4γ4 on soft agar lawns of S. aureus 
RN4220 cells carrying pPN174 that encodes a type II-A CRISPR system targeting 
the amidase gene (gp68) of φNM4γ4 (CRISPR174) (Figure 2.4). PCR and Sanger 
sequencing of the resulting PCR amplicons confirmed escape mutation in the 
PAM and seed of the target of CRISPR174 (Figure 2.3). 
 
5.9 Phage construction  
We used a variation of a previously described method (Lemay et al., 2017). 
φNM4γ4256rev was created by propagating φNM4γ4 liquid culture of cells 
harboring pPN250 which contains the protospacer and PAM of CRISPR256 
flipped onto the opposite strand as well as the surrounding upstream and 
downstream homology regions for recombination with the φNM4γ4 genome. 
Recombinant φNM4γ4256rev plaques were isolated on a soft agar lawn of RN4220 
pGG14, which encodes a type III-A CRISPR-Cas system targeting the sequence 
present in φNM4γ4 and not in φNM4γ4256rev.  Subsequent PCR and Sanger 
sequencing of the resulting PCR amplicons confirmed the flipped target. 
 
5.10 Spacer Acquisition in S. aureus Liquid Culture 
Overnight cultures were launched from single colonies and diluted to an optical 
density at 600 nm (OD600) of ~0.1 in BHI, 5 mM CaCl2, and the appropriate 
antibiotics. After 1 hour and ten minutes, optical density (OD600) was measured 
for each culture, and each sample was normalized to an equal cell density. 
Cultures were then infected with φNM4γ4, φNM4γ4PAM, φNM4γ4Seed, 
φNM4γ4256rev, or mock infected at a multiplicity of infection (MOI) of 100 for 
thirty minutes prior pelleting infected cells, removing the supernatant, and flash 
freezing the pellets in liquid nitrogen. Frozen pellets were kept at -80°C until 
ready for DNA extraction. For 24 hour spacer acquisition assay (Figure 3.1), three 
cultures of pWJ40 prepared as above and each normalized to an OD600 of ~0.5 
prior to infection with φNM4γ4 at a MOI of 1 for 24 hours. Infected cultures 
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were pelleted, the supernatant was removed, and immediately prepared for 
DNA extraction.  
 
5.11 Spacer Acquisition in S. thermophilus Liquid Culture 
Overnight cultures were launched from single colonies and diluted to an optical 
density at 600 nm (OD600) of ~0.1 in LM17 with 10 mM CaCl2. After 1 hour and 30 
minutes of outgrowth, the optical density (OD600) was measured for each culture, 
and each sample was normalized to an equal cell density. Cultures were then 
infected with Φ2972 or mock infected at a multiplicity of infection (MOI) of 10 for 
thirty minutes prior pelleting infected cells, removing the supernatant, and flash 
freezing the pellets in liquid nitrogen. Frozen pellets were kept at -80°C until 
ready for DNA extraction. 
 
5.12 PCR amplification of expanded CRISPR loci for high-throughput 
sequencing in S. aureus 
CRISPR plasmids were isolated from RN4220 cells with modified QIAprep Spin 
Miniprep Kit protocol (Qiagen) as previously described (Modell et al., 2017). We 
used 200 ng (log phase) of plasmid as input for encrichment PCR of the CRISPR 
locus with Phusion DNA Polymerase (Thermo) with the following primer mix: 
oPN287 and cocktail containing an equal mixture of oPN288, oPN289, and 
oPN290. For 24 hour infection assay, H188 and JM257, JM248 and JM258, and 
JM249 and JM259 were used to amplify the CRISPR for the three cultures 
respectively. To differentiate between samples during multiplexed high-
throughput sequencing, variants of oPN287 containing randomized 5 nucleotides 
(NNNNN) followed by 3-6 nucleotide barcode at 5’ end. Amplicons 
corresponding to the size of expanded CRISPR arrays were gel purified allowing 
for the removal of unexpanded CRISPR arrays. Purified amplicons were then 
prepared for sequencing with the TrueSeq Nano DNA Library Prep protocol 
(Illumina), using a final concentration of 1.36x Sample Purification Beads 
(Ilumina) following end repair for further size selection, followed by high-
throughput sequencing with the MiSeq platform. 
 
5.13 PCR amplification of expanded CRISPR loci for high-throughput 
sequencing in S. thermophilus 
Genomic DNA was isolated from DG7710 cells by first treating with modified 
Wizard Genomic DNA Purification protocol for gram-positive bacteria 
(Promega): bacterial cell pellets were resuspended in 0.5 M EDTA, pH 8.0 
supplemented with 200 &g ml-1 lysozyme (Sigma) and incubated at 37 °C for 25 
min prior to pelleting and removing the supernatant. The standard Wizard 
protocol for gram-positives was then followed as described by the manufacturer 
(Promega). We used 200 ng (log phase) of plasmid as input for PCR of the 
CRISPR locus with Phusion DNA Polymerase (Thermo) with the following 
primer mix: oPN737 with oPN738, oPN757, oPN758, or oPN759 depending on 
whether JAV25, JAV25-BIM01, JAV25-BIM02, or JAV25-BIM03 was used. To 
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differentiate between samples during multiplexed high-throughput sequencing, 
variants of oPN737 containing randomized 5 nucleotides (NNNNN) followed by 
3-6 nucleotide barcode at 5’ end. Amplicons corresponding to the size of 
expanded CRISPR arrays were gel purified allowing for the removal of 
unexpanded CRISPR arrays. Purified amplicons were then prepared for 
sequencing with the TrueSeq Nano DNA Library Prep protocol (Illumina), using 
a final concentration of 1.36x Sample Purification Beads (Ilumina) following end 
repair for further size selection, followed by high-throughput sequencing with 
the MiSeq platform.  
 
5.14 Spacer acquisition in soft agar 
Overnight cultures were launched from single colonies and diluted to an optical 
density at 600 nm (OD600) of ~0.1 in BHI and the appropriate antibiotics. After 1 
hour and ten minutes, optical density (OD600) was measured for each culture, and 
each sample was normalized to an equal cell density. Cultures were then 
concentrated to a final density of OD600 ~125, infected at with φNM4γ4, 
φNM4γ4PAM or φNM4γ4Seed at MOI 2.5, mixed with soft BHI soft agar containing 
5 mM CaCl2 and then plated BHI agar with the appropriate antibiotics. In order 
to quantify initial number of cells infected, prior to infection an aliquot of each 
culture was serially diluted and plated on BHI plates. Following overnight 
incubation at 37 °C, soft agar plates were photographed and the number of 
surviving bacteriophage-immune mutant colonies (BIMs) were quantified with 
ImageJ32. To assay for spacer acquisition, individual colonies were picked and 
lysed with lysis buffer containing 50 ng/µl lysostaphin (Ambi) as described 
before (Heler et al., 2015). Following centrifugation (21,000g), the supernatant of 
each sample was used a template for TopTaq PCR amplification (Qiagen) with 
the primers oPN479 and oPN292. The resultant PCR amplicons were then 
analyzed on 2% agarose gels and the percent of BIMs containing expanded 
arrays (CRISPR BIMs) was determined (Figure 2.5). The spacer acquisition rate 
for each infection was then calculated based on the percent of CRISPR BIMs 
divided by the initial number of cells infected (Figure 2.4C and Figure 2.5). 
 
5.15 In vitro CRISPR-Cas9 cleavage assay 
174CRISPR RNA and tracrRNA (IDT cat# 1072532) were purchased from IDT 
and annealed to form crRNA174:tracrRNA RNA duplexes according Alt-R 
CRISPR-Cas9: In vitro cleavage of target DNA with ribonucleoprotein complex 
protocol (IDT). All RNA oligonucleotides used in this study are listed in 
Supplementary Data File 2.Target DNA substrates were generated by PCR of 
purified φNM4γ4 genomic DNA with Phusion DNA Polymerase (Thermo) using 
oPN144 and oPN562 and then purified by gel extraction. Cleavage assays were 
preformed similarly as described previously (Jinek et al., 2012). Briefly, 
crRNA:tracrRNA and Cas9 (NEB #MO386)  were allowed form RNP complexes 
at room temperature for 10 minutes and then diluted to a final concentration of 
6.25, 12.5, 25, 50 and 100 nM following to the addition of target DNA. All 
reactions were incubated at 37°C for 5 minutes before the digestion with 
proteinase K (NEB #P8107) to stop the reactions and liberate target DNA and 
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then stored at -80°C until ready for further analyzed. Samples were visualized on 
2% agarose gel with SYBR Gold Nucleic Acid Gel Stain (Invitrogen #S11494) and 
the abundance of cleavage products quantified by automated electrophoresis and 
imaging using a Tapestation 4200 (Agilent). 
 
5.16 In vivo CRISPR-Cas9 cleavage of viral DNA 
To observe CRISPR-Cas9 cleavage of anti-viral targets, overnight culture of 
RN4220 cells carrying the pC194 (CRISPR-), pPN136 (SR), or pPN174 
(CRISPR174) were diluted to an OD600 of ~0.1 with the appropriate antibiotic and 
5 mM CaCl2. After 1 hour and ten minutes of growth, optical density (OD600) was 
measured for each culture, and each sample was normalized to equal cell 
density. Cultures were then infected at MOI 5 with φNM4γ4, φNM4γ4PAM or 
φNM4γ4Seed for 20 minutes prior to centrifugation and flash-freezing of cell 
pellets. All samples were stored at -80°C until ready for genomic DNA (gDNA) 
purification using the DNeasy Blood and Soft Tissue protocol for Gram-Positive 
organisms (Qiagen). In order assay for viral gDNA cleavage we preformed 
modified Anchor PCR by utilizing components of the 5’ RACE System for Rapid 
Amplification of cDNA Ends Version 2.0 kit (Invitrogen Life Sciences). In brief, 
200 ng of purified genomic DNA was incubated with dCTP at final concentration 
of 200 &M for 2.5 minutes at 94°C degrees to denature dsDNA. The reactions 
were chilled on ice for 1 minute prior to the addition of recombinant terminal 
deoxynucleotidyl transferase (TdT) (Invitrogen Life Sciences). Incubation at 37°C 
for 10 minutes allows for the addition dC-homopolymeric tail to the 3’ ends of 
dsDNA ends generated by Cas9-mediated cleavage and creates abridged anchor 
primer (AAP) binding site (Invitrogen Life Sciences). TdT is then heat inactivated 
at 65°C for 10 minutes. dC-tailed DNA was then amplified with Taq DNA 
polymerase (Invitrogen Life Sciences) using the AAP and oPN656 upstream of 
CRISPR174 protospacer. Finally amplicons were visualized on 2% agarose gel 
and amplicons were purified by gel extraction for Zero Blunt TOPO PCR cloning 
(Invitrogen Life Sciences). 
 
5.17 Bacterial infection growth curves 
Viral infections were preformed in a microplate reader as previously described 
(Goldberg et al., 2014; McGinn and Marraffini, 2016) with minor alterations. 
Overnight cultures were launched in triplicate from single colonies and diluted 
to an OD600 of ~0.1 with the appropriate antibiotic and 5 mM CaCl2.  After 1 hour 
and ten minutes of growth, optical density (OD600) was measured for each 
culture, and each sample was normalized to equal cell density (OD600 ~ 0.4) and 
loaded into a 96-well plate (Cellstar, 655180). Individual cultures were then 
infected with φNM4γ4, φNM4γ4PAM or φNM4γ4Seed at an MOI 1. For infections at 
high MOIs (Fig. 5D), cells were prepared as above but infected at an MOI 100 in 
bulk culture (5 ml) and the infection were allowed to proceed in the shaking 
incubator for 30 minutes before an aliquiot of each culture was then loaded into a 
96-well plate. Optical density measurements were then taken every 10 minutes 
for 24 hours in a microplate reader (TECAN Infinite 200 PRO) to generate growth 
curves. At the end of 24 hours, an aliquot of each culture was lysed in colony 
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lysis buffer contains 50 ng/&l lysostaphin (Ambi) as described before (Heler et 
al., 2015) and the supernatant was used as template in PCR to assay for spacer 
acquisition using oPN479 and oPN292 or oPN635 and oPN292. The resulting 
amplicons were then analyzed on a 2% agarose gel. 
 
5.18 Bacterial co-infection growth curve assays 
As before, overnight cultures were launched, diluted to an OD600 of ~0.025, and 
then normalized to equal cell density (OD600 ~ 0.1) prior to infection with 
φNM4γ4 at a MOI 10. The infections were allowed to proceed in the shaking 
incubator for 30 minutes before the optical density (OD600) was re-measured. 
Cultures were then loaded into a 96-well plate and infected with φNM1γ6PAM at 
MOI 1. Optical density measurements were then taken every 10 minutes for 24 
hours in a microplate reader (TECAN Infinite 200 PRO) to generate growth 
curves. At the end of 24 hours, an aliquot of each culture was lysed in colony 
lysis buffer contains 50 ng/&l lysostaphin as described before (Heler et al., 2015) 
and the supernatant was used as template in PCR to assay for spacer acquisition 
using oPN635 and oPN292. The resulting amplicons were then analyzed on a 2% 
agarose gel. 
 
5.19 High Throughput Sequencing Data Analysis 
Spacers were extracted from raw MiSeq FASTQ files and aligned to reference 
phage genomes using Python. Spacers that aligned perfectly to each reference 
genome were assigned to genomic position at the 5’ end of the alignment and 
reads were aggregated based on each unique spacer sequence. In order to avoid 
bias introduced into the data set due to duplication of the CRISPR array, reads 
containing expanded CRISPR arrays comprising of the original priming spacer 
(spc174, spc256, spc300, spc303, spc305, spca, spcb , or spcg) were discarded. 
Following aggregation, the flanking protospacer adjacent motif (PAM) and 
strand for each spacer was determined based on the reference genome. To 
account sequencing bias introduced as result of enrichment PCR, all spacer read 
counts were normalized as described previously (Modell et al., 2017). When 
conventional spacers primers were used to amplify CRISPR loci this 
normalization step was skipped. Each unique spacer was then sorted into 1-kb 
bins and each bin was divided by the number of 5’-NGG-3’ sequences CRISPR 
loci derived from S. pyogenes SF370 or 5’-NGGNG-3’ for CRISPR loci derived 
from S. thermophilus DGCC7710 CRISPR3 within each bin in order to account for 
observation that spacer acquisition occurs primarily from sequences immediately 
upstream of PAMs (Heler et al., 2015). Reads per million (RPM) were calculated 
as RPMtot or RPMphage as desired previously (Modell et al., 2017). 
When assessing expanded CRISPR arrays with two anti-viral spacers 
(Figs. 5A and S5A-E), both spacers were extracted pooled from three liquid 
cultures, aligned to φNM4γ4 genome, and the genomic position, PAM, and 
strand were determined for each spacer as before. Each anti-viral spacer pair was 
then grouped into 1-kb bins based on the distance between their respective 
positions in the φNM4γ4 genome.  The proportion of anti-viral spacer pairs in 
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each bin was then calculated by dividing by the total number of pairs. To 
examine groups of doubly expanded arrays that all arise from primed acquisition 
against the same viral target within φNM4γ4 (Figure 3.1), CRISPR loci were 
sorted into groups based on the first acquired spacer in the array and the 
distance between each anti-viral spacer was calculated. 
 
5.20 Statistical analysis 
The basis for the statistical analysis used in this thesis are listed in the section 
bellow 
 
5.20.1 Growth Curve Analysis 
For growth curves in Figure 3.2B-G and Figure 3.3A-D, error bars represent the 
standard error of four biological replicates 
 
5.20.2 In vitro CRISPR-Cas9 Cleavage Assay Analysis 
For the cleavage assay in Figure 2.8, error bars represent the standard error of 3 
biological replicates. 
 
5.20.3 Efficiency of Plaquing Assay Analysis  
For EOP assays in Figure 2.2, Figure 2.4, Figure 2.10 and Figure 3.2, error bars 
represent the standard error of 3 biological replicates. 
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Table 5.1. Strains used in this study 
 
Strain Description Source s 
RN4220 S. aureus strain Kreiswirth et al., 1983 
DGCC7710 S. thermophilus strain Barrangou et al., 2007 
JAV25 CRISPR1 knockout DGC7710 (CRISPR3-naïve) This study 
JAV25-BIM01 JAV25 BIM with spacer alpha This study 
JAV25-BIM02 JAV25 BIM with spacer beta This study 
JAV25-BIM03 JAV25 BIM with spacer gamma This study 
JAV27 CRISPR1 and CRISPR3 knockout DGC7710 Varble et al., 2019 
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Table 5.2. Plasmids used in this study 
 
Plasmid Description Source 
pGG14 Type III-A CRISPR-Cas system targeting the sequence present in φNM4γ4 
and not in φNM4γ4256rev 
G. Goldberg PhD thesis 
pGG32 Type II-A CRISPR-Cas system with a CRISPR array comprising of a single 
repeat 
Heler et al 2015 
pPN23 Cas9 only CRISPR-Cas system with BsaI spacer for oligo cloning This study 
pPN91 Type II-A CRISPR-Cas system with BsaI spacer for oligo cloning This study 
pPN92 ∆leader Type II-A CRISPR-Cas system with BsaI spacer for oligo cloning This study 
pPN86 pLR This study 
pPN136 ∆leader SR This study 
pPN174 ∆leader CRISPR174 This study 
pPN182 WT-CRISPR174 This study 
pPN183 Cas9-CRISPR This study 
pPN249 656 bp from φNM4γ4 for construction of pPN250 This study 
pPN250 656 bp from φNM4γ4 for construction of φNM4γ256rev This study 
pPN256  ∆leader CRISPR256 This study 
pPN285 ∆leader dcas1 CRISPR174  This study 
pPN290 dcas9 Type II-A CRISPR-Cas system with BsaI spacer for oligo cloning This study 
pPN294 ∆leader dcas9 CRISPR174  This study 
pWJ40 Type II-A CRISPR-Cas system with a CRISPR array from SF370 Heler et al 2015 
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Table 5.3. Primers used in this study 
 
Oligo Sequence Function 
oPN246 TTTCTATTTCCATtcgtgctataattatactaattttataaggagg Check for escapers of CRISPR174 
targeting 
oPN247 attatagcacgaATGGAAATAGAAATTAAATTTAACGAAACGTTC Check for escapers of CRISPR174 
targeting 
oPN287 AGTGCGATTACAAAATTTTTTAGAC Forward primer for enchrichment PCR 
oPN288 AAAACAGCATAGCTCTAAAACT Primer #1 for reverse primer cocktal 
for enchrichment PCR 
oPN289 AAAACAGCATAGCTCTAAAACG Primer #2 for reverse primer cocktal 
for enchrichment PCR 
oPN290 AAAACAGCATAGCTCTAAAACA Primer #3 for reverse primer cocktal 
for enchrichment PCR 
oGG38 AAGATAAAGAATTTGCTCAAGACG For confirming 256 flip target 
oGG40 ACCATTAAAACTCGTCATTCTTTC For confirming 256 flip target 
oPN292 CTTTCTCAAGTTATCATCGGCAATG Assay CRISPR174 spacer acquistion 
oPN479 AAAATTTTTTAGACAAAAATAGTCTACGAG Assay CRISPR174 spacer acquistion 
oPN635 GTAATGATTTACTAAATGTTAATGTATCA Assay CRISPR174 spacer acquistion 
oPN144 TATCTCATATTTAATAGTTATTTAATAACTGTAAGATTCCCTATAAT
TAATG 
For creation of the in vitro cleavage 
assay substrate from NM4g4 genomic 
DNA 
oPN562 attatagcacgaATACGGTGGCTCAAGTCAATC For creation of the in vitro cleavage 
assay substrate from NM4g4 genomic 
DNA 
oPN547 CATTATTACCTTTAACATTAGCTACTGTG Anchor PCR reverse primer 
oPN283  GATGGAACAAACttattgaataaaagatatgagagatttatctaatt
tc 
Gibson assembly of pPN86 fragment #1 
oPN284 AGCCACTTCATCCtcgtgctataattatactaattttataaggag Gibson assembly of pPN86 fragment #1 
oPN285 attatagcacgaGGATGAAGTGGCTAGTTTAC Gibson assembly of pPN86 fragment #2 
oPN286 ttttattcaataaGTTTGTTCCATCACACTACTC Gibson assembly of pPN86 fragment #2 
oPN548 CATTAGTTCAACGTTTTAAAGATACAGAATTTCACAAAATGTTT Gibson assembly of pPN249 fragment 
#1 
oPN549 AACATAAATATATTTGATTCAATCGTATCTGTTTTAATATACGT Gibson assembly of pPN249 fragment 
#1 
oPN550 CGATTGAATCAAATATATTTATGTTACAGTAATATTGACTTTTAAAA
AAGG 
Gibson assembly of pPN249 fragment 
#2 
oPN551 GTATCTTTAAAACGTTGAACTAATGGGTGCTTTAG Gibson assembly of pPN249 fragment 
#2 
AV186 AATCGATAACCACATAACAGTCATAAAAC Gibson assembly of pPN250 fragment 
#1 
oPN565  ACACACATAACTAAAGCTAAGAGTAATCAAAGGATGTTTACGTCCTG
TTG 
Gibson assembly of pPN250 fragment 
#1 
AV187 GTTTTATGACTGTTATGTGGTTATCGATT Gibson assembly of pPN250 fragment 
#2 
oPN564 CCTTTGATTACTCTTAGCTTTAGTTATGTGTGTTTTACAGTCGTTGA
GGCAG 
Gibson assembly of pPN250 fragment 
#2 
H237 ggcgtactgatgaagattatttcttaataactaaaaatatgg Gibson assembly of pPN23 
H238 tttagttattaagaaataatcttcatcagtacgccaaccagcc Gibson assembly of pPN23 
RH486 aaacTGATACATTAACATTTAGTAAATCATTACGg BsaI cloning to construct pPN174, 
pPN182, pPN183, pPN294 
RH487 aaaacCGTAATGATTTACTAAATGTTAATGTATCA BsaI cloning to construct pPN174, 
pPN182, pPN183, pPN294 
JM110 Gttttagagctatgctgttttgaatggtcccaaaactgagaccagtc
tcggaagctcaaa 
Gibson assembly of pPN77 
JM115 attcaaaacagcatagctctaaaaCttataccatatttttagttatt
aagaaataatctt 
Gibson assembly of pPN77 and pPN136 
fragment #2 
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Table 5.3. Primers used in this study (continued). 
 
JM90 GAGAAGATTGAAAAAATCTTGACTTTTCG Gibson assembly of pPN91, pPN92 fragment #1, and 
pPN136 fragment #2 
oPN280 GTCTCTTGAATGAGACAAATGCACCATGTTAAAAATA
CC 
Gibson assembly of pPN91 and pPN92 fragment 
#1 
JM91 CGAAAAGTCAAGATTTTTTCAATCTTCTC Gibson assembly of pPN91 fragment #2 and 
pPN136 fragment #1 
PS285 CTAAAGGCCTAAATGGTgCCATAATATCGCTAGC Gibson assembly of pPN285 fragment #1 
H293 GCAAAAATGGATAAGAAATACTCAATAGGC Gibson assembly of pPN285 fragment #1 and 
gibson assembly of pPN290 fragment #2 
PS284 GCTAGCGATATTATGGcACCATTTAGGCCTTTAG Gibson assembly of pPN285 fragment #2 
H294 TATTGAGTATTTCTTATCCATTTTTGCCTCC Gibson assembly of pPN285 fragment #2 and 
gibson assembly of pPN290 fragment #1 
H295 AACACGCATTGATTTGAGTCAGC Gibson assembly of pPN290 fragment #1 
H296 TCCTAGCTGACTCAAATCAATGCG Gibson assembly of pPN290 fragment #2 
oGG140 aaaGGTCTCGTTTTAGAGCTATGCTGTTTTGAATGGT
CCCAAAACAACATTGCCG 
Gibson assembly of pPN136 fragment #1 
H188 NNNNNAGTCAAAATTTTTTAGACAAAAATAGTC Applification of CRISPR arrays in 24 hour 
infection assay replicate #1 
JM248 NNNNNTAGCAAAATTTTTTAGACAAAAATAGTC Applification of CRISPR arrays in 24 hour 
infection assay replicate #1 
JM249 NNNNNCAGCAAAATTTTTTAGACAAAAATAGTC Applification of CRISPR arrays in 24 hour 
infection assay replicate #2 
JM257 NNNNNAGTCTTTCTCAAGTTATCATCGGC Applification of CRISPR arrays in 24 hour 
infection assay replicate #2 
JM258 NNNNNTAGCTTTCTCAAGTTATCATCGGC Applification of CRISPR arrays in 24 hour 
infection assay replicate #3 
JM259 NNNNNCAGCTTTCTCAAGTTATCATCGGC Applification of CRISPR arrays in 24 hour 
infection assay replicate #3 
oPN737 AGAAAAGATATCCTACGAGG Amplifcation of CRISPR3 array of S. 
thermophilus DGC7710 
oPN738 CTCTTTAGCGTTTAGAATTTG Amplifcation of CRISPR3 array of S. 
thermophilus DGC7710 
oPN757 TCGTCCAAGTTGCCCTCATG Amplifcation of CRISPR3 array of S. 
thermophilus JAV25-BIM01 
oPN758 ACGTCAATGACAAAGAATGT Amplifcation of CRISPR3 array of S. 
thermophilus JAV25-BIM02 
oPN759 TCTTTTTGTTGGTAATAAACG Amplifcation of CRISPR3 array of S. 
thermophilus JAV25-BIM03 
AV664 cttgggcagaaaaccttgtagatg Gibson assembly for JAV25 construction 
fragment #1 
AV665 AGTCACGTTACGTTATgaacttggctttttaaaatac
acg 
Gibson assembly for JAV25 construction 
fragment #1 
AV666 ACCCTTGGACTTTCGTCactactaacttgttggcaag
g 
Gibson assembly for JAV25 construction 
fragment #2 
AV667 caagggcgatgaccttcaagg Gibson assembly for JAV25 construction 
fragment #2 
AV672 ATAACGTAACGTGACTGGCAAGA  Gibson assembly for JAV25 construction 
fragment #3 
AV673 GACGAAAGTCCAAGGGTTTATTG Gibson assembly for JAV25 construction 
fragment #3 
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Table 5.4. Spacers used in this study 
 
Spacer 
name/CRISPR# 
Sequence (5'-3') position in 
phage genome 
strand PAM (5'-
3') 
174 TGATACATTAACATTTAGTAAATCATTACG 39099-39128 bottom AGG 
256 ACACACATAACTAAAGCTAAGAGTAATCAA 12480-12509 top AGG 
300 TACTAAATCACCTTACAACACTTCAACTAG 19911-19940 top TGG 
303 AGGAATTGAGACACCTCAATATATACTTGC 15220-15249 top TGG 
305 TAATACAGGTTTTTACAAAAGCTTTACCAT 5962-5991 top AGG 
a CATGAGGGCAACTTGGACGATTGATAAGGT 24038-24067 top TGGCG 
b TACATTCTTTGTCATTGACGTGGACATGCA 30072-30171 top TGGCG 
γ GTTTATTACCAACAAAAAGAAAAAAATATA 29393-29422 top TGGAG 
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Table 5.5 Spacers used in this study 
 
Spacer 
name/CRISPR
# 
Sequence (5'-3') position 
in phage 
genome 
strand PAM 
(5'-3') 
174 TGATACATTAACATTTAGTAAATCATTACG 39099-39128 bottom AGG 
256 ACACACATAACTAAAGCTAAGAGTAATCAA 12480-12509 top AGG 
300 TACTAAATCACCTTACAACACTTCAACTAG 19911-19940 top TGG 
303 AGGAATTGAGACACCTCAATATATACTTGC 15220-15249 top TGG 
305 TAATACAGGTTTTTACAAAAGCTTTACCAT 5962-5991 top AGG 
a CATGAGGGCAACTTGGACGATTGATAAGGT 24038-24067 top TGGCG 
b TACATTCTTTGTCATTGACGTGGACATGCA 30072-30171 top TGGCG 
γ GTTTATTACCAACAAAAAGAAAAAAATATA 29393-29422 top TGGAG 
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